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Makoni, Nyasha J., University of Missouri-St. Louis, December 2020. 
Interactions of the NLRP3 Inflammasome Complex. Major Professor: Dr. Michael 
R. Nichols. 
The innate immune system is the first line of defense in response to 
danger signals or invasion by pathogens. One of the major pathways in the 
innate immune system involves a three-protein complex known as the NLRP3 
inflammasome. This complex, mainly found in immune cells, is comprised of 
NLRP3, ASC, and procaspase-1. The individual proteins are separate under 
normal conditions, and only assemble in response to external stimuli to form a 
caspase-1-activating complex. Ultimately, activated caspase-1 facilitates 
production of interleukin-1β (IL-1β), an inflammatory cytokine. The NLRP3 
inflammasome has been implicated in a variety of inflammatory disorders 
including Alzheimer’s disease (AD). Amyloid beta (Aβ) is the protein that causes 
AD and Aβ deposits in the brain activate microglia. Continuous activation of 
microglia results in a chronic inflammatory state hence neuroinflammation is a 
characteristic feature of AD pathology. 
However, the actual events by which Aβ activates the inflammasome are 
still unknown. In addition, the actual structure of the inflammatory complex and 
how that relates to caspase-1 activation is yet to be determined. Hence, my 
research focused on determining the interactions between Aβ and the NLRP3 
inflammasome, and how they lead to caspase-1 activation. To conduct these 
studies, I expressed full-length, mutants, and truncated versions of the 
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inflammasome proteins using a mammalian ExpiCHO-S system. This was the 
first time anyone had ever attempted to use this cell line to express these 
proteins. Proteins were successfully isolated from the lysates and inclusion 
bodies. Fusion tags were added to improve solubility. After purification by affinity 
and size-exclusion chromatography, recombinant proteins were characterized by 
SDS-PAGE and immunoblotting. Although monomers were observed, high 
degree of oligomerization revealed the propensity of the proteins to aggregate. 
Biophysical techniques also confirmed the presence of protein aggregates. 
Efforts to break the pre-formed aggregates involved applying stringent conditions 
such as thermal and chemical denaturation, detergents, and reducing agents.  
The next aspect of the studies involved performing functional assays with 
the recombinant caspase-1 proteins in order to determine which exact domains 
are required for enzyme activity. Using a fluorescence assay, I observed 
enzymatic activity with procaspase-1 although it was transient. This discovery 
was surprising and exciting since the proenzyme had been previously dubbed 
inactive in the published literature. On the other hand, the reconstituted p20p10 
and CARDp20 domains had no activity under similar conditions. Some 
publications, however, have observed enzyme activity with reconstituted p20p10 
fragments. 
I also investigated the nature of the interactions between Aβ and the 
NLRP3 inflammasome using two approaches: cell stimulation assays, and 
solution interactions with recombinant proteins. In agreement with previous 
literature, I observed direct interactions between Aβ protofibrils and NLRP3 
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protein. Thus, the studies I conducted provide some insightful findings regarding 
the nature of the interactions between Aβ and the inflammasome. In addition, 
they offer new perspectives relating to the actual structure of active caspase-1 




CHAPTER 1: INTRODUCTION 
1.1. Innate immunity 
Innate immune system is the first line of defense against pathogens 
(bacteria, viruses, fungi) [24-28]. It has evolved to be a quite sophisticated 
system for sensing “danger” whilst remaining unresponsive to the molecules and 
particles regarded as posing no threat to the general well-being of cells [29]. This 
system senses pathogens and other microbes via pattern recognition receptors 
(PRRs) [30, 31]. PRRs are mainly found in immune and inflammatory cells such 
as monocytes, microglia, macrophages, neutrophils, and dendritic cells [18, 24, 
28]. The main classes of PRRs are Toll-like receptors (TLRs), nucleotide 
oligomerization and binding domain (NOD)-like receptors (NLR), C-type lectin 
receptors (CLRs), RIG-I (retinoic acid inducible gene-I)-like receptors (RLRs), 
and IFI200 family member absent in melanoma 2 (AIM2) [24-27, 29, 32-35]. 
PRRs can be extracellular/ transmembrane (TLRs) or intracellular (NLRs, RLRs, 
AIM2) [36]. TLRs, located in plasma and endosomal membranes, detect 
pathogen associated molecular patterns (PAMPs) and danger-associated 
molecular patterns (DAMPs) in the extracellular space [18, 24, 27, 36]. PAMPs 
are unique to microbials and are critical in microbial function [bacterial 
lipopolysaccharide S (LPS), flagellin, viral RNA etc] while DAMPs are basically 
endogenous or modified host molecules such as adenosine triphosphate (ATP), 
amyloid-beta (Aβ), uric acid, hyaluronan as well as heat shock proteins (hsp) -70 
and -90 [30, 32, 37]. LPS, a well-known TLR4 ligand [38], is found on the outer 
wall of gram-negative bacteria. PRRs can sense a variety of stimuli such as 
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microbial cell wall components and nucleic acids, uric acid crystals, ATP, and Aβ 
[29, 30]. After sensing stimuli, PRRs promote the assembly of intracellular, multi-
protein complexes called “inflammasomes” that activate inflammatory caspases 
thus resulting in the production of cytokines and chemokines [25, 26, 39]. 
Inflammasomes are cytosolic protein complexes (about 700 kD in size) 
that mediate immune responses (via activation of caspases) in the event of 
microbial infection or cellular damage [25, 26, 30, 39-42]. The inflammasome 
complex was initially isolated from extracts of human THP-1 monocytic cells by 
Tschopp and co-workers and was described as a caspase-activating complex 
[39]. In other reports, inflammasomes have been described as “…molecular 
platforms activated upon cellular infection or stress that trigger the maturation of 
proinflammatory cytokines such as interleukin-1β to engage innate immune 
defenses” [29]. Many reviews have been written on inflammasomes [29, 33, 35, 
43-46]. 
Inflammasomes are made up of a sensor (NLR family protein), an adaptor 
(ASC) [apoptosis-associated speck-like protein containing a caspase recruitment 
domain (CARD)], and an effector (a caspase) [35]. To date, five PRRs 
[nucleotide-binding oligomerization domain-, leucine-rich repeat- and pyrin 
domain (PYD)-containing 1/3 (NLRP1/3), NOD-like receptor CARD domain 4 
(NLRC4), Pyrin and AIM2] have been found to form inflammasomes. However, 
four key inflammasomes have been studied so far (NLRP1, NLRP3, NLRC4, 
AIM2) [33, 35, 42, 47].  
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The human NLR family of intracellular receptors consists of 22-23 
members [33, 36, 42]. These receptors not only sense microbials but are also 
triggered by non-microbial particles leading to the activation of caspases 1- and -
5. Subsequently, the proinflammatory cytokines interleukin- 1-beta (IL-1β) and 
interleukin 18 (IL-18) are released and may cause pyroptosis which is a 
proinflammatory cell death process [39, 48]. NLR family of proteins utilize ASC 
as the adaptor protein although other ASC-independent inflammasome 
complexes exist [25, 29, 43, 45].  
The nucleotide-binding oligomerization domain-, leucine-rich repeat- and 
pyrin domain-containing 3 (NLRP3) inflammasome is part of a highly regulated 
innate immune system and is an emerging area of research attracting the most 
interest of any of the inflammasomes. Prolonged and excessive production of IL-
1β causes tissue damage and this is the characteristic of many inflammatory and 
autoimmune disorders as well as numerous cancers, cardiovascular, and 
neurodegenerative diseases such as Alzheimer’s disease (AD) [33, 49]. 
Activation of the NLRP3 inflammasome has been implicated in the occurrence of 
AD [27, 49-53]. The interplay between TLR signaling, AD, and the NLRP3 
inflammasome has been reviewed here [34]. 





1.2. Amyloid beta (Aβ) and Alzheimer’s disease (AD) 
Alzheimer’s disease (AD) is a neurodegenerative disease which is the 
most common cause of dementia and accounts for 60-70% of the cases [34, 37, 
49, 54-56]. AD can be familial or sporadic as in most cases. Although aging is the 
main risk factor for developing AD, genetic factors which increase overall 
production of amyloid beta (Aβ) above a critical threshold as well as 
environmental factors (diet, sedentary lifestyle) contribute towards developing the 
disease [34, 57, 58]. Genetic factors leading to early onset AD include mutations 
in the amyloid precursor protein (APP) [58, 59], presenilin genes (PS1/2) [58, 60, 
61], and presence of the apolipoprotein E4 (APOE4) gene (late onset) [62, 63]. 
Although extensive research has been conducted to find drug therapies against 
Aβ [49, 64-73], currently there is no effective cure for this debilitating disease. AD 
pathology usually starts 20-30 years prior to the manifestation of clinical 
symptoms. It is characterized by extracellular Aβ deposits (senile plaques), 
intracellular tau tangles, neuronal loss, synaptic damage, and ultimately cognitive 











Fig 1.1 The Alzheimer’s disease (AD) brain is characterized by extracellular senile (amyloid 
beta) plaques, intracellular tau tangles, enlarged ventricles, and cortical shrinkage compared 
to the healthy brain. Severe loss of brain tissue ultimately leads to dementia in AD patients. 




Amyloid beta (Aβ), a 38-43 amino acid peptide, is responsible for causing 
AD [77]. This protein is processed from its parent protein APP [58, 60, 78] which 
is an integral membrane protein. As shown in Fig 1.2 [1], cleavage by two 
aspartyl proteases (β and γ secretases) generates Aβ-42 and Aβ-40 fragments. 





Fig 1.2 Processing of amyloid precursor protein (APP), an integral membrane protein, occurs 
via amyloidogenic and non-amyloidogenic pathways. β- and –γ secretases facilitate the 
generation of amyloid beta fragment via the amyloidogenic pathway [1].  
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Due to the two the extra hydrophobic residues (Ile, Ala) at the C-terminus, 
Aβ-42 has a greater propensity to aggregate into β-sheet structures [64, 79, 80] 
and is predominant in senile plaques [81]. The Aβ aggregation pathway is shown 




Aβ42 aggregates were found to be stable and resistant to denaturants 
[82]. Many AD-related genetic mutations result in increased amounts of Aβ-42 vs 
Aβ-40 [58]. A critical AD biomarker is reduced cerebrospinal fluid (CSF) levels of 
Aβ-42 [57, 83-85] while the Aβ-40 levels remain the same [84, 86] resulting in a 
higher Aβ-40/ Aβ-42 ratio. Under normal conditions, Aβ clearance is facilitated by 
microglia [49, 87-89] and via translocation to the blood stream and the 
cerebrospinal fluid [56]. Various microglial receptors including scavenger 
receptors (SR), TLRs, CD36, and NLRs are involved in the uptake and clearance 
of Aβ as reviewed by Doens et al [90]. In the case of AD, dysregulation and 
Fig 1.3 Aβ aggregation pathway. Unstructured Aβ monomers undergo aggregation to form 
soluble oligomers (ranging from dimers to high order protofibrils) and ultimately, insoluble 
fibrillar species. An alternative route involving the annulus, dodecamer, and amylospheroid is 
distinct from the protofibrillar-fibrillar pathway [20].  
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subsequent elevation of Aβ levels results in the accumulation of insoluble protein 
aggregates in the brain [51, 52, 91]. Senile Aβ plaques in the brain activate 
microglia (immune cells in the brain) resulting in the production of inflammatory 
factors [51, 52, 91]. Although the natural levels of Aβ40 are much higher than 
those of Aβ42 [54], the former does not form aggregates compared to the latter 
[57]. According to the amyloid hypothesis theory [58, 78], formation of senile 
plaques in the brain is the main cause of AD pathology [92]. Dysregulation of Aβ 
metabolism results in the deposition of neurotoxic Aβ plaques that eventually 
trigger a range of processes leading to neurodegeneration [58, 74, 78]. However, 
more recent studies have disproved this model and have revealed that plaque 
formation occurs way after the manifestation of the disease [54]. 
Different forms of Aβ exist [54], ranging from soluble species (monomers, 
oligomers, protofibrils, Aβ-derived diffusible ligand ADDLs) [79, 93-98] to 
insoluble fibrils. Studies have shown that fibril formation and amyloid deposition 
is not a prerequisite for microglia activation [19, 23, 56, 99, 100]. Contrary to 
reports that implicate fibrils as the toxic species [78, 101, 102], newer studies 
support the “oligomer hypothesis” [64, 103] which implicates soluble Aβ species 
such as oligomers [97, 104-109], protofibrils [19, 23, 100], and ADDLs [98] as the 
most deleterious. Thus, it has been proposed that a “halo” of soluble Aβ species 
surrounding the plaques causes the toxicity in the brain.  
Many in vitro cell stimulation studies with Aβ resulted in the secretion of 
inflammatory cytokines such as tumor necrosis factor α (TNFα) and IL-1β [56, 
110-112]. Our lab has been extremely thorough in characterizing the various 
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forms of Aβ [100, 113]. Using size-exclusion chromatography (SEC), we can 
isolate pure monomers and protofibrils (PF). Pre-fibrillar forms of Aβ were found 
to induce TNFα production in THP1 cells [114]. Later experiments would identify 
PF as the most toxic species compared to both monomers and fibrils [19, 100]. 
Cell-uptake experiments conducted with primary murine microglia cells indicated 
that the cells preferentially take up PF compared to monomers [22]. Similarly, a 
previous study had reported that primary microglia cells internalized soluble and 
fibrillar Aβ differently. However, the cells only partially degraded both forms of Aβ 
and released most of the protein still intact thus promoting accumulation of 
aggregated protein [87]. All these findings clearly show the varying toxicity of Aβ-
42 species and their involvement in the inflammatory response processes 
facilitated by immune cells. 
 
1.3. Neuroinflammation and AD 
Neuroinflammation is characteristic of AD pathology [28, 51-53]. Data has 
shown that both soluble and insoluble Aβ species are neurotoxic and are 
involved in activating the NLRP3 inflammasome [19, 23, 37, 53, 56, 100, 115]. 
Heneka and colleagues showed cross-seeding between microglia-derived ASC 
specks and Aβ monomers thus promoting aggregation of the latter [2]. In 
addition, they showed that Aβ-ASC composites augment NLRP3 inflammasome 
activity and subsequent cell death [116]. Aβ deposits/ senile plaques in the brains 
of AD patients cause continuous activation of microglia [49]. Ultimately, this 
results in the prolonged release of inflammatory cytokines, IL-1β and TNFα, 
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leading to a chronic inflammatory state, neuronal loss, and ultimately dementia 
[57]. Overproduction of IL-1β, due to dysregulation of the innate immune system, 
is the main cause of inflammation [49, 89]. 
Various reports have implicated the NLRP3 inflammasome in AD-related 
neuroinflammation [37, 49, 51, 53, 56, 115, 117]. Elevated amounts of IL-1β were 
found in AD brains [118]. A later study also reported the discovery of elevated IL-
1β and IL-6 in the cerebrospinal fluid of Alzheimer’s patients [117]. Stimulation of 
primary mouse and immortalized microglia with Aβ fibrils (coupled with LPS 
priming) also resulted in lysosomal damage and the release of mature IL-1β. 
Control experiments with NLRP3/ ASC-deficient macrophages failed to activate 
IL-1β maturation [37].  
In other studies, in vivo multiphoton imaging technique was used to study 
APPswe/PS1d9xYFP (B6C3-YFP) transgenic mice bearing mutations associated 
with early-onset AD. These AD-model experiments were conducted to show the 
effect of plaque deposition on microglial activation. They discovered that 
microglia surrounded the areas of plaque formation and morphological changes 
were detected in the neurites surrounding the plaques [119]. These findings were 
in agreement with the amyloid hypothesis theory [64]. Moore and colleagues 
showed the involvement of the CD36 receptor in facilitating uptake of soluble Aβ 
species by macrophages resulting in NLRP3 activation [115]. Further studies by 
Heneka and colleagues showed increased caspase-1 activation in brains of mild 
cognitive impairment (MCI) and AD patients [53]. In vitro studies conducted by 
the Nichols group [23] and others [56, 116] confirmed the secretion of IL-1β by 
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Aβ-stimulated microglia. Fig 1.4 summarizes the studies by the Nichols group 




A.                                       B. 





The involvement of the NLRP3 inflammasome in this inflammatory 
response ignited our interest hence we decided to get a better understanding of 
this inflammatory complex. Recent reviews explain in depth the roles of Aβ and 
microglia in neuroinflammatory processes and subsequent neurodegeneration 
[28, 120]. It is important to note that apart from Aβ, tau protein and other 
amyloidogenic proteins also activate the NLRP3 inflammasome via similar 
mechanisms [76, 97]. 
 
Fig 1.4 summarizes findings from 3 previous publications from the Nichols lab. Aβ PF were 
identified as the most toxic species [19]. In addition, primary murine microglia were found to 
internalize PF more than monomers [22]. Panel A. Size-exclusion chromatography (SEC) 
elution profiles of Aβ-42 purification in aCSF buffer on a Superdex 75 column. Protofibrils 
and monomers elute in two distinct peaks. Panel B. Data from ELISA experiments shows 
that TNFα and IL-1β mRNA production (left and right panel respectively) is reduced in the 
MyD88−/− microglia in response to Aβ PF stimulation Panel C. Schematic shows the 
involvement of TLRs in Aβ PF uptake. Experiments with MyD88 knockout mice confirmed 
the involvement of this cytosolic adaptor protein in the TLR pathway. Thus, the findings 




1.4. Structure and assembly of the NLRP3 inflammasome 
The nucleotide-binding oligomerization domain-, leucine-rich repeat- and 
pyrin domain (PYD)-containing 3 (NLRP3) inflammasome also known as 
cryopyrin/ NALP3 is a cytoplasmic receptor which is normally expressed in 
immune cells (predominantly in the microglia) [28]. NLRP3, a member of the NLR 
family, is the most characterized inflammasome to date [44, 45, 121, 122]. This 
protein complex is made up of three proteins namely NLRP3 (sensor protein), 
ASC (an adaptor protein also known as PYCARD), and the cysteine protease 
caspase-1 as shown in Fig 1.5. NLRP3 binds with ASC via homotypic PYD-PYD 










Various studies have identified NLRP3 as a vital component of the 
inflammasome complex. In addition, NLRP3 oligomerization is a key process in 
the inflammasome assembly process [39, 121, 123]. The NACHT domain of 
NLRP3 (protein) is common to all NLR members and it oligomerizes in the 
presence of ATP thus promoting activation of the protein complex [18, 31, 36, 40, 
47]. Ting and co-workers showed that cryopyrin (NLRP3) exhibited ATPase 
activity and co-immunoprecipitation studies verified that it interacted with ASC 
only in the presence of ATP. Further studies revealed that the Walker A motif 
(located in the NACHT domain) is responsible for ATP binding. Mutation of the 
critical residues in this region abolished interactions with ATP [124]. On the other 
hand, the leucine-rich region (LRR) senses PAMPs and DAMPs and is involved 
in autoregulation of the inflammasome [125, 126]. However, Jerala and 
colleagues provided evidence disputing the previous claims regarding the 
functions of the LRR. Truncated NLRP3 proteins lacking the LRR were 
Fig 1.5 The NLRP3 inflammasome complex is made up of NLRP3 (senses stimuli via the 
leucine-rich region LRR), ASC (adaptor protein), and caspase-1 (effector protein) which is 
a cysteine protease. The domains making up each individual protein are highlighted. The 
dashed lines show the homotypic interactions, facilitated by hydrophobic and charged 
residues, that keep the three proteins together. In the presence of stimuli, the NLRP3 
inflammasome assembles resulting in the activation of caspase-1 which subsequently 
cleaves proIL-1β to mature IL-1β. *The actual stoichiometric components of each 
individual protein in the complex are still unknown.  
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responsive to stimuli in a manner similar to that of the full-length NLRP3. Thus, 
the group proposed that the PYD may have some autoinhibitory effect and keeps 
the inflammasome inactive in the absence of stimuli [127].  
Studies identified ASC as an inflammasome adaptor protein [128, 129]. 
Gumucio and colleagues reported direct interactions between pyrin and ASC 
[125]. Dowds et al showed that cryopyrin (NLRP3) co-immunoprecipitated with 
ASC. In addition, siRNAs targeting endogenous ASC prevented IL-1β secretion 
thus indicating the importance of ASC in inflammasome assembly [130]. Thus, 
the three proteins that constitute the NLRP3 inflammasome all play vital roles in 
the assembly of the protein complex. Upon sensing danger signals, NLRP3 
inflammasome proteins assemble to form a caspase-1-activating facilitating 
platform resulting in IL-1β maturation and cytokine release coupled with 
pyroptosis. 
 
1.5. Structural studies of the NLRP3 inflammasome proteins 
Many studies have been conducted on the pyrin domains of both NLRP3 
and ASC and are summarized in a report compiled by Stehlik and colleagues 
[131]. ASC2, a pyrin-only protein (POP) was used as a model to study the pyrin 
domain. Nuclear magnetic resonance (NMR) studies on recombinant ASC2 
conducted by Hill and colleagues showed six parallel helices, characteristic of the 
death-domain (DD) proteins. Sequence alignment of ASC2 showed some degree 
of similarity with the pyrin domains of ASC and NALP1 (NLRP1), particularly the 
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presence of conserved hydrophobic residues [132]. Do and Park performed 
crystallization studies using recombinantly-expressed POP1 at 3.6 Å [133]. 
Although many studies have been done to determine the significance of 
the residues in the PYD domains of both NLRP3 and ASC [4, 5, 134, 135], very 
few studies have been done on the CARD domain. Using multiple point 
mutations to study the pyrin domain of ASC, various groups discovered the role 
of charged & hydrophobic residues in facilitating oligomerization [5, 134, 136]. 
Sagara and co-workers discovered that these mutations abolished the formation 
of ASC filaments. In addition, C-terminal deletion experiments showed that a 
fragment containing a minimum of 90 amino acids was necessary for filament 
formation [134]. Two binding surfaces on ASC PYD were found to be involved in 
its self-association and interactions with NLRP3 PYD [5, 135, 136]. Interestingly, 
ASC PYD self-association binding affinities were found to be much stronger than 
those with NLRP3 PYD [135]. 
On the other hand, there is quite a few biophysical studies that have been 
conducted with some domains of the inflammasome proteins. Initial NMR studies 
on ASC PYD were done by Otting and co-workers [137]. The de Alba group also 
conducted some ASC structural studies. In their earlier NMR studies with full-
length human ASC expressed in E.coli, they were able to determine the residues 
involved in the CARD domain interactions [138]. In later studies they utilized 
atomic force microscopy (AFM), NMR relaxation techniques, and circular 
dichroism (CD) to determine ASC structure and solubility at neutral and acidic pH 
(4.0). Their data revealed that ASC is made up of two independent 6-helix 
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bundles separated by a flexible linker as shown in Fig 1.6. In addition, the 
structure was not perturbed by changes in pH. The size of ASC oligomers 
remained unchanged at both pH conditions [17]. The protein was more soluble 
under acidic conditions as physiological pH promoted oligomerization and 
filament formation [17]. Studies by another group also revealed the CARD 






Figure 1.6 Structure of ASC. A ribbon structure of full-length ASC based on the solution 
structure solved by de Alba and colleagues. It shows the pyrin and CARD domains as 




Wu and colleagues utilized cryogenic electron microscopy (cryo-EM) to 
study ASC PYD filaments at near atomic resolution for the first time and their 
data confirmed the importance of opposite surface charges in the formation of 
filaments. They also showed that both PYD and CARD domains are involved in 
filament formation [140, 141]. Cryo-EM and solid-state NMR structural studies 
conducted by Hiller and colleagues using mouse ASC suggested the PYD 
facilitated filament formation while the flexible CARD domain remained exposed 
outside the filament [4]. Physiological pH conditions were found to promote 
formation of ASC filaments just like the previous findings by de Alba and 
colleagues [17]. 
By modeling the ASC-CARD dimer, de Alba and co-workers used a 7-
member ring model for ASC oligomerization [142]. Further analysis of the 
individual PYD and CARD domains by TEM indicated that the two domains 
formed structurally distinct filaments. Moreover, full-length ASC filaments were 
noticeably different from those formed by ASC PYD only. Contrary to the 
previous cryo-EM reports that only the PYD is involved in the formation of ASC 
filaments [4], TEM and NMR studies by the de Alba group showed that CARD-
CARD interactions are also essential in filament formation [143]. Fluorescence 
studies revealed that both PYD and CARD domains were essential in ASC foci 
formation during inflammasome assembly [144]. Single molecule fluorescence 
resonance energy transfer (FRET) experiments would also prove that the two 
domains were in very close proximity during oligomerization [145]. These findings 
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reveal that ASC CARD is not only involved in the recruitment of caspase-1 but 
also participates in ASC filament formation with PYD. It is important to also note 
that the filament formation experiments were mostly conducted under non-
physiological conditions and may not reflect the actual cellular processes. 
Nonetheless, all these findings emphasize the importance oligomerization during 
inflammasome assembly and the directionality of domain-domain interactions.  
In other studies, Bae and Park reported the crystal structure of NLRP3 
PYD at 1.7Å resolution. Just like the ASC PYD, the surface of the NLRP3 PYD is 
made up of charged and hydrophobic residues that are crucial in promoting self-
dimerization [146]. Thus, these various structural studies provided a better insight 
on the key residues and interactions involved in keeping the inflammasome 
complex intact. 
 
1.6. ASC speck formation 
ASC-dependent inflammasomes undergo nucleation-dependent 
polymerization. Many groups have studied ASC oligomerization during 
inflammasome activation and assembly. ASC has been described as a 
“molecular glue” which brings the inflammasome proteins together. When 
overexpressed separately, the PYD and CARD domains of ASC formed filaments 
[128]. Structural studies have shown that after activation, the inflammasome 
proteins oligomerize and recruit ASC which forms fiber-like structures that 
ultimately assemble into large particles known as “specks”. Numerous reports on 
ASC speck formation have been published [3, 141, 147-151]. 
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Initial studies by Alnemri and colleagues reported that ASC dimers were 
involved in speck formation ultimately resulting in the formation of a 
supramolecular complex termed “pyroptosome.” In addition, they revealed that 
only the pyrin domains of ASC were involved in the assembly while the CARD 
domains participated in the recruitment of caspase-1 [147]. The notion that ASC 
dimers are the basis of filament formation was further investigated by Egelman 
and colleagues [141]. Later studies would prove the involvement of the CARD 
domain during the formation of the inflammasome complex [143, 144]. The 
kinetics involved in speck formation were studied by Gumucio and co-workers. 
Confocal laser scanning microscopy time-lapse studies conducted using ASC-
YFP (yellow fluorescent protein)-transfected HeLa cells revealed ASC 
aggregation to be an extremely fast process i.e at 20 µM, the collision rate of two 
ASC dimers is 6x1011 sec-1 per cell. Diffusion was the main process involved in 
speck formation. The specks formed in both cytoplasmic and nuclear 
compartments. Moreover, the rate of depletion of ASC from the cytoplasm was 
found to be constant. The authors proposed a two-step process for speck 
formation involving rapid diffusion of ASC dimers followed by their (dimers) 
binding to the growing speck [148]. Follow-up experiments by Sester and 
colleagues later would utilize a flow cytometry-based assay to assess 
inflammasome assembly [152].  
Using recombinantly-expressed proteins, Wu and colleagues showed that 
the pyrin domain of NLRP3 is required for polymerization with ASC-PYD. While 
NLRP3-PYD alone did not induce ASC-PYD polymerization, addition of the 
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nucleotide binding domain NBD (NLRP3-PYD-NBD) resulted in nucleation of 
ASC filaments. Fluorescence polarization assays were done to assess ASC-PYD 
filament formation. Cryo-EM studies of ASC-PYD filament at near atomic 
resolution also revealed the role of opposing charges in filament assembly [141]. 
The same group also performed studies with the absent-in-melanoma 2 (AIM2) 
inflammasome. The studies revealed that ASC-dependent inflammasomes (both 
NLRP3 and AIM2) assemble via a unified mechanism involving nucleation-
induced polymerization [140, 141].  
Recombinant ASC-PYD was shown to form fibers that facilitated prion-like 
polymerization by converting inactive ASC into an active prion form. However, 
mutations of charged and hydrophobic residues (R41A, D48A, and P40A) 
resulted in the loss of prion-forming capabilities [149]. In vitro and in vivo studies 
by Latz and co-workers also illustrated the prion-like nature of ASC [150]. 
Pelegrin and colleagues suggested that the extracellular NLRP3 
inflammasome exists as oligomeric particles. Their immunoblot analysis indicated 
the release of inflammasome components when mouse bone-marrow derived 
macrophages (BMDMs) were stimulated with LPS/ Nigericin. Co-
immunoprecipitation assays showed interactions between extracellular ASC and 
NLRP3. Time-lapse confocal microscopy with mCherry-tagged ASC and cross-
linking experiments with succinimidyl-ester diazirine reagent (SDA) showed 
formation of ASC specks and oligomers respectively [153]. Another group 
showed that mutating the key charged residues in the binding surfaces prevented 
speck formation [154]. Broz and colleagues also studied ASC speck assembly 
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and discovered that the pyrin domain facilitated assembly into helical filaments 
while the CARD was involved in cross-linking these filaments. Mutating key 
residues in the CARD domain not only blocked CARD/CARD homotypic 
interactions, but also resulted in larger and less dense specks. These specks did 
not promote caspase-1 activation, release of IL-1β or pyroptosis [3]. 
In conclusion, the formation of ASC specks is a tightly controlled, very 
rapid, all-or-none process. Initial aggregation of ASC is slow, but nucleation 
speeds up the process thus promoting speck formation. Detailed reviews have 
described ASC speck formation as well as the intra- and -extracellular functions 
of ASC specks [155, 156]. A recent review by de Alba also explored structure, 
interactions, and dynamics of ASC to a greater depth [157]. 
 
1.7. Activation of the inflammasome 
The NLRP3 inflammasome is very distinct from other inflammasomes 
because it is activated by a wide variety of ligands such as pathogens, 
environmental irritants or endogenous danger particles released during tissue 
injury or cell stress [25, 26, 29, 45, 122, 158]. Activation of the NLRP3 








Figure 1.7 Activation of the NLRP3 inflammasome. The figure shows the two-signal mode 
of activating the NLRP3 inflammasome as proposed by Liu and colleagues [18]. The 
priming step which involves the TLR signaling pathways is triggered by DAMPs and 
PAMPs. The transcription factor Nf-κB facilitates synthesis of pro-IL-1β and optimal NLRP3. 
The activation step is initiated by NLRP3 activators such as ATP and involves three 
pathways; potassium efflux, generation of reactive oxygen species (ROS), or 
phalysosomal rupture. Activation promotes assembly of the inflammasome complex 
which activates caspase-1 and ultimately, IL-1β secretion. 
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The initial step termed “priming” or Signal 1 is induced by toll-like receptor 
(TLR) ligands such as bacterial LPS. Basal levels of NLRP3 proteins are very low 
and are only upregulated in the event of stimuli. The priming step involves 
myeloid differentiation primary response 88 (MyD88) signaling [23] and LPS-
induced protein synthesis of NLRP3 transcripts via the transcription factor Nf-κB. 
This results in the assembly of the caspase-1 processing machinery i.e. 
expression of pro-IL-1β and optimal NLRP3 [159]. It has been suggested that 
NLRP3 is produced in an autoinhibited form that is released in the presence of 
NLRP3 activators [28]. The activation step or Signal 2 involves NLRP3 activators 
such as ATP and thus leads to activation of caspase-1 and ultimately, production 
of mature IL-1β. 
Common NLRP3 activators include Aβ, uric acid crystals, ATP, silica, 
asbestos, aluminum salts, and hyaluronan [37, 53, 123, 160-164]. Silica and 
asbestos stimulate production of reactive oxygen species (ROS) while crystalline 
and particulate ligands (alum, silica) result in membrane destabilization [160, 
161]. Studies showed that uptake of soluble Aβ species such as oligomers and 
protofibrils (PF) [23, 56] and insoluble fibrillar Aβ [2, 37, 53, 116, 158] by 
microglia results in NLR3 inflammasome activation. 
Though structurally diverse, inflammasome activators somehow share a 
common mechanism of activation. Despite numerous studies that have been 
conducted on the NLRP3 inflammasome, it is still quite unclear whether NLRP3 
directly binds to any of its activators. Various mechanisms have been proposed 
regarding to NLRP3 activation. One such mechanism proposes a possible direct 
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interaction between the activating molecules and the LRR domain of NLRP3 after 
entering the cell. Another possible scenario is the modification of membrane 
proteins by the activators thus triggering a particular signaling cascade. 
Nonetheless, various reports have suggested that activation of the NLRP3 
inflammasome occurs via three distinct mechanisms: potassium efflux; the 
generation of mitochondria-derived reactive oxygen species (ROS); and 
phagolysosomal destabilization [29, 30, 35, 42, 45-47, 165]. 
Potassium (K+) efflux acts upstream of NLRP3 inflammasome activation. 
Almost all NLRP3 activators, especially pore-forming bacterial toxins and ATP, 
induce potassium efflux via P2X7, an ATP-gated cation channel ([42, 47, 166]. 
Dubyak and colleagues showed that activation of caspase-1 by the P2X7 
receptor (P2X7R) was dependent on TLR signaling and Nf-κB-facilitated protein 
synthesis. Their studies showed that LPS/ ATP stimulation facilitated caspase-1 
activation and subsequent secretion of mature IL-1β. Although they identified 
LPS priming as an important prerequisite step in the activation of the 
inflammasome by P2X7R, this step alone was not sufficient in activating the 
receptor hence further stimulation by ATP was required. Nigericin (an ionophore 
and P2X7R mimic) was also found to induce K+ efflux after LPS priming [163].  
Interestingly, K+ efflux regulates Ca2+ signaling to some extend (via 
promoting Ca2+ influx) [167-169]. Extracellular Ca2+ stimulates G protein-coupled 
calcium sensing receptors (GPCRs) such as GPCR6A [168] and CASR [167]. 
Subsequently, the inflammasome is activated upon sensing increased 
intracellular Ca2+ levels [167, 168] coupled with a decrease in cellular cyclic 
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adenosine monophosphate (cAMP) levels. Interestingly, binding of cAMP to the 
NBD region of NLRP3 prevents inflammasome activation [167].  
Many studies have proposed that crystalline/ particulate particles such as 
monosodium urate (MSU) crystals, silica, and asbestos are taken up by cells via 
endocytosis (phagocytosis) subsequently inducing ROS production and 
inflammasome activation [160, 161, 170]. Studies by Tschopp and colleagues 
[160, 170] showed that MSU, silica and asbestos stimulated the secretion of 
mature IL-1β by THP-1 cells and human monocyte-derived macrophages. 
Treating the cells with cytochalasin D and latrunculin A (which inhibit actin 
polymerization) prevented mature IL-1β secretion upon stimulation with asbestos 
and MSU. However, stimulation with nigericin was not affected. Knockdown of 
p22phox, the common NADPH oxidase subunit, and the use of ROS inhibitors 
such as N-acetyl-L-cysteine (NAC) and (2R,4R)-4aminopyrrolidine-2,4-
dicarboxylate (APDC) severely diminished IL-1β production upon cell stimulation 
[160]. 
Studies by Latz and colleagues demonstrated that pretreatment of human 
peripheral blood mononuclear cell (PBMCs) with cytochalasin D before 
stimulation with silica and MSU impaired IL-1β production. As shown previously 
by Tschopp et al, stimulation by non-crystalline activators (ATP and R848) was 
not affected by cytochalasin D [161]. 
Hyaluronan (HA), a glycosaminoglycan released from the extracellular 
matrix after tissue injury, acts as an endogenous signal for inflammasome 
activation. HA stimulation of peritoneal macrophages showed dose-dependent 
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release of mature IL-1β which was diminished upon digestion of HA with 
hyaluronidase or chondroitinase [164]. 
On the other hand, some studies have proposed that the fluctuations in 
the levels of other ions (Na+ influx, Cl- efflux) affect the cell membrane potential 
and overall cell volume resulting in inflammasome activation [171]. Cell swelling 
and regulatory volume decrease (RVD) processes maintain the overall cellular 
homeostasis and any changes are sensed by the inflammasome [172]. Pelegrin 
and co-workers emphasized that although K+ efflux played a vital part in 
activating the inflammasome, that alone was not sufficient. They proposed the 
interplay between cell volume and K+/ Cl- efflux and a possible common 
mechanism utilized by all inflammasome activators [171]. Prior studies showed 
that high amounts of extracellular chloride were found to have a negative effect 
on the secretion of IL-1β [173]. Other groups later mentioned Cl- efflux via 
chloride intracellular channel (CLIC) proteins as a crucial pathway in the 
activation of the inflammasome [174-176]. Moreover, they discovered that Cl- 
efflux promotes the interaction between NLRP3 and NIMA-related kinase-7 
(NEK7) which promotes NLRP3 oligomerization and subsequent formation of 
ASC specks [175]. Thus, the authors proposed Cl- efflux as an additional priming 
step during inflammasome activation in addition to K+ efflux [176].  
In sum, all these studies show the versatility of the NLRP3 inflammasome 
and its particulate nature. However, there is no single unifying event to describe 
inflammasome activation. A plethora of diverse ligands activate this protein 
complex and perhaps these particles perhaps trigger a similar downstream 
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pathway that is sensed by the NLRP3 inflammasome. However, it is still quite 
unknown whether there is any direct binding between these activators and 
NLRP3. 
 
1.8. Regulation of the NLRP3 inflammasome 
Various mechanistic pathways are involved in the regulation of the NLRP3 
inflammasome activity as reviewed here [35, 47, 122]. These include post-
translational modifications (PTMs) (with phosphorylation and ubiquitination being 
the common ones), chemical and small molecule inhibitors as well as NLRP3 
interacting partners. As reviewed by Lamkanfi and Dixit, bacterial factors and 
viral particles also modulate inflammasome activity and function(s) e.g. inhibition 
of caspase-1 activity by orthopoxvirus-encoded serpins [26]. Many kinases have 
been implicated in the activation of the NLRP3 inflammasome and they include 
protein kinase C (PKC) [177], c-Jun N-terminal kinase (JNK), spleen tyrosine 
kinase (Syk) [178-182], interleukin-1 receptor-associated kinase1 (IRAK-1) [183], 
Bruton’s tyrosine kinase (BTK) [184], and proline-rich tyrosine kinase (Pyk2) 
[185]. 
1.8.1. Protein kinases A, C, D (PKA, PKC, PKD) 
Post-translational modifications (PTMs) play a vital role in inflammasome 
regulation with phosphorylation being one common feature. PKA phosphorylates 
Ser 291 (human Ser 295) in the NACHT domain of NLRP3 thus favoring 
ubiquitination and subsequent degradation of the protein ([186-188]. 
Phosphorylation of the same residue by PKD however promotes inflammasome 
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activation [189]. Phosphorylation of Ser 533 of NLRC4 by PKC resulted in 
activation of the inflammasome whilst immuno-depletion of the kinase from cell 
lysates and the use of rottlerin, a well-known PKC inhibitor, significantly inhibited 
phosphorylation of the residue and ultimately caspase-1 activation [177].  
1.8.2. Syk kinase and JNK signaling 
Phosphorylation of NLRP3 (Ser 194) by JNK during priming positively 
regulates inflammasome activation [190]. Syk, a non-receptor tyrosine kinase 
normally expressed in immune cells, also plays vital roles in the processes that 
govern inflammasome activation [191]. A Syk-Card9-controlled signaling pathway 
(Card9 being the downstream protein) was implicated in the proinflammatory 
response by murine bone-marrow-derived macrophages (BMDMs) stimulated 
with fungi (C. albicans) [178]. Mitsuyama and co-workers provided evidence on 
the role of the Syk-JNK signaling pathway (independent of Card9) in the 
phosphorylation of mASC Tyr 144 (Tyr 146 in humans) located in the CARD 
domain. They revealed that phosphorylation of ASC promotes its oligomerization 
and subsequently, activation of caspase-1. Although phosphorylation of ASC is 
vital, that alone is insufficient to induce speck formation in the absence of stimuli 
[180]. Mutating the critical residues, deletion of both Syk and Card9 genes, and 
pre-treatment of cells with Syk inhibitor (R406) all prevented caspase-1 activation 
and IL-1β secretion upon stimulation [178, 180]. Interestingly though, Syk 
inhibition and deletion did not affect caspase-1 activation and IL-1β maturation 
when cells were stimulated by LPS/ ATP/ Nigericin thus suggesting that 
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inflammasome activation by these ligands utilizes a Syk-independent pathway 
[178].  
Lin and colleagues showed that the kinase domain of Syk directly binds to 
both ASC and NLRP3 [182]. In contrast to previous studies suggesting that 
stimulation by  ATP/nigericin/alum/MSU utilizes a Syk-independent pathway 
[178], employing Syk inhibitors (SykI and BAY61-3606) resulted in decreased 
amounts of secreted IL-1β by stimulated macrophages [182]. These 
discrepancies could be attributed to the different inhibitors used or the origin of 
the cells used in the experiments i.e BMDMs [178] vs murine primary liver fetal 
macrophages [182]. Nunez and colleagues showed that 3,4-methylenedioxy-β-
nitrostyrene (MNS), a well-known kinase inhibitor, interacts directly with the NOD 
and LRR domains of NLRP3 thus blocking its ATPase activity [181]. Meanwhile, 
studies by Latz and co-workers revealed that phosphorylation of Ser5 (located in 
the pyrin domain) negatively regulates inflammasome assembly [192]. 
Dephosphorylation by phosphatase 2A (PP2A) [192] and protein tyrosine 
phosphatase non-receptor 22 (PTPN22) [193] reversed the process. 
All these findings indicate the importance of phosphorylation in the 
regulation of the inflammasome. In addition, Syk kinase is activated by various 
stimuli and depending on the stimuli, takes on various mechanistic pathways. 
Another important aspect highlighted is how the cell type used when conducting 




1.8.3. Bruton’s tyrosine kinase (BTK) 
BTK is a member of the Tec family of tyrosine kinases (TK) that are 
structurally related to the Syk kinase. The kinase directly interacts with both 
NLRP3 and ASC ultimately facilitating oligomerization of ASC. Studies by Morita 
and co-workers revealed that BTK inhibitors abolished inflammasome activation 
in stimulated cells resulting in reduced ASC oligomerization and smaller specks. 
Additional in vivo experiments proved that ibrutinib (BTK inhibitor) had some 
neuroprotective effects in mice models of ischemic brain injury [184]. Other 
studies emphasized the role of BTK and tubulin polymerization during 
inflammasome activation [194-196]. Shuttling of NLRP3 to the microtubule-
organizing center (MTOC) is an essential step in the inflammasome assembly 
and activation process [195].  
1.8.4. Interleukin-1 receptor-associated kinase1 (IRAK-1) 
IRAK-1 is a TLR signaling molecule that activates the NLRP3 
inflammasome during simultaneous stimulation of TLR (by LPS) and NLRP3 (by 
ATP). Upon stimulation, IRAK-1 interacts with ASC but the authors were not able 
to determine its exact involvement in the activation process [183]. 
1.8.5. IκB kinase alpha (IKKα) 
IKKα facilitates NF-κB signaling and mediates the expression of genes 
involved in immune responses [197]. The kinase is found in both the cytoplasm 
and the nucleus and its translocation to the nucleus occurs upon stimulation (by 
activators such as TNFα) resulting in NF-κB-mediated gene transcription [198]. 
Martin and colleagues showed that under normal conditions, interactions 
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between IKKα and ASC prevent inflammasome activation. However, in the 
presence of stimuli, Signal 2 prompts the recruitment of a phosphatase which 
has an inhibitory effect on the kinase hence allowing free ASC to participate in 
inflammasome assembly [199]. Loss of IKK kinase activity results in elevated 
inflammasome activity [200-202]. 
1.8.6. Ubiquitination 
Ubiquitination by ubiquitin ligases has emerged as one of the many 
significant mechanisms involved in immune regulation [35, 203, 204]. Although 
ubiquitination generally inhibits activation of the NLRP3 inflammasome, 
ubiquitination by the ligases Pellino2 (targets NLRP3) or linear ubiquitin chain 
assembly complex (LUBAC, targets ASC) activates the inflammasome [35].  
NLRP3 is activated via deubiquitination during both TLR-priming and ATP-
activation. Deubiquitination by deubiquitinating enzymes (DUBs) activates the 
inflammasome [205]. However, A20 (a DUB located in the cytoplasm) negatively 
regulates the inflammasome by inhibiting NF- κB [206, 207]. Yuan and 
colleagues identified BRCC3, a DUB which positively regulates the NLRP3 
inflammasome by deubiquitinating the LRR region of NRP3 prior to assembly. 
Inhibition of BRCC3 by an isopeptidase suppresses inflammasome activation 
[208]. Just like BRCC3, ubiquitin-specific peptidase 50 (USP50) positively 
regulates NLRP3 activation by targeting Lys 63 of ASC thus promoting ASC 
oligomerization and speck formation [209]. Other DUBs, USP7 and USP47, also 
modulate NF-κB activity and their blockage by inhibitors suppresses 
inflammasome activation [210]. Thus, DUB inhibitors are potential therapeutic 
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agents for inflammatory disorders. A review by Moretti and Blander 2020 
explores in depth the various deubiquitination mechanisms involved in 
inflammasome regulation [35]. 
1.8.7. Sumoylation 
Protein modification via sumoylation is a vital regulatory process and at 
present three small ubiquitin-like modifier (SUMO) proteins have been identified 
in mammals [211]. Sumoylation of NLRP3 at multiple lysine residues by SUMO 
E-3 ligase (localized in the mitochondria) negatively regulates the NLRP3 
inflammasome. Loss of sumoylation occurs upon stimulation with NLR-ligands 
(Signal 2) thus SUMO proteases activate the inflammasome [212]. Interactions 
between NLRP3 and UBC9, a SUMO-conjugating enzyme, allow SUMO1 to 
modify NLRP3 at Lys 204. This promotes inflammasome activation, 
oligomerization of ASC, and ultimately maturation of IL-1β. Meanwhile, 
deSUMOylases such as SUMO-specific protease 3 (SENP3) reverse these 
processes and seven mammalian SENPs have been identified to date [213].   
1.8.8. NIMA-related kinase 7 (NEK7) 
NEK7 belongs to the family of mammalian NIMA (never in mitosis gene a)-
related kinases and is involved in the progression of the cell cycle by facilitating 
mitotic spindle formation [194, 214]. It is a multifunctional serine-threonine 
(Ser/Thr) kinase which acts downstream of K+ efflux and directly activates the 
NLRP3 inflammasome by regulating expression of genes involved in NLRP3 
signaling [215, 216]. According to recent studies, expression levels of both NEK7 
and NLRP3 showed a positive correlation [215] and interactions between the two 
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proteins have been reported. In the presence of stimuli, NEK7 binds to the LRR 
and NACHT of NLRP3 and in doing so induces oligomerization of the latter [214, 
217, 218]. NLRP3 inhibitors MCC950 [219] and oridonin [220] inhibit interactions 
between NEK7 and NLRP3. Hence, NEK7 has emerged as a plausible 
therapeutic target for NLRP3-related disorders [194, 216].  
1.8.9. NOD-like receptor family CARD domain containing proteins 
(NLRC) 
NLRC proteins have been known to have an inhibitory effect on 
inflammasome activation. NLRC5 [221] and NLRC3 [222-225] interact with both 
ASC and caspase-1 thus disrupting the interactions between the two 
inflammasome proteins and preventing ASC speck formation. The presence of 
NLRC3 was found to prohibit inflammasome assembly and ultimately causing a 
decline in the amounts of secreted IL-1β [225]. 
1.8.10. Heat shock proteins 
Heat shock proteins (Hsp) also play vital roles in inflammasome 
regulation. Hsp90 is a chaperone that confers a protective effect to NLRP3 while 
in its inactive state [226]. Previous studies showed that Hsp90 works with a co-
chaperone protein, suppressor of the G2 allele of Skp1 (SGT1), which is normally 
associated with ubiquitin ligase [227]. Binding of Hsp90 to NLRP3 prevents 
degradation of the latter. After priming, Hsp90 is released thus allowing NLRP3 
to participate in inflammasome assembly [226]. In contrast, Hsp70 negatively 
regulates the inflammasome by binding to NLRP3. However, the interactions are 
disrupted upon stimulation with NLRP3 activators [228]. 
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1.8.11. NLRP3 inflammasome inhibitors  
Chemical inhibitors and isolated domains of inflammasome proteins also 
regulate inflammasome assembly as reviewed here [25]. Pyrin-only proteins such 
as POP1/ ASC2 not only bind to ASC but also inhibit the kinase activity of IKKs 
thus preventing subsequent NF-κB activation [229]. Likewise, POP2 negatively 
regulates the inflammasome by binding to ASC [230] while CARD-only proteins 
(COPs) such as INCA and ICEBERG pose the same effect when bound to 
caspase-1 [231]. One group designed stapled peptides that could inhibit NLRP3 
activation by interacting with the pyrin domain of ASC thus preventing formation 
of specks [232]. A similar strategy was employed by Hafner-Bratkovic and 
colleagues who designed various small peptide inhibitors with sequences 
identical to specific regions of NLRP3 inflammasome proteins [233]. On the other 
hand, synthetic chemical inhibitors such as Bay 11-7082 [234], MCC50 [219, 
235-237], CY-09 [238], IFN39 [239], and tranilast (TR) [240] have been reported. 
In addition, natural products such as oridonin [220], shikonin (a naphthoquinone) 
[241], parthenolide [234], and resveratrol [242] were also successful in 
suppressing inflammasome activation and assembly. Recent reviews discussed 
various NLRP3 inflammasome inhibitors and their modes of action [33, 243].  
All the above findings prove the versatility and diverse nature of the 
mechanistic pathways involved in inflammasome regulation. These controlled 
processes allow assembly of the inflammasome complex only in the presence of 
stimuli. More so, inflammasome regulation prevents its persistent stimulation that 
would result in a prolonged inflammatory state. It is also important to note that 
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certain signaling pathways are only triggered by specific ligands and may not be 
responsive to other activators. Although inflammasome regulators use somehow 
distinct pathways, they all regulate the immune response in a controlled manner.  
 
1.9. Caspase-1 
Caspase-1 belongs to the class I (inflammatory) caspases and is the first 
caspase that was discovered in mammals [6, 244]. It is known as the “effector” 
protein of the inflammasome complex [32, 33, 39] and a report mentioned that 
caspase-1 was released as part of a stable, high molecular weight (HMW) 
complex [245]. This cysteine protease facilitates the maturation of the pro forms 
of interleukins 18 (IL-18) and 1-beta (IL-1β). A recent publication, however, 
identified p62 (autophagy adaptor protein) as a potential caspase-1 substrate 
[246]. In their recent review, Julien and Wells describe the use of proteomics as a 
vital tool in identifying caspase-1 substrates [247]. The many roles of caspases 
(including caspase-1) are reviewed here [247-251]. The enzyme is released as 
an inactive zymogen and its recruitment to the inflammasome platform facilitates 
its activation via induced proximity dimerization leading to autoproteolysis [16, 
252-262]. Inhibitors block the dimerization process [263]. Although caspase-1 is 
required for IL-1β production, it is not necessarily required for pyroptosis [264].  
1.9.1. Initial characterization of caspase-1 
The enzyme was originally isolated in 1989 from stimulated THP1 cell 
lysates [265, 266] and human peripheral blood monocytes [266] and was later 
named interleukin-1β (IL-1β) converting enzyme (ICE) [6, 244]. Treatment of the 
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enzyme with iodoacetate and N-ethylmaleimide (reagents which modify 
cysteines) rendered the enzyme inactive hence they identified it as a cysteine 
protease. Interestingly though, the enzyme was not affected by E64, a well-
known inhibitor of cysteine proteases [265]. Similarly, isolation of the enzyme 
from cell lysates followed by purification, molecular cloning, and transfection 
yielded an active enzyme as confirmed by IL-1β cleavage [6, 244]. Both 
reversible aldehyde (Thornberry 1992) and irreversible ketone-based inhibitors 
[6, 267, 268] had a negative effect on the activity of the recombinant human 
enzyme.  
1.9.2. Caspase-1 structural studies 
Structural studies such as amino acid sequencing and mass spectrometry 
(MS) revealed the primary structure of the proenzyme. These early findings also 
provided information regarding the active site location and the folding of the full-
length protein [7, 8]. The released proenzyme termed p45 (~45 kD) undergoes 
autoproteolytic cleavage at three aspartic acid (D) residues to produce p20 (~20 
kD) and p10 (~10 kD) fragments [6] as shown in Fig 1.8A. Scheer and colleagues 
later revealed the sequential autoproteolytic cleavage of caspase-1 [14]. The 
active enzyme was identified as a heterodimer made up of p20 and p10 subunits 
[6]. The active site, composed of Cys 285 & His 237, was found in the p20 
subunit [7, 8, 269]. However, both the p10 and p20 were found to be essential in 
rendering the enzyme active [6, 269]. By employing protease digestion of 
peptides, a four-residue recognition sequence (Ac-YVAD-AMC) was identified as 
the minimal substrate for caspase-1. The caspase-1 nomenclature identifies the 
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cleavage site D as the P1 position as shown in Fig 1.8 B. The P1’ position 
(adjacent to the P1 position) favors a small, nonpolar residue [6, 270]. 
 
 
X-ray crystallization studies would later reveal the crystal structure of 
recombinant human caspase-1 bound to chloromethylketone [8], reversible 
aldehyde inhibitors [7], or malonate [11, 12]. The inhibitors occupied the S1 
position (an extremely basic region which binds to the side chain of aspartic acid) 
Fig 1.8 Structure of human caspase-1 Panel A. shows the three aspartic acid cleavage 
sites (D) and the active Cys 285 residue located in the p20 domain. The card domain 
linker (CDL) separates the CARD and the p20 subunit while the interdomain linker (IDL) 
separates the p20 and p10 domains. The prodomain is made up of the CARD, CDL, and 
IDL. Panel B. Typical caspase-1 substrate showing key recognition sites. P1 represents 
the cleavage site (D). The P1’ position favors a small, hydrophobic residue such as 
glycine (G) or alanine (A). Substitutions in the P2 and P2’ positions are much tolerable 
and have no significant effect on substrate specificity. 
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located in the active site thus enabling the enzyme to adopt an open-like 
conformation which favors substrate binding [11, 12]. These studies revealed the 
conformation of the active enzyme as a heterotetramer (p202p102) composed of 
symmetrical p20p10 dimers linked by hydrophobic interactions and hydrogen 
bonds [7, 8, 11] contrary to previous findings [6]. The outstanding questions 
regarding actual structure of the active caspase will be explored in detail in 
chapter 5. 
1.9.3. Caspase-1 functionalization assays 
Functionalization assays were conducted to study the mechanisms of 
caspase-1 autoproteolysis and to also determine the role of each caspase-1 
domain. Considering the prodomain of caspase-1 (initial 122 amino acids on the 
N terminus ~ 11 kDa and includes the CARD), previous findings reported its 
importance in keeping the pro-caspase-1 in an inactive state thus its removal 
would permit dimerization and subsequent enzyme activation [6, 271-273]. 
However, other studies would also prove the importance of the prodomain in 
stabilizing the enzyme by promoting dimerization and autoproteolysis thus its 
removal renders the enzyme inactive [21, 262, 274-278]. Interestingly, other 
groups completely disagreed with these notions and argued that the prodomain 
is dispensable and has little to no effect on caspase-1 activity [14, 279, 280]. 
Considering the complexity of the mechanisms governing caspase-1 activation, 




1.10. Aβ-NLRP3 inflammasome interactions  
Interactions between Aβ and the NLRP3 inflammasome have been an 
area of interest although it is still not quite clear how Aβ stimulates 
inflammasome activation. Either there is a direct interaction between Aβ and the 
inflammasome proteins (most likely NLRP3 the sensor protein) or perhaps 
another indirect pathway involving intermediate proteins and complex signaling 
pathways. Direct interactions between Aβ and ASC specks were reported by the 
Heneka group [2, 116, 158]. Using a cell-free assay, another group demonstrated 
the direct interactions between Aβ and NLRP3 [281]. These interactions are 
further explored in Chapter 6. 
 
1.11. Recombinant expression of inflammasome proteins from the literature 
1.11.1. NLRP3 and ASC proteins 
Many groups have utilized bacterial expression systems to express 
inflammasome proteins. These systems are ideal for producing large amounts 
protein in a short period of time. The downfall, however, is that bacterial 
expression systems do not offer desirable post translational modifications (PTMs) 
(such as methylation, phosphorylation, ubiquitination, acetylation, glycosylation 
among others) that are critical for the overall functioning of the proteins. With this 
in mind, we opted to use the ExpiCHO-S mammalian recombinant expression 
system. It is important to note that this is the first time this cell line has been used 
to express NLRP3 inflammasome proteins.  
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A number of groups utilized recombinant systems to obtain NLRP3 
inflammasome individual proteins and/ or domains for functional studies. The 
earliest ASC studies were done by two different groups [125, 128]. Sagara and 
colleagues were the first to isolate ASC from human promyelocytic leukemia 
(HL60) cells. They characterized the then novel protein and later designed a 
DNA construct which was transfected into Cos 7 cells [128]. In their follow-up 
studies to study ASC filament formation, they transfected Cos 7 cells with either 
WT or mutant GFP-tagged ASC PYD then used fluorescence microscopy for 
visualization. Deletion mutants were used to determine the minimum ASC 
fragment required for filament formation while the amino-acid substitution 
mutants provided information on the role of charged and hydrophobic residues in 
the self-association of ASC PYD. In addition, E. coli-expressed ASC PYD 
constructs were purified and used for NMR studies [134].  
Gumucio and colleagues investigated the role of pyrin in apoptosis. They 
used a yeast two-hybrid system in which WT pyrin acted as a “bait” to capture 
and identify its binding partners. Co-expression of pyrin and ASC in 293T and 
HeLa cells followed by co-immunoprecipitation and colocalization assays 
confirmed the interactions between the two proteins. They transfected the same 
cell lines with CMV-GFP and either myc-pyrin or FLAG-ASC or both to study 
speck formation [125]. Using YFP-ASC expressed in HeLa cells, they studied the 
kinetics of ASC aggregation leading to speck formation [148].  
Hill and colleagues [5] also utilized both bacteria and mammalian systems. 
They expressed GST-ASC PYD (WT and mutants), Pyrin PYD, and PYD only 
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protein (POP1) in E. coli. In vitro translation of full-length ASC, NLRP3, and 
POP1 with slightly different constructs was conducted using TNT T7 coupled 
reticulocyte lysate system. Subsequent in vitro binding assays with GST-tagged 
WT and mutant ASC PYD fusion proteins indicated that ASC core mutations 
(E13A, K21A, R41A, D48A, D51A) abolished any interactions with NLRP3 and 
POP1. Interestingly, binding between the WT ASC and the mutants was reduced 
but was not completely abolished. A trend similar to the in vitro assays was 
observed upon conducting co-expression of the proteins in HEK 293T cells 
followed by co-immunoprecipitation experiments. HEK 293T cells are an 
excellent choice because they normally do not express inflammasome 
components. Although the ASC mutants affected binding of ASC and NLRP3, 
they didn’t affect overall folding of the proteins [5]. Based on these findings, 
follow-up studies by the same group looked at how the mutations associated with 
familial Mediterranean fever affected the structure and function of PYD of pyrin 
(protein) [136]. 
Other groups also utilized the HEK 293T mammalian cell line to express 
NLRP3 inflammasome proteins. For example, Satoh and colleagues utilized the 
HEK cell system to perform transient expression of all three inflammasome 
proteins to be used as western blot antibody controls while analyzing the 
expression levels of each protein in human neural cell lines [282]. Another group 
expressed FLAG-tagged full-length NLRP3 and a variety of NLRP3-deletion 
mutants lacking the pyrin domain or the LRR region in order to identify the 
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targets of 3,4-methylenedioxy-β-nitrostyrene (MNS), a kinase inhibitor known to 
inhibit the NLRP3 inflammasome [181].  
 To study the mechanisms involved during pyroptosis, Fernandes-Alnemri 
et al utilized THP-1 macrophages stably expressing recombinant GFP-ASC 
[147]. Upon stimulation of the cells with LPS and treatment with various 
activators, pyroptosome assembly was observed by confocal microscopy. In 
addition, ASC pyroptosomes isolated and purified from stimulated THP-1 cells 
were found to activate WT procaspase-1 (but not the inactive C285A mutant) 
thus prompting IL-1β maturation. WT and mutant ASC constructs (K26A) were 
expressed together with FLAG-tagged procaspase-1 in HEK 293T cells then 
activated by incubation at 37 oC. The point mutation prevented ASC 
pyroptosome formation thus emphasizing the importance of the PYD in ASC self-
assembly. In vitro experiments with purified recombinant ASC that was 
expressed in bacteria cells yielded functional pyroptosomes which enabled 
procaspase-1 activation. Low intracellular K+ triggered ASC oligomerization and 
ultimately pyroptosis [147]. 
In order to reconstitute an active inflammasome, Chen and colleagues 
transfected WT or mutant ASC constructs with pyrin domain mutations (R41A, 
D48A, and P40A) in HEK 293T cells stably expressing FLAG-NLRP3, 
procaspase-1, and pro-IL-1β. Upon treatment with Nigericin, inflammasome 
activation was observed only in cells containing the WT or P40A mutant thus 
reinforcing the importance of charged and hydrophobic residues in PYD self-
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oligomerization and inflammasome assembly. They also utilized bacterial 
recombinant expression systems [149].  
The Pelegrin group also utilized the HEK cell line to express recombinant 
mcherry-and YFP-tagged ASC proteins for speck-formation studies. Addition of 
these specks to WT macrophages or cell-free supernatants of stimulated 
macrophages resulted in an increase in caspase-1 activity and IL-1β release. 
Oligomers of YFP-tagged NLRP3 D303N, the mutant associated with cryopyrin-
associated periodic syndromes (CAPS) that involve inflammation, caused 
nucleation of red fluorescent protein (RFP)–tagged ASC upon co-expression in 
HEK cells. The mutant NLRP3 specks also co-localized with extracellular ASC in 
cell-free supernatants [153].  
Nunez and colleagues also co-expressed WT NLRP3 and/or inflammatory 
disease-associated mutants (R260W, D303N, E637G) with ASC in HEK cells. 
The mutants resulted in enhanced Nf-κB activation and IL-1β secretion. Similarly, 
the same trend was observed when THP-1 cells were transfected with WT/ 
mutant NLRP3 constructs only (since THP-1 cells have endogenous ASC). 
Moreover, the mutants exhibited binding to ASC in the absence of stimuli 
whereas no binding was observed with WT NLRP3 [130].  
Apart from mammalian recombinant expression systems, bacterial 
systems were also extensively used in these studies. Most studies were focused 
on the formation of filaments by ASC which is an important step in the 
inflammasome assembly process that leads to speck formation and subsequently 
recruitment of caspase-1. de Alba utilized E. coli to express full-length hASC for 
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NMR structural studies [17, 138]. In another study to identify the binding surfaces 
on ASC PYD responsible for self-association as well as binding with NLRP3 
PYD, they utilized the same system to express the pyrin domains of both ASC 
and NLRP3 and the ASC PYD L25A mutant that prevents oligomerization [135].  
Broz and colleagues also used E. coli to express recombinant ASC pyrin 
domain (residues 1-91 with a C-terminal His tag) for conducting studies on ASC 
filament formation [3]. Likewise, Wu and colleagues studied formation of ASC 
PYD and caspase-1 CARD filaments using Alexa488- and-GFP labelled fusion 
proteins while also employing point mutations that disrupted the oligomerization 
process. Using cryo-EM, they determined the structure of ASC PYD (at a 
resolution of 3.8 Å) [141] and AIM PYD filaments [140]. Apart from the GFP 
fusion tag, the group also introduced MBP and SUMO solubility tags into their 
gene constructs. In addition, they also studied caspase-1 polymerization in the 
presence of card-only proteins (COPs) known as INCA and ICEBERG that are 
known to have an inhibitory effect on inflammasome assembly [231]. In order to 
conduct these experiments, the group utilized both E. coli and insect cells to 
express various domains of all three inflammasome proteins (NLRP3, ASC, and 
caspase-1) [140, 141, 231].  
On the other hand, Hiller and colleagues also studied formation of ASC 
filaments in vitro using recombinant mouse ASC (FL and ASC PYD) expressed in 
E. coli cells. They also introduced a GSGSLE linker into their constructs to 
minimize the effect of the included His-tag [4]. Later they designed a 
fluorescence polarization assay to test the effect of small molecules on filament 
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formation using bacterial- expressed WT hASC PYD and the K21A mutant 
incapable of forming filaments. To enable fluorescent labeling of the PYD 
fragments, they also engineered a single mutation (E97C) [283].  
Since previous studies had primarily focused on filament formation by 
human ASC PYD, de Alba and colleagues opted to use both FL ASC and ASC 
CARD expressed in E. coli for their studies. Using FL ASC presented a better 
model for determining the formation of ASC filaments. By incorporating 
computational methods, NMR, and TEM, they discovered that the PYD and 
CARD domains of ASC formed structurally distinct filaments. In addition, both 
domains were found to be crucial in the assembly of ASC filaments. TEM images 
showed a ring-like structure (~ 7 nm diameter), previously reported by Bryant and 
colleagues [284], which acted as the building block for filament assembly [143]. 
Apart from the COPs studies by Edelman and colleagues, other groups 
were interested in hNLRP3 pyrin domain-only proteins containing (POPs) which 
also prevent assembly of the inflammasome via interactions with ASC PYD. 
Reed and colleagues [229] performed in vitro interactions to demonstrate the 
binding between the PYD domains of ASC and POP1 (also known as ASC2) 
expressed in E. coli. Co-expression of the protein domains in HEK 293T cells 
followed by co-immunoprecipitation also yielded similar results. The group’s 
findings demonstrated the role of POP1 in preventing assembly of the 
inflammasome via blocking activities of both IKKα and IKKβ, and subsequently 
NF-κB activation [229]. Studies by Hill and colleagues would later reveal the 
structure and dynamics of E. coli- expressed POP1 [132]. Using bacterially 
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expressed proteins, Park and colleagues also determined the crystal structures 
of NLRP3 PYD (residues 3-110) [146] and residues 1-89 of cellular pyrin domain-
only protein 1 (cPOP1) [133] at resolutions of 1.7Å and 3.6 Å respectively. 
Narayanan & Park generated the CARD domains of ASC and caspase-1 in E. 
coli. In vitro binding studies with purified proteins showed that there were no 
interactions between the CARD domains of the two proteins [139]. 
 
1.11.2. Caspase-1  
Conversely, some research groups solely focused their studies on 
caspase-1 due to its interesting function as an enzyme. As far back as the late 
80s and early 90s after the enzyme was initially isolated from THP-1 and human 
peripheral blood monocytes [6, 244, 265, 266], researchers were already taking 
advantage of recombinant expression systems to express the full-length protein 
and/ or domains on a preparative scale since endogenous protein amounts were 
insufficient for functional assays.  
Two groups isolated caspase-1 from THP-1 monocytes and obtained the 
copy DNA (cDNA) via molecular cloning. Transfection of Cos-7 cells with the 
expression vector containing the DNA insert successfully yielded an active full-
length caspase-1 [6, 244]. Later, another group that utilized a bacterial 
recombinant system was able to express and isolate FL caspase-1 from the 
inclusion bodies. The refolded protein underwent autoproteolytic cleavage into 
the active form that facilitated cleavage of pro-IL-1β [9].  
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Brady and colleagues utilized an E.coli expression system to express the 
individual p20 and p10 domains of human procaspase-1 since initial expressions 
with eukaryotic systems were unsuccessful. Proteins were isolated from the 
inclusion bodies, purified then carefully refolded. Subsequently, refolded proteins 
were used to conduct enzyme activity studies and for structural analysis by x-ray 
crystallography [8, 10]. Likewise, a few groups that also utilized the same 
approach were successful in producing a catalytically active enzyme [13, 14, 16]. 
In addition, two separate groups led by McDowell [11, 12] and Livingstone [7] 
proceeded to conduct crystallographic studies with recombinant caspase-1 
obtained from refolded p20 and p10 fragments.  
Other research groups would later establish protocols regarding the 
expression of caspases using E.coli systems and the subsequent purification, 
refolding, and characterization procedures. They explored various conditions 
(buffers, pH, salt, detergents, denaturants, stabilizing agents, inhibitors) in an 
effort to establish the optimum conditions ideal for isolating a functionally stable 
enzyme [285, 286]. 
Two different groups also utilized E.coli systems to express caspase-1 
p30 fragment (made up of p20 and p10 domains). While one group was 
interested in studying caspase-1 typical behavioral features such as enzymatic 
activity and stability [15], the other incorporated the GST fusion tag in their 
proteins in a study focusing on the regulation and expression patterns of 
caspase-1 subfamily of proteins [287].  
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In a slightly different approach, wild-type and mutant caspase p35 
fragments were expressed using the same expression system to study the 
sequential cleavage at respective aspartate residues thus leading to 
autoprocessing of the enzyme [14]. In contrast, Wilson et al utilized mammalian 
Cos7 cells to conduct transient expression of caspase-1 p30 WT and/or MUT 
fragments and ultimately monitored IL-1β processing [7]. 
Vandenabeele and colleagues used a different mammalian expression 
system (HEK 293T) to express the full-length human caspase-1 and the 
enzymatically inactive C285A mutant for functionalization studies. In addition, 
they also expressed other caspase-1 mutants, D27G and R45D, for further 
functional assays in an effort to determine the importance of these key residues 
in the interaction with ASC and self-oligomerization of the CARD domain 
respectively [278]. The Schroder group also used HEK cells to express an 
engineered, uncleavable caspase-1 construct containing a thrombin cleavage 
site to study the impact of the CARD-domain linker (CDL) (removal) in processes 








1.12. Overall summary and research goals: 
All the afore-mentioned studies in this chapter have demonstrated the 
interplay between Aβ, Alzheimer’s disease (AD), and the NLPR3 inflammasome. 
The NLRP3 inflammasome has been implicated in a variety of inflammatory 
disorders including AD. The involvement of the innate immune system in AD is 
well-documented and neuroinflammation is a characteristic feature of AD 
pathology. Despite its role in the immune response, not much is known about the 
NLRP3 inflammasome regarding its exact structure or mechanism of activation. 
Moreover, the actual events involved in the activation of the inflammasome by Aβ 
are still unknown. Previous studies of the three inflammasome proteins by other 
groups mainly focused on X-ray crystal structure determination, NMR and 
computational methods to map the binding surfaces, mutation studies to identity 
key amino acid residues, and peptide truncations to determine the minimal 
fragment length required for protein-protein interactions. In addition, numerous 
studies also focused on speck formation by ASC. However, none of these 
studies determined the actual stoichiometry of the inflammasome proteins 
(individually and as a complex) and how that relates to their overall function. 
Thus, the goals of this project are: to study each individual inflammasome 
protein and how these three proteins interact; to determine the nature of the 
interactions between Aβ protofibrils and the NLRP3 inflammasome proteins; to 
understand the mechanisms of activation of the elusive caspase-1, and thus 





CHAPTER 2: METHODS 
Since endogenous amounts of the inflammasome proteins in immune cells 
are very low, recombinant expression provides an excellent alternative of 
obtaining these proteins in large amounts for subsequent structural studies and 
functional assays. In these studies, the NLRP3 inflammasome proteins were 
overexpressed in a mammalian ExpiCHO-S cell line. Many studies utilize 
bacterial systems because these are relatively cheap to maintain, easy to culture, 
and they produce large amounts of protein in a very short time. However, 
bacterial systems do not offer the post-translational modifications that eukaryotic 
systems provide hence the reason why a mammalian cell was chosen for these 
studies. This chapter highlights the experimental methods employed in these 
studies: recombinant protein expression and harvesting of expressed proteins; 
purification and characterization of proteins by biochemical and biophysical 
methods of analyses; functional assays such as caspase-1 activity studies, Aβ-
NLRP3 inflammasome interaction assays, and Aβ-ASC aggregation assays. 
 
2.1. Gene design and synthesis 
Protein sequences (with calculated molecular weights, Mw) for human 
NLRP3 (AAI43363; 118,163 Da), NLRP3 pyrin domain (residues 3-110; 12,483 
Da), human ASC (NP_037390; 21,626 Da), human procaspase-1 (P29466; 
45,156 Da), caspase-1 p20 subunit ( residues 120-297; 19,844 Da) and caspase-
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1 p10 subunit (residues 317-404; 10,244 Da) were obtained from NCBI and 
entered in the GeneArt Gene Project Configurator (Life Technologies/ 
ThermoFisher). Several different gene insert configurations were used that 
contained the following from the 5’ end:  Kozak initiation sequence, Ig κ-chain 
secretion sequence or not, hexa-histidine (His) tag, enterokinase (EK) or tobacco 
etch virus (TEV) protease cleavage site, gene of interest, and a stop codon.  
Fusion proteins were also constructed with yeast small-ubiquitin-related 
modifier (SUMO) (Q12306; 11,352 Da) with R64T and R71E mutations termed 
SumoStar [288, 289], mammalianized bacterial maltose-binding protein (MBP) 
containing mutations D82A, K83A, E172A, N173A, K239A, A312V, I317V, 
E359A, K362A, D363A [290], and glutathione- S transferase (GST) Schistosoma 
japonicum, (AAC00518; 21,626Da) [291]. A GST C-terminal linker 
(SDGSSMGSS; 814 Da) was introduced (Temple and Dong PDB 6N8U). A point 
mutation, K21A, was incorporated into the GST-ASC PYD fusion protein [2-5]. 
Gene synthesis and initial plasmid preparation was done by Life 
Technologies/ThermoFisher. All the relevant information with regards to the 
recombinant full-length proteins and /or domains that were expressed and 









Table 2.1. Information on all the expressed proteins. ** Early MBP constructs containing 
10 mutations that were supposed to improve protein expression. * Later MBP constructs 
bearing the 2 mutations essential for expression and purification A312V, I317V. Extinction 
coefficients  and pI values were calculated using available online tools. 
Ext coefficient calculations: https://web.expasy.org/protparam/ (W 5690, Y 1490, C 120) 
pI calculations: https://web.expasy.org/compute_pi/ 
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2.2. Plasmid amplification 
Plasmids (2 μL, 1 μg/μL) were added to 50 μL chemically-competent 
TOPSHOT Escherichia coli (E. coli) cells (ThermoFisher) followed by incubation 
of the vial on ice for 30 min, in a 42 °C water bath for 30 s, and then back on ice. 
250 μL of super optimal broth with catabolite repression (SOC) medium was 
added and the vial was shaken on its side in a 37 °C incubator for 1 h at 225 
rpm. Using a sterile pipette tip, 20 μL of the cell transformation solution was 
spread evenly on pre-warmed in 100 mm petri dishes containing a hardened 
1.5% agar/100 μg/mL ampicillin/Luria broth (LB) solution. The plate was inverted 
and incubated quiescently at 37 °C overnight. The next day individual colonies 
were inoculated into a sterile 250 mL Erlenmeyer flask containing 200 mL of 100 
μg/mL ampicillin/LB solution and the solution was incubated at 37 °C with rotary 
shaking overnight. DNA was isolated by maxi-prep (PureLink HiPure, 
ThermoFisher) according to manufacturer’s guidelines and the yields were 
typically 0.5 mL of 1.5 mg/mL pure plasmid (A260/A280 = 1.8). 
 
2.3. ExpiCHO-S cell culture 
The ExpiCHO-S™ cell line (ThermoFisher) is a mammalian cell system 
adapted to grow to high densities in serum-free ExpiCHO Expression Medium 
(EM). ExpiCHO-S cells in EM were maintained at 37 °C and 8% CO2 in either 
250 mL or 500 mL sterile Erlenmeyer shake flasks on a MidSci 19 mm orbit 
shaker set at 120 rpm. Three days post-thaw, viable cell density was determined 
using Trypan Blue with a Cellometer cell counting device. Thereafter, cell density 
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and viability were recorded every other day. Log phase cultures typically 
maintained viability at >90%. Cells were allowed to achieve a density of 4 × 106 
cells/mL (~4-5 days), whereupon they were sub-cultured by 20x dilution into pre-
warmed EM. Cells were passaged three times before transfection. At higher 
densities, the cells exhibited some clumping but that was expected, and the 
clumping did not affect the cell growth and/or viability.   
 
2.4. Transfection and expression 
Prior to transfection, ExpiCHO-S cells were grown to a density of 4-6 × 106 
cells/mL. On day −1, pre-transfection, the cells were split to 3-4 × 106 cells/mL 
and allowed to grow overnight. On the day of transfection, day 0, the cell viability 
was confirmed to be 95-99% and the cells were diluted to 6 × 106 cells/mL with 
pre-warmed EM (50 mL total) into a 250 mL shaker flask. As per the GIBCO 
ExpiCHO™ Expression System Kit manufacturer’s protocol, the plasmid DNAs 
were diluted into the cold OptiPro Serum-free Complexation Medium SFM (50 µg 
plasmid in 2 mL SFM. The ExpiFectamine™ CHO Reagent was diluted with 
SFM, gently mixed with plasmid DNA, and the ExpiFectamine CHO / plasmid 
DNA complexes were incubated at 25 °C for 1-5 minutes. To co-express the 
three inflammasome proteins, 15 µg of each plasmid was used (combined 45 µg 
plasmids per 250 mL flask). The mixture was slowly added to the cells while 
swirling the flask gently during addition. The cells were incubated on an orbital 
shaker in a humidified 37 °C incubator at 8% CO2. On day 1 after transfection, 
the ExpiCHO Feed and ExpiFectamine Enhancer were added directly to the 
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flasks. A rabbit IgG-expressing control vector was used as a positive control for 
transfection and expression in ExpiCHO-S cells. 
 
2.5. Protein harvesting 
Harvesting was done 8-13 days post-transfection initially but later modified 
to only 2 days post-transfection. ExpiCHO-S cells were collected and centrifuged 
at 1,000g for 10 min. Medium (M) was removed. Cell pellets were washed in 
phosphate buffered saline pH 7.4 (PBS) containing 10 mM Na2HPO4 and 150 
mM NaCl, weighed, and 4 mL of lysis buffer containing a protease inhibitor 
cocktail was added per gram weight of cells. Various lysis buffer compositions 
were utilized: Protocol #1 (150 mM NaCl, 20 mM Tris, pH 7.4), Protocol #2 (150 
mM NaCl, 20 mM Tris, 1% Triton X-100, 1% deoxycholic acid, and 0.1% SDS, 
pH 7.4) or Protocol #3 where 1% NP-40 replaced SDS in the buffer used in 
Protocol #2. For these experiments, Protocol #3 was mainly used. Cells were 
then homogenized on ice using a Dounce tissue homogenizer for 5 min. After 
homogenization, the cell samples were centrifuged at 22,000g for 20 min at 4 °C 
and the supernatant, or lysate (L), was collected. The pellet was washed with 
phosphate or HEPES buffers, solubilized in 6-8 M guanidine hydrochloride 
(GuHCl) buffers, sonicated for 5 min, and centrifuged at 22,000g for 20 min. In 
some preparations, either 1 mM or 5 mM dithiothreitol (DTT) was also included in 
the solubilization buffer. The ensuing supernatant was collected as the inclusion 
body (IB) fraction. Solubilized inclusion bodies were refolded overnight in 
refolding buffer (50 mM HEPES pH 8.0, 100 mM NaCl, 10% sucrose, 1 or 5 mM 
57 
 
DTT). 4 mL solubilized IB were added to 46 mL refolding buffer. For caspase-1 
fragments refolding experiments, 100 mM malonate (Sigma Aldrich Lot# BCBW 
2461) or 1 µM caspase-1 inhibitor (Enzo Life Sciences, Ac-YVAD-CHO Cat # 
ALX-260-027-M001) were added to the refolding buffers. Briefly, equimolar 
amounts of solubilized caspase-1 p20 and p10 fragments were combined to 1 
mL then added dropwise to refolding buffer to make a total volume of 50 mL. 
Refolding was done overnight at 4 oC with rotation. Centrifugation (22,000g for 
20 min) was done the next day to remove any floating debris before proceeding 
with purification. 
 
2.6. Nickel affinity chromatography 
Medium samples (approx. 50 mL) were dialyzed overnight in 3.5 L of 
dialysis buffer (20 mM Na2HPO4, 500 mM NaCl) before purification. Affinity 
purification of lysates, inclusion bodies, and medium samples was done using a 
20 mL Ni SepharoseTM 6 Fast Flow column (GE Healthcare). The lysates and 
inclusion bodies were centrifuged for 10 min at 17,000g at room temperature to 
remove loose debris. Samples were then loaded onto the column using a 50 mL 
Superloop (GE Healthcare). The Binding Buffer (A) (20 mM Na2HPO4, 500 mM 
NaCl, 20 mM Imidazole, pH 7.4) was allowed to flow for 5 column volumes (100 
mL) to remove the unbound proteins. Proteins of interest were then eluted in 
Elution Buffer (B) (20 mM Na2HPO4, 500 mM NaCl, 500 mM Imidazole, pH 7.4). 
No linear gradient was created therefore the proteins eluted when the elution 
buffer started flowing at 100%. Elution was maintained for 3 column volumes (60 
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mL). 2 mL fractions were collected at a flow rate of 1 mL/min and approximate 
concentrations were determined from the UV absorbance trace.  
 
2.7. Size exclusion chromatography (SEC) 
Inflammasome proteins were separated on Superdex (75 and 200) or 
Superose 6 columns using an AKTA fast protein liquid chromatography (FPLC) 
system (GE Healthcare). Affinity-purified proteins were purified by SEC without 
prior treatment. In addition, various sample treatment strategies were employed 
to maximize amount of soluble (stable) species obtained as shown in Table 2.2.  
 
Table 2.2 Various protein treatment strategies employed prior to size-exclusion 




After sample treatment, protein samples were centrifuged at 17,000g (10 
min), allowed to cool for 5 min then eluted. Various elution buffers used include 
10mM phosphate pH 7.4, 20 mM HEPES pH 8.0, and 10mM Acetate pH 3.6 
containing 150mM NaCl, reducing agents (5% BME, 2 mM DTT), detergents 
(NP40, CHAPS, Tween, SDS), and/or denaturants (2M GuHCl). The flow rate 
was set to 0.5 mL/min and 0.5 mL fractions were collected. Bovine serum 
albumin (BSA, 0.5 -1 mL sample volume, 2.5 or 5 mg/mL) was routinely run as 
both a control protein and a blocking agent to prevent non-specific binding to the 
Superdex resin.  
 
2.8. SEC- multi-angle light scattering (SEC-MALS) 
MALS data were obtained in line with SEC purifications as previously 
described [113] using a DAWN DSP instrument with fixed detectors from Wyatt 
technology. Data analysis was done using the Astra 4.90.08 software. Baseline 
correction, normalization, and calculation of the delay volume were all based on 
BSA data from detector 11. The Debye plot gave a summary of the molecular 
weight (s) of the proteins relative to BSA monomer (66 kD). 
 
2.9. Dynamic light scattering (DLS)  
DLS measurements (to obtain hydrodynamic radii of proteins RH) were 
conducted with a Wyatt Technology DynaPro instrument (DP-AMB-01, 
Manufactured 05-2005). Measurements were taken using a QS 1.50 mm DLS 
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cuvette. 35 µL samples were loaded into a clean cuvette using a gel-loading tip 
while making sure there were no air bubbles. The cuvette was capped after 
loading sample and the sides clean were wiped clean with a Kimwipe. Control 
measurements were done with 2 mg/mL pure BSA sample dissolved in PBS or 
SEC-purified BSA peak fraction. Superdex 75/200-purified inflammasome 
proteins were analyzed. As described previously [113], light scattering intensity 
was collected at a 90° angle using a 5 s acquisition time. Calculations for 
diffusion coefficients D of particle were done using the autocorrelated light 




(where KB is the Boltzmann’ constant, T is temperature in K, ƞ is solvent 
viscosity, RH is the hydrodynamic radius). The Dynamics 6.7.1 software 
generated autocorrelation curves (intensity autocorrelation vs time µs), intensity 
histograms (% intensity vs R nm), and mean RH values for each peak. 
 
2.10. Circular Dichroism (CD)  
CD studies were conducted using a Jacso 1500 spectrometer. A Jasco 
J/0556 cuvette with a 0.1 cm pathlength was used for the measurements and the 
sample volume was 200 µL. Affinity-purified ASC medium fractions ~0.4 mg/mL 
were analyzed under physiological (PBS pH 7.4) and acidic conditions 
(phosphoric acid pH 3.8). Twenty continuous scans were done for each sample 
from 260 nm to 190 nm. Control buffer spectra were obtained, averaged, and 
subtracted from the protein spectra. Spectra were obtained using a scan speed 
of 100 nm/min, 2 nm bandwidth, and a 4 sec data integration time. A response 
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factor of 200 mdeg/1.0 OD was applied. The obtained ([θ]obs, deg) values were 
converted to mean residue ellipticity ([θ], deg cm2 dmol−1) using the equation [θ] 
= [θ]obs × (MRW/10lc), where MRW is the mean residue molecular weight of 
ASC (21,626 g/mol divided by 195 residues), l is the optical path length (cm), and 
c is the concentration (g/cm3). 
 
2.11. Transmission electron microscopy (TEM) 
For TEM studies, affinity-purified ASC medium sample was used. ASC 
sample was diluted to 18.5 µM in PBS buffer then 10 µL of the sample solution 
was placed onto a 200-mesh formvar-coated copper grid (Ted Pella, Inc.). The 
sample was adsorbed to the grid for 10 minutes and the excess sample was 
removed by Kimwipe. The grid was then washed three times by placing it face-
down in a droplet of water. After washing, staining was done with uranyl acetate 
(Electron Microscopy Sciences, Hatfield, PA) for 10 minutes and excess stain 
was removed. The grid was air dried and then visualized with a JEOL JEM-2000 
FX transmission electron microscope operated at 200 keV. 
 
2.12. Protein concentration determination 
Protein concentrations were determined in-line during affinity purification 
or SEC by UV 280 nm absorbance using the following extinction coefficients 
calculated using Expasy bioinformatics tools: NLRP3 (119,620 M-1 cm-1), NLRP3 
pyrin domain (21,270 M-1 cm-1), ASC (24,870 M-1 cm-1), procaspase-1 (27,470 M-
1 cm-1), caspase-1 p20 (14, 230 M-1 cm-1), caspase-1 p10 (8,730 M-1 cm-1). 
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Additionally, concentrations of the eluted affinity fractions were also determined 
by bicinchoninic acid (BCA) assay (ThermoFisher) in microplate format using 
colorimetric measurement at 562 nm on a Molecular Devices SpectraMax plate 
reader. Proteins fractions measured directly after affinity purification were in 
elution buffer containing 500 mM imidazole, therefore a standard curve was 
constructed in the same concentration of imidazole. UV absorbance 
measurements at 280 nm were also made after pooling and overnight dialysis of 
the protein fractions in PBS, Tris or HEPES buffers. 
 
2.13. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) and western blotting 
Protein fractions obtained from the affinity purification (1-5 μg) were mixed 
1:1 with Laemmli SDS sample buffer containing 5% β-mercaptoethanol (BME) 
and heated at 95 °C for 5 min. 20 μL was then loaded onto a 4-20% gel and run 
under denaturing conditions. HL-60 whole cell lysate (Santa Cruz Biotechnology) 
was used as a positive control for all inflammasome proteins and typically run in 
lane 2 with Mw markers (PageRuler Plus pre-stained 10-250 kD, ThermoFisher) 
in the first and last lanes of each gel. Proteins were then transferred to a PVDF 
membrane, dried and blocked with a 5% milk solution for 1 h. After blocking the 
membrane was washed 3x (5 min each) with PBS containing 0.2% Tween 20. 
Membranes were then incubated with specific antibodies for each protein diluted 
in PBS containing 0.1% Tween 20 and 1% milk for 1 h under gentle rotation (70 
rpm). Antibodies used were anti-NLRP3 (8N8E9, ThermoFisher, 1:250 dilution; 
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NBP-2-03947, Novus, 1:500; AG-20B-0014, AdipoGen, 1:1000), anti-ASC 
(PYCARD, ThermoFisher, 1:1000 dilution and B-3, Santa Cruz, 1:1000 dilution), 
anti-caspase-1 (MAB6215, R&D Systems, 1:5000 dilution; PA1440, Boster 
Biological, 1:1000; EPR16883, Abcam, 1:20,000), anti-His-tag (HIS.H8, 
ThermoFisher, 1:1000 dilution), anti-IL-1β (Cat# AF-201-SP, R&D systems, 
1:2000), and anti-GST-tag (Cat# 32839-05111T, AssayPro, 1:1,000). A second 
wash step was followed by incubation with species-specific HRP-conjugated 
secondary antibodies for 1 h. After washing, the membrane was then treated with 
Pierce ECL substrate for 1 min under vigorous rotation (120 rpm). Biomax XAR 
film was exposed to the membrane and developed. In later cases, Bio-Rad 
ChemiDoc MP was used for imaging. Immuno dot blots were conducted in a 
similar manner. Samples (1.7 µL) were applied to a pre-wetted nitrocellulose 
membrane, allowed to dry for 5 min and blocked and washed as described 
above. Membrane was incubated with respectively primary and HRP-conjugated 
secondary antibodies followed by ECL reagent with wash steps in between, then 
imaged. 
 
2.14. In vitro caspase-1 reconstitution assays 
Caspase-1 reconstitution assays were conducted in order to obtain a 
stable, refolded active enzyme. For these studies, two approaches were utilized. 
The first method involved re-solubilizing affinity-purified p10 and p20 fragments. 
Briefly, affinity peak fractions were pooled, went through a series of buffer 
exchanges with 6M GuHCl/ 0.5 mM DTT at 5,000xg using Amicon 
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Ultracentrifugal filter devices (10,000 MWCO). p10 and p20 domains were 
concentrated to 1 mL separately, incubated 15 min at room temp then loaded 
onto Superdex 200 columns using phosphate buffer (10 mM Phosphate, 150 mM 
NaCl, 2 mM DTT). SEC-purified p20 and p10 fractions were combined in 
equimolar amounts, incubated for 1 hour at 4 oC then samples analyzed by 
further SEC purification, SDS-PAGE, and immunoblotting. The second approach 
involved overnight solubilization and refolding of combined p10 and p20 IBs +/- 
inhibitors (1mM Ac-YVAD-CHO and 100 mM malonate) to stabilize the refolded 
protein. Refolded samples were then purified by affinity and SEC and further 
analyzed by gel electrophoresis under denaturing conditions followed by 
immunoblotting. 
 
2.15. Caspase-1 activity assays 
A fluorescence assay [6, 14, 269, 285, 292] was developed to assess 
caspase-1 activity of the recombinant full-length caspase-1, fragments, and 
reconstituted domains. This assay utilizes a synthetic caspase-1 tetrapeptide 
substrate that was designed based on the minimum recognition sequence of the 
enzyme [6]. The synthetic substrate is generally in the form Ac-XXXD-AMC/AFC; 
D represents the aspartate cleavage site, 7-Amino-4-methylcoumarin/ 7-amino-4-
trifluoromethylcoumarin (AMC/ AFC) are coumarin-based fluorogenic motifs.  
Various storage methods were explored in an effort to retain active enzyme. 
These include storing the proteins in solution at 4 oC or frozen at -80 oC, and also 
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adding protein stabilizing cocktail (4X solution, Thermofisher, Prod# 89806, Lot# 
SLBT4106) to the SEC-purified fractions. 
To optimize the assay, 30 nM of Human Caspase-1 (Active) Recombinant 
Protein (Millipore Cat # CC126), 30 µM substrate (Ac-YVAD-AMC and Ac-
WEHD-AMC, Enzo Life Sciences, Cat # ALX-260-024-M001 and ALX-260-057-
M001 respectively), and 1 µM reversible and irreversible inhibitors (Enzo Life 
Sciences, Ac-YVAD-CHO Cat # ALX-260-027-M001 and z-YVAD-fmk Cat # ALX- 
260-020-M001) were used [10, 13-16, 21, 293]. The structure of AMC is shown in 
Fig 2.1.  
 
Fig 2.1 Structure of 7-Amino-4-methylcoumarin (AMC) which is fluorogenic. AMC is 
released from the synthetic caspase-1 substrate Ac-WEHD-AMC upon cleavage by 
caspase-1 enzyme. Fluorescence assays were conducted with a Cary Eclipse fluorometer 
and emission scans were recorded using an excitation wavelength of 350nm and 
monitoring emission from 400-500 nm. However, emissions at 450 nm were recorded. Fig 





For assays conducted with the recombinant protein, a minimum of 700 nM 
enzyme was used for assaying. The enzyme and substrate plus/ minus inhibitor 
were mixed in a cuvette in enzyme assay buffer (25 mM HEPES, 1 mM EDTA, 
25 mM KCl, 10% Sucrose, 1 mM DTT, pH 7.4) and the total reaction volume was 
100 µl as shown in Table 2.3.  
 
The samples were covered and kept at room temperature in between 
measurements. Fluorescence emission measurements were done in a quartz 
cuvette. Emission scans were conducted on a Cary Eclipse fluorometer using 
350 nm excitation and emission scan from 400-500 nm, 5/5 slits, 600 V. To 
observe change in fluorescence over time, emission intensities were recorded at 
450 nm. Time-course kinetic measurements were also done by also monitoring 
450 nm emission. 
Table 2.3 The reaction vessel components for the caspase-1 activity assay. Final 
concentration of active enzyme is 1.8 µg (30 nM) and substrate (30µM). As for 
recombinant enzyme, a minimum of 700 nM was required to obtain activity. Enzyme 





2.16. Tobacco etch virus (TEV) cleavage reactions 
To cleave the MBP and SUMO fusion tags from the recombinant proteins, 
AcTEV Protease Kit (Invitrogen Cat # 12575-015) was used. Protein samples 
were dialyzed overnight using slide-a-lyzer cassettes (ThermoScientific, Prod# 
66380, 10 000 MWCO) in Tris buffer (50 mM Tris-HCl, pH 8.0, 0.5 mM EDTA) to 
get rid of the high amount of imidazole. To the reaction tube containing assay 
buffer, 20 µg of fusion protein was mixed with 1mM DTT, 10 U enzyme and the 
rest of the volume with water to a total of 150 µL. In some instances, the amount 
of fusion protein and/or enzyme was scaled up to 10x to maximize cleavage. The 
reaction tube was incubated at 30 oC for 4-6 hours and aliquots were collected at 
various time points. The reaction was quenched with SDS sample buffer 
containing 5% β-mercaptoethanol. The aliquots were stored at -20 oC for future 
use. Samples were then heated for 5 mins at 95 oC and allowed to cool then 
proceeded with SDS-PAGE and western blotting. Further analysis of the cleaved 
samples was done by affinity purification of the reaction vessel contents. The 
flow through (FT) and the eluted fractions were collected separately then 
concentrated 10x by Microcon centrifugal filter devices (various MWCO) for dot 
blot analysis. 
 
2.17. Interleukin 1-beta (IL-1β) cleavage assays 
To test the potency of our recombinant pro-caspase-1, commercial human 
pro-IL-1β (Sino Biological Cat # 10139-H07E) was used as a substrate. To 
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optimize the assay, Human Caspase-1 (Active) Recombinant Protein (Millipore 
Cat # CC126) was used as a positive control for caspase activity. Briefly, the 
reaction was done in a microcentrifuge tube by combining 1.8 μg caspase-1 
enzyme with 500 ng/mL IL-1β protein in caspase-assay buffer cocktail (25 mM 
HEPES, 1 mM EDTA, 25 mM KCl, 10 % Sucrose, 1 mM DTT, pH 7.4) to a total 
of 100 µL. A time-course reaction was done for 4 hours at 25 oC then the reaction 
was quenched by adding SDS sample buffer containing 5% β-mercaptoethanol. 
The aliquots were stored at -20 oC until the cleavage assay was complete. 
Samples were then heated for 5 mins at 95 oC and allowed to cool then 
proceeded with SDS-PAGE and western blotting. Detection was done with 
human IL-1β/ IL-1F2 polyclonal goat antibody (R&D Systems). 
 
2.18. Aβ protofibril preparation and purification 
Lyophilized Aβ-42 was purchased from ERI Amyloid Laboratory, LLC 
(Oxford, CT) (formerly W. M. Keck Biotechnology Resource Laboratory) and 
stored at −20 °C. Aβ peptide was resuspended in 100% hexafluoroisopropanol 
(HFIP) (Sigma-Aldrich, St. Louis, MO) to yield a 1 mM Aβ solution then aliquoted 
in sterile microcentrifuge tubes. The tubes were left uncovered at room 
temperature overnight in a fume hood to allow the HFIP to evaporate completely. 
The following day, the aliquots were capped and stored in desiccant at −20 °C. 
Aβ−42 protofibrils were prepared as described previously [19]. Lyophilized Aβ 
aliquot (1 mg) was reconstituted in 100 µL of 50 mM NaOH followed by 900 µL 
prefiltered (0.22 μm filters) artificial cerebrospinal fluid [aCSF, 15 mM NaHCO3, 1 
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mM Na2HPO4, 130 mM NaCl, and 3 mM KCl, pH 7.8] to yield 250 μM Aβ 
solution. The mixture was incubated at room temperature for 15-30 minutes then 
centrifuged at 17,000 x g for 10 min. The supernatant was loaded onto the 
column and eluted in aCSF (pH 7.8). Fractions (0.5 mL) were collected, and 
concentrations were determined from the SEC UV absorbance trace.   
 
2.19. Aβ- NLRP3 inflammasome interactions 
To study the interactions between Aβ and the inflammasome proteins we 
used two approaches. The first approach utilized recombinant inflammasome 
proteins for in vitro binding assays with isolated Aβ protofibrils. For these assays 
SEC-purified fractions of recombinant inflammasome proteins were used. 
Equimolar amounts (2 µM final concentration) of Aβ PF, ASC, FL NLRP3 or 
Pyrin, and FL pro-caspase-1 were combined in PBS buffer and incubated for 1-2 
hours at 4 oC and/ or room temperature to allow binding. This assay was 
designed based on previous studies [139]. In these experiments, the assumption 
is that the expected binding events between the proteins will occur and that the 
concentrations used are optimum. After incubation, immunoprecipitation was 
done with anti-ASC, anti-NLRP3, or anti-caspase-1 antibodies followed by SDS-
PAGE and immunoblotting with antibodies specific to each protein of interest. 
An alternative approach involved isolating the endogenous inflammasome 
from stimulated immune cells. For these studies, THP-1 monocytes/ 
differentiated macrophages as well as microglia (both primary murine and 
immortalized BV-2) were utilized. Briefly, cells were stimulated with either Aβ PF 
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or a combination of LPS/nigericin then pull-down assays were used to analyze 
the proteins present in the lysates as explained in detail in sections below. 
 
2.20. Cell culture 
2.20.1. THP-1 monocytes 
THP-1 monocytes purchased from American Type Culture Collection 
(ATCC, Manassas, VA) were grown in Roswell Park Memorial Institute (RPMI) 
1640 (HyClone, Logan, UT) containing 2 mM L-glutamine, 25 mM HEPES, 1.5 
g/L sodium bicarbonate, supplemented with 10% FBS (HyClone), 50 U/mL 
penicillin, 50 µg/mL streptomycin (HyClone), and 50 µM β-mercapto-ethanol. 
Cells were maintained at 37 oC and 5% CO2 in 75 cm2 (10 mL volume) and 150 
cm2 (20 mL volume) Corning culture flasks with canted necks. The cells were 
passaged and replenished with fresh growth medium twice a week.  
 
2.20.2. Primary microglia cells 
Primary microglia cells were isolated from wild-type (WT) C57BL/6 mice 
(Harlan Laboratories). Microglia were isolated as previously described [19, 294] 
from 3–4 day old mouse pups. Briefly, brains were isolated under sterile 
conditions, minced, and trypsinized. The brain tissue was then resuspended in 
complete Dulbecco’s modified eagle’s medium (DMEM, HyClone) growth 
medium containing 10% fetal bovine serum (FBS), 4 mM L-glutamine, 100 U/mL 
penicillin, 0.1 mg/mL streptomycin and 0.25 µg/mL amphotericin-B, OPI medium 
supplement (oxaloacetate, pyruvate, insulin) (Sigma-Aldrich), and 0.5 ng/mL 
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recombinant mouse granulocyte-macrophage colony-stimulating factor (GM-
CSF) (Life Technologies). The cell suspension was filtered, centrifuged, 
resuspended in complete medium and seeded into Corning 150 cm2 culture 
flasks with canted neck. Mixed glial cultures were maintained at 37 °C in 5% CO2 
until confluent (1–2 weeks). For experiments, microglia were detached from the 
adherent astrocyte layer by shaking the flask at 250 rpm for 6 hours or overnight 
at 37 °C in 5% CO2 and collecting the medium.  
 
2.20.3. BV-2 microglia 
Immortalized BV-2 murine microglia were cultured as previously described 
[19] in DMEM [High glucose (4.5 g/L) + Sodium pyruvate (Hyclone) containing 50 
U/mL penicillin, 50 µg/mL streptomycin, 50 µM β-mercaptoethanol, and 5% fetal 
bovine serum (FBS), Hyclone]. Cell-stimulation experiments were performed 
using serum-free medium or growth medium containing 2% FBS. Cells were 
grown in 75 cm2 culture flasks and passaged once a week when they reached 
confluency. The growth medium was removed using a sterile pasteur pipette by 
vacuum suction. The flask was rinsed with sterile PBS carefully (without 
disturbing the cells) by gentle swirling 2-3 times. After suctioning the PBS, 1 mL 
of 0.25% trypsin (HyClone) pre-warmed at room temp was added to the flask. 
Incubation of the flask was done at 37 oC in 5% CO2 for 10 mins to allow cell 
dislodging. Afterwards, 9 mL of growth medium was then added to inactivate 
trypsin and cells were spun at 400g for 10 mins. The pellet was resuspended in 
10 mL growth medium (1:10 dilution normally done but 1:6 dilution could be done 
72 
 
if the cells had to reach confluency faster) and transferred to a 75 cm2 culture 
flask for further growth. 
 
2.21. Cell stimulation assays 
2.21.1. Suspension cell lines 
For cell stimulation experiments, THP-1 monocytes were centrifuged at 
1,000g for 10 mins and the cell pellet was resuspended in fresh warmed assay 
medium containing 2% serum. Cell concentrations of 1x106 cells/ml were used 
(300 µL cells in 48-well plates, 500 µL in 24-well plates, 2-3 mL in 6-well plates). 
Cells were primed with 100 ng/mL ultrapure LPS (InvivoGen, E.coli K12, Cat # 
tlrl-peklps) for 6 hours then stimulated with 5-10 µM nigericin (Sigma SML 1779, 
Lot# 108M 4196V) for 30 minutes at 37 oC in 5% CO2. Five experimental 
conditions were tested as shown in Fig 2.2 below.  
Fig 2.2 Six-well plate experimental set-up for the LPS Nigericin cell 




Alternatively, stimulation was done with 5-10 µM Aβ protofibrils for 6 
hours. After incubation, the entire medium from each well was carefully removed 
and kept in a labelled Eppendorf tube. Centrifugation was done at 1,000g for 10 
mins to remove cell debris and the supernatants were stored at -20 oC for ELISA 
analysis. The remaining pellets were rinsed once with 50-100 µL sterile PBS. 
Lysis was done immediately by resuspending and pipet mixing each pellet in 100 
µL radioimmunoprecipitation assay (RIPA) lysis buffer (150 mM NaCl, 20 mM 
Tris, 1M EDTA, 1% Triton X-100, 1% deoxycholic acid, 0.1% SDS) containing 40x 
dilution of protease inhibitor cocktail. The tubes were incubated for 15 min at 
room temp then the lysate went through a second spin to remove debris (if any). 
Samples were stored in the fridge at -20 oC until further analysis. 
 
2.21.2. Adherent cells lines 
For adherent cells (PMA-differentiated THP-1 macrophages, primary and 
immortalized BV-2 microglia), cell stimulation assays were done in a slightly 
different manner. THP-1 monocytes were prepared as noted in above section. To 
differentiate the monocytes into macrophages, 100 ng/mL phorbol 12-myristate 
13-acetate (PMA) was added to the growth medium used to resuspend the cell 
pellet. Cell concentrations of 1x106 cells/mL were used and cells were added to 
wells (300 µL in 48-well plates, 500 µL in 24-well plates, 2-3 mL in 6-well plates) 
and allowed to adhere overnight. Cell adherence to the bottom of the plates was 
verified by light microscopy. The medium containing PMA was replaced with 
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fresh, warmed growth medium and cells were left to incubate overnight at 37 oC 
in 5 % CO2. As for the primary and BV2 microglia cells, 5x105 cells/ml were 
plated overnight in growth medium. On the day of cell treatment, old medium was 
removed from all wells which were then rinsed with warmed assay medium. Cells 
were stimulated with LPS/ nigericin or Aβ PF as described in section above. After 
treatment, the medium samples were collected from each well, kept in labeled 
Eppendorf tubes then stored at -20 oC for TNFα ELISA analysis. The wells were 
rinsed twice with sterile PBS then lysed with RIPA buffer containing protease 
inhibitor cocktail. Swirling of the plate and pipetting was done several times 
during the lysis step followed by 15 min incubation step at room temp. Lysates 
were collected and stored at -20 oC for further analysis.  
 
2.22. Co-immunoprecipitation (Co-IP) assays 
For the immunoprecipitation experiments, magnetic Protein G Dynabeads 
(Invitrogen, ThermoFisher, Cat # 10003D) were vortexed for about 30 seconds 
then 50 µL (1.5 mg) transferred to each microcentrifuge tube. The tubes were 
placed on a dynamagnet (DynaMag-2, Invitrogen, Cat#12321D) to separate the 
beads from the solution. The supernatants were removed and discarded. About 
2-5 µg of antibodies (ASC-B3, NLRP3 8N8E9,) were diluted in wash buffer (1X 
PBS with 0.02% Tween 20). To each tube, 200 µL of antibody solution was 
added then the tubes were incubated for 0.5 -1 hour at room temperature on a 
rotating shaker. Afterwards, the tubes were placed on a magnet and 
supernatants discarded. The beads were washed by gentle pipetting in wash 
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buffer then discarding the wash. The antibodies were cross-linked to the beads 
as outlined in the BS3 cross-linking section. After crosslinking, the washed beads 
were incubated with 100-500 µL cell lysates at room temperature for 30 mins to 
an hour with shaking. The tubes were then placed on a magnet and the 
supernatants were transferred to clean tubes for later analysis. The beads were 
washed 3x, resuspended in 100 μL wash buffer then the bead suspension was 
transferred to a clean tube to avoid co-elution of proteins bound to the tube wall. 
After removing and discarding the supernatants, elution was done by adding 20 
μL of elution buffer (50 mM Glycine pH 2.8) and 10 μL of pre-mixed Laemmli 
Sample Buffer/ 5% BME followed by heating for 5 mins at 95 oC. The tubes were 
left to cool for a few mins, placed on a magnet, and the supernatants were 
analyzed by SDS-PAGE or stored at -20 oC for later use. Immunoblotting was 
done with anti-ASC (B-3, Santa Cruz, 1:1000 dilution), anti-NLRP3 (8N8E9, 
ThermoFisher, 1:250 dilution), and anticaspase-1 (PA1440, Boster Biological, 
1:1000) antibodies. Anti-Aβ antibodies used were affinity-purified apAbSL 79-2 
(PF-specific antibody generated in the Nichols Lab) and Ab5 (Mayo clinic). 
Loading control probing was done with GapDH (Invitrogen, Cat# MA5-15738) 
and α-tubulin (Thermofisher, Cat# PA5-39836) antibodies. 
 
2.23. BS3 cross-linking 
During immunoprecipitation, cross-linking was done with BS3, a water-
soluble homobifunctional N-hydroxysuccinimide ester (NHS ester) amine 
crosslinker (ThermoScientific, Lot # UE281932) to prevent co-elution of the 
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antibody. After incubating the beads with the antibody (according to the Co-IP 
protocol), the beads were washed twice with 200 μL fresh Conjugation Buffer (20 
mM Sodium Phosphate buffer, 0.15 M NaCl, pH 8.0). The beads were recovered 
on the magnet and the supernatants were discarded. Right before use, 100 mM 
BS3 was prepared in Conjugation Buffer then this stock solution was further 
diluted to 5 mM with Conjugation Buffer (1:20). For each sample tube, 250 μL of 
5 mM BS3 was used. Resuspension of the beads was done in 250 μL of 5 mM 
BS3 followed by incubation at room temperature for 30 min with tilting/rotation. 
The cross-linking reaction was quenched by adding 12.5 μL of Quenching Buffer 
(1M Tris, pH 7.5) then further incubated at room temperature for 15 min with 
tilting/rotation. The cross-linked beads were washed three times with 200 μL of 
PBST (1X PBS with 0.02% Tween 20) then recovered on the magnet. 
Supernatants were discarded followed by Co-IP and antigen elution. 
 
2.24. Trichloroacetic acid (TCA) precipitation 
TCA-acetone precipitation was used to extract proteins from lysates of 
cells stimulated in serum-free medium. TCA stock (T0699, Sigma, Lot # 
SLBX1977) was diluted in sterile milliQ water to make a 20% solution. Protein 
samples were then mixed in a 1:1 ratio with diluted TCA then incubated on ice for 
an hour. The samples were later spun in a microcentrifuge at 15,000g for 10 min 
at 4 oC. The supernatants were removed leaving protein pellets intact. The 
pellets were washed with slightly greater volume (~100 μL) ice-cold acetone by 
swooshing the tube gently without pipet mixing. The samples were spun again for 
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5 mins in a 4 oC microcentrifuge at 15,000g. The acetone was gently removed 
and discarded. A total of 3 acetone washes were done with centrifugations in 
between. The pellets were then allowed to air dry at room temp to drive off 
acetone. When pellets were completely dry, they were re-suspended in SDS 
sample buffer with 5% BME and slightly sonicated to dissolve the pellets 
completely. To the samples that still had residual TCA (sample buffer turned 
yellow), neutralization was done with 1M Tris buffer which was added dropwise 
until samples turned blue again. Alternatively, re-suspension was done in 4% 
SDS only for subsequent BCA-assay analysis. The samples were incubated for 5 
mins at room temp, heated at 95 oC for 5 mins, and then allowed to cool down. 
20 μL of each sample was loaded onto a suitable gel for electrophoresis, 
transferred to PVDF membrane, and later analyzed by immunoblotting. 
 
2.25. Cytokine enzyme-linked immunosorbent assay (ELISA) 
Supernatants were analyzed by TNFα ELISA to determine amounts of 
cytokines secreted. Briefly, 100 µL of 2 µg/mL capture antibodies from R& D 
Systems (anti-human monoclonal MAB610, anti-mouse polyclonal AF-410-NA) 
were plated into 96-well plates overnight at room temperature followed by a wash 
(PBS with 0.05% Tween 20) the next day. To each well, 300 μL Blocking Buffer 
(PBS containing 1% BSA, 5% sucrose, 0.05% NaN3) was added then plates 
were incubated for at least 1 h at room temperature. Afterwards, the samples 
were washed 3x. Successive treatments (with 3 washes in between steps) were 
done with 50 μL samples or standards for 2 h, 100 μL of biotinylated detection 
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antibodies [(R & D systems, BAF210,polyclonal anti-human antibody, 0.1 µg/mL), 
(BAF410, 0.2 µg/mL)] diluted in detection antibody diluent (20 mM Tris with 150 
mM NaCl and 0.1% BSA) for 2 h, 100 μL of streptavidin-horseradish peroxidase 
(HRP) (R&D Systems) diluted 200 fold into conjugate diluent (PBS with 1% BSA) 
for 20 min, and 100 μL of equal volumes of 3,3’,5,5’ tetramethylbenzidine (TMB) 
and hydrogen peroxide (KPL, Gaithersburg, MD) for 20-30 min. The reaction was 
stopped by the adding 50 µL of 1% H2SO4 solution. The optical density of each 
sample was analyzed at 450 nm with a reference reading at 630 nm using a 
SpectraMax 340 absorbance plate reader (Molecular Devices, Union City, CA). A 
standard curve was constructed by serial dilution of a TNFR standard from 2000 
to 15 pg/mL. TNFα concentrations in the samples were calculated from the 
standard curve. When necessary, samples were diluted 3 to 5-fold to fall within 
the standard curve. 
 
2.26. Aβ-ASC aggregation assays 
To conduct the aggregation assays, freshly purified Aβ monomers and 
GST-ASC proteins were used (GST-ASC PYD, GST-ASC PYD K21A, GST-ASC 
CARD). GST-ASC proteins were purified with both Superdex 75 and 200 
columns using PBS buffer. SEC-purified void and included peak fractions were 
diluted 1:10 or 1:100 (ASC:Aβ) depending on the amounts of protein available. 
aCSF buffer (1 mM Na2HPO4 , 1.5 mM NaHCO3, 3 mM KCl, 130 mM NaCl, pH 
7.8) was used for the aggregation assays. Each reaction tube contained Aβ 
monomers and ThT, both at 10 uM final concentrations, ASC protein, and the 
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rest of the volume was made up to 600 ul with aCSF. Three separate 
microcentrifuge tubes were used, one for each ASC protein. After obtaining 
fluorescence value for 0h time point, the sample from each tube was split into 
three tubes (n=3) with 200 ul of solution in each tube. The tubes were incubated 
quiescently at 37°C as shown in Fig 2.3. Aβ-ASC solutions were assessed by 
thioflavin T (ThT) fluorescence at different time points. Fluorescence emission 
scans (460-520 nm) were acquired on a Cary Eclipse fluorescence 
spectrophotometer using excitation wavelength of 450 nm. Emission scans were 
integrated from 470-500 nm to provide a numerical value of ThT relative 
fluorescence values.  
 
Fig 2.3 Aβ-ASC aggregation assays. Briefly, mixtures SEC-purified Aβ monomers 
and GST-ASC proteins plus ThT in aCSF (pH 7.8) buffer were incubated 
quiescently at 37°C. ThT fluorescence was assessed at various time points. Using 
excitation wavelength of 450 nm, fluorescence emission scans (460-520 nm) were 
acquired on a Cary Eclipse fluorescence spectrophotometer and integrated from 
470-500 nm to provide a numerical value of ThT relative fluorescence values. 
Schematic by Dr. Nichols. 
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CHAPTER 3: DEVELOPMENT OF A MAMMALIAN EXPICHO CELL SYSTEM 
FOR EXPRESSION OF NLRP3 INFLAMMASOME PROTEINS 
The ExpiCHO-S system was chosen for the transient expression of 
NLRP3 inflammasome proteins because of these specific features: as a 
mammalian cell line it allows desirable post-translational modifications; these 
modified CHO cells grow in suspension thus allowing for easier harvesting of 
proteins from the expression medium; the cells grow to extremely high densities 
while maintaining good cell viability therefore maximizing yields.  
The classic CHO cells are great for transient expression but are not as 
efficient as HEK293 cell line which is the most common system for transient 
protein expression. The ExpiCHO-S cells, however, are designed for stable 
expression of proteins with extremely high efficiency. The protein yields obtained 
from ExpiCHO-S expression systems surpass by far the amounts obtained when 
using standard CHO, HEK 293T, and Expi293F cell lines [295, 296]. In addition, 
inclusion of a hexa-histidine tag allowed for the selective purification of the 
desired proteins by Ni2+ affinity chromatography. 
 
3.1. The pcDNA3.4-TOPO mammalian vector is ideal for recombinant 
expression of inflammasome proteins 
The plasmid vector chosen for these studies was pcDNA3.4-TOPO, which 
enables constitutive expression of exceptionally high levels of recombinant 
protein in mammalian ExpiCHO-S cells. As shown in Fig 3.1 top panel, the vector 
contains a topoisomerase cloning site, the full-length human cytomegalovirus 
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(CMV) immediate-early promoter/enhancer, and both ampicillin and neomycin 
resistance genes for subcloning. The synthesized gene that was inserted into the 
plasmids contained a Kozak sequence, hexa-histidine (His) tag for purification 
purposes, and either an enterokinase (EK) or tobacco etch virus (TEV) cleavage 
site for removal of the His tag if desired. 
In some of the insert sequences, an Ig κ-chain secretion sequence was 
included [297, 298] to enable secretion of the expressed proteins into the 
medium as shown in the Fig 3.1 bottom panel A. Otherwise, the proteins were 
expressed intracellularly (Fig 3.1 panels B and C). DNA sequences for the 
protein inserts (full-length and subunits of human NLRP3, ASC, and caspase-1 
proteins) were optimized using the GeneArt Gene Synthesis platform 
(ThermoFisher/Life Technologies). Synthesis and cloning of the designed DNA 
into the pcDNA3.4 TOPO vector were also done commercially (Thermo 







Fig 3.1 Top: Plasmid vector with human NLRP3 gene inserted. Plasmid synthesis, 
amplification, and sequencing was done by Life Technologies Bottom: The design of 
the genes showing the Kozak initiation sequence, hexa-histidine tag, and a cleavage 
site in all constructs. A secretion tag (Ig κ-chain) and an enterokinase (EK) cleavage 
site were included in the initial gene design Panel A. Modifications were done to 
remove the secretion sequence and a tobacco-etch virus (TEV) cleavage site was 
introduced Panel B. MBP and/or SUMO fusion tags were later introduced as shown in 




Small ubiquitin-like modifier (SUMO) and maltose-binding protein (MBP) 
fusion tags were later added to the gene design to enhance solubility of the 
recombinant proteins. The SUMO protein is relatively small ~11 kD. Yeast SUMO 
with R64T/R71E mutations was used and it works in mammalian cells. As shown 
previously, the mutations prevent cleavage during expression [288]. On the other 
hand, MBP is a relatively large protein ~42 kD. Initially, the mammalianized 
version of bacterial MBP (mMBP) which contained 10 mutated residues (D82A, 
K83A, E172A, N173A, K239A, A312V, I317V, E359A, K362A, D363A) [290] was 
utilized. These 10 mutations were expected to enhance expression and yields of 
the MBP-fusion proteins but further literature search revealed that only 2 
mutations (A312V, I317V) were necessary for purification and expression. The 
other 8 mutations assisted in protein crystallization by reducing flexibility of the 
linker thereby not necessary for our studies. Therefore, later constructs (MBP-
p20, MBP-p10) contained only the essential 2 mutations. A tobacco-etch virus 
(TEV) protease site was also introduced to allow for removal of the fusion tags 
from the protein of interest. 
 
3.2. ExpiCHO-S cells maintain great cell viability at high densities and are 
ideal for recombinant expression of proteins in suspension 
The ExpiCHO-S mammalian cell line was used for the recombinant 
expression of NLRP3 inflammasome proteins and was chosen over bacterial cell 
expression systems to ensure that all relevant post-translational modifications 
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(PTMs) were maintained. As discussed in detail in Chapter 1, PTMs play an 
essential part in the regulation of the NLRP3 inflammasome hence the need to 
employ a mammalian cell line for our studies. ExpiCHO-S cells have been mostly 
used in the transient and stable production of secreted antibodies and 
biotherapeutics (compared to the generic HEK293 cell line), are designed to 
grow in suspension and can accommodate very high cell concentrations (>107 
cells/ml) hence they seemed to be a great model system for our studies [295, 
296].  
The overall flow of ExpiCHO-S experimental cell work is shown in Fig 3.2 
panel A and an image of the cells is shown in panel B. ExpiCHO-S cells were 
cultured in serum-free EM and subcultured 2-3 times before transfection in order 
to optimize cell growth and viability. Cell clumping was observed at high 
densities, but this did not affect the growth of the cells, thus confirming the 
adaptation of the cell line to a high-density environment. Following transfection 
as described in the Methods, ExpiFectamine Enhancer and ExpiCHO Feed were 
added to the flasks on day 1 post-transection to improve transfection efficiency 









Fig 3.2 ExpiCHO-S cell culture, transfection, and protein expression. Panel A. 
Initiation of the process begins with culturing of the suspension ExpiCHO-S cells in 
sterile Erlenmeyer shake flasks under continuous rotation at 37 °C in 8% CO2 and 
passaging several times before transfection. Monitoring and confirmation of high cell 
viability prior to, and during, expression is an important parameter. Application of 
ThermoFisher Feed and Enhancer on day 1 post-transfection enhances the protein 
expression process allowing acquisition of ExpiCHO-S-expressed proteins typically 
within 2-13 days post-transfection. Schematic by Dr. Nichols. Panel B. Image of 




3.3.    ExpiCHO-S cells maintained good cell viability during the expression 
period and proteins were detected within 4 days post-transfection 
Good cell viability is an important parameter for high-yield protein 
expression in the ExpiCHO-S cell line. Viability was determined over the course 
of the expression and although there was a modest decrease in viability, it 
routinely stayed above 70% for most of the plasmids (Figure 3.3 panel A). Small 
variations in viability were observed depending on the types of plasmids used 
(data not shown).  
The efficiency of transfection and expression was evaluated using a 
positive control antibody-expressing pcDNA vector and assessing the production 
of secreted rabbit IgG antibody. A time course of rabbit IgG protein expression 
and secretion was obtained by taking aliquots from the medium of the expression 
flasks on different days and performing an immuno-dot blot analysis on the 
samples. The findings demonstrated that expression and secretion of rabbit IgG 
protein occurred as early as day 4 post-transfection (Fig 3.3B, top panel). Further 
analysis of the control rabbit IgG control expression after harvest indicated that 
the protein was secreted and not present in the non-transfected medium, lysate 














Fig 3.3. Monitoring ExpiCHO-S cell viability and secretion of proteins into the medium. 
ExpiCHO-S cells maintained good viability during the course of the protein 
expression. Panel A. Time-dependent measurements of cell viability during the 
expression period after transfection with control rabbit IgG (circles) or ASC plasmids 
(triangles). Cell viability was generally above 70% until the day of harvest. Fig by Dr. 
Nichols. Panel B. A dot blot analysis was used to detect the expression and secretion 
of rabbit IgG in ExpiCHO-S medium samples. The time-dependence of rabbit IgG 
expression is shown in the upper panel. The lower panel shows the absence of rabbit 
IgG in untransfected ExpiCHO-S cells and the presence of rabbit IgG in the 
transfected ExpiCHO-S medium, but not the lysate (L) or inclusion bodies (IB) 
fractions.  




3.4.    Incorporating detergents, reducing agents, and protein stabilizers in 
the buffers used during harvesting and lysate preparation maximized 
protein yields 
Expression of inflammasome proteins was done in a similar manner to 
that of the antibody and the proteins were typically harvested 2-13 days post-
transfection. After going through published protocols from various sources in the 
literature [10, 16, 231, 285, 286, 299], various buffers and harvesting protocols 
were employed. Modifications were done over the course of time in order to 
maximize the protein yields as shown in Table 3.1.  
 
The main focus was on the cell lysate preparation, wash steps, 
solubilization of inclusion bodies, and refolding. Three ExpiCHO-S fractions 
(medium, lysate, and inclusion bodies) were collected from each protein 
expression flask as described in the Methods. Medium fractions (M) consisted of 
supernatants after low-speed centrifugation of the ExpiCHO-S cells. In-between 
wash steps with phosphate or HEPES buffers (50 mM HEPES pH 8.0, 300 mM 
NaCl, 1 M GuHCl, 5 mM DTT, 1% Triton X-100) were included to get rid of 
contaminants and cell debris to ensure getting proteins of the highest purity. The 
ensuing cell pellets were mechanically disrupted with a Dounce homogenizer in 
the presence of protease inhibitors, centrifuged at 20,000g for 20 min, and the 
supernatant collected as the lysate (L). Initially, the most basic Lysis Buffer was 
used (150mM NaCl, 20mM Tris pH 7.4) but over time various additives were 
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added to maximize protein extraction as shown in Table 3.1. The pellet remaining 
after the lysate spin was solubilized in 8 M GuHCl, sonicated for 5 min, and the 
solubilized supernatant was obtained as the inclusion body (IB) fraction. To 
improve the IB solubilization process, later preps utilized modified Solubilizing 
Buffer (6 M GuHCl, 25 mM Tris, 5mM DTT pH 7.5) followed by sonication. The 
samples were incubated overnight at 4 oC with rotation and subjected to 
centrifugation again (22,000g, for 20 min) to remove debris. Solubilized IB were 
added dropwise to refolding buffer followed by overnight refolding (50 mM 
HEPES pH 8.0, 100 mM NaCl, 10% sucrose, 1 or 5 mM DTT) at 4 oC with 
rotation. After another centrifugation step, the supernatant was used as the IB.  
Table 3.1 The various buffer protocols and modifications introduced during the 
harvesting, lysis, solubilization, refolding, and purification processes to maximize 




3.5.    The three inflammasome proteins were successfully co-expressed in 
ExpiCHO-S cells 
Some groups have successfully co-expressed NLRP3, ASC, and 
caspase-1 in HEK cells for microscopy assays (to study ASC speck formation) 
and co-immunoprecipitation studies (to study binding between the proteins) thus 
indicating successful inflammasome assembly [153, 235, 236, 300, 301]. Co-
transfection of Cos7 cells with caspase-1 and pro-IL-1β resulted in secretion of 
mature IL-1β [244].  
The three inflammasome proteins (FL NLRP3, pro-caspase-1, ASC) were 
co-expressed in ExpiCHO-S cells. The lysates were affinity-purified followed by 
SDS-PAGE and immunoblotting with specific antibodies against each of the 
proteins as shown in Fig 3.4.  All three proteins were successfully co-expressed 
according to the input lanes 4-6 (affinity-purified peak fractions 10-12 
respectively) when probed with antibodies against ASC (Panel A), caspase-1 
(Panel B), and NLRP3 (Panel C). Interestingly, all three proteins appeared as 
monomers under denaturing conditions but tend to form SDS-resistant 

















































After successfully verifying the co-expression of all three inflammasome 
proteins, the next step was to do co-immunoprecipitation (Co-IP) assays to test 
whether all three proteins existed in a complex. Co-IP experiments were 
conducted with ASC B3 antibody. Affinity-purified fraction 11 (lane 5) was used 
for the Co-IP experiments. As shown in Fig 3.4 A-C, there were not any 
differences between the input (lane 5) and the unbound protein (lane 8) 
indicating that little to no protein was actually bound to the antibody crosslinked 
to the magnetic beads. Moreover, no proteins were detected in the IP lysates 
(lane 10) thus further agreeing with the fact that the ASC protein did not bind to 
the antibody during the immunoprecipitation process. A possible explanation 
could be that ASC is in a complex with NLRP3 or caspase-1 (or both) and the 
binding epitope is obstructed thus preventing its binding to ASC B3.  
 
Fig 3.4 Immunoblots showed that three inflammasome proteins were successfully co-
expressed. Lysates of co-expressed proteins were affinity-purified and used to 
perform IP assays. IP was done with 2 μg ASC-B3 as explained in detail in the 
Methods section followed by SDS-PAGE, transfer, and immunoblotting. Immunoblots 
were probed with (Panel A) ASC (22 kD), (Panel B) caspase-1 (45 kD), and (Panel 
C) NLRP3 (118 kD) antibodies. Lane 2 contained HL-60 positive control lysate. Lanes 
3, 7, 9 were empty. Lanes 4- 6 represent affinity-purified co-expressed proteins. 
Sample in lane 5 was used as the input for IP. Lane 8 represents the unbound 




3.6. Affinity purifications of His-tagged proteins yielded high amounts of 
expressed proteins 
3.6.1. Affinity purifications of NLRP3, ASC, and caspase-1 p10  
Figure 3.5 shows the 17 protein constructs that I expressed successfully in 
ExpiCHO-S cells. His-tagged proteins in all three fractions (M, L, and IB) were 








Proteins were detected in-line with UV absorbance at 280 nm. Non-His-
tagged proteins passed through the column as flow through in 20 mM Na2HPO4, 
500 mM NaCl, 20 mM imidazole pH 7.4. His-tagged proteins were eluted with 20 
mM Na2HPO4, 500 mM NaCl, 500 mM imidazole pH 7.4 and produced well-
defined elution peaks. BCA protein assays were also conducted on the eluted 
fractions and used to corroborate the UV-absorbance-determined concentration.  
Fig 3.6 shows one of the earliest affinity purifications of secreted ASC. In 
this case, we were still optimizing the affinity purification protocol using a linear 
gradient. Since the ASC contained a secretion sequence, presumably all the 
protein would be in the medium sample. UV280 nm trace indicated two ASC elution 
peaks that are labelled as peak 1 and peak 2. The peak fractions would be used 
for circular dichroism studies in Chapter 4. 
 
 
Fig 3.5. Schematic showing constructs of all full-length and truncated proteins that 
were successfully expressed in ExpiCHO-S mammalian cells. A total of 17 proteins 
were expressed. The initial FL NLRP3 and ASC constructs had the Ig κ-chain 
secretion sequence to allow secretion into the medium during expression. Later 
constructs did not feature the secretion tag. GST, MBP, and SUMO fusion tags were 
later introduced to improve solubility of proteins. Caspase-1 active site mutants 
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Fig 3.6 Affinity purification of His-tagged secreted ASC medium. 41 mL of day 10 
medium sample was loaded into a superloop and purified using a Ni SepharoseTM 6 
Fast Flow column as described in the Methods. The sample was loaded on the 
column and washed in Buffer A (20 mM imidazole) followed by elution in Buffer B (500 
mM imidazole) using a linear gradient (purple line). Protein concentration was 
monitored in-line by UV absorbance at 280 nm (A280). Elution of His-tagged proteins 
started at 92 mL as shown by the buffer B line. Two ASC peaks (1 and 2) were eluted 
and taken for further analysis. BCA assay determined the protein concentrations as: 




Figure 3.7A depicts the affinity purification of the ExpiCHO-S-expressed 
NLRP3 IB fraction. This particular NLRP3 gene was designed with a secretion 
sequence, but much of the detectable 118 kD NLRP3 protein was found in the IB 
or L fractions, not the medium. The BCA-determined protein concentration from 
the collected fractions aligned well with the in-line UV-determined protein 
concentration. Quantitative integration of the elution peaks for IB and L fractions 
indicated that a much higher amount of NLRP3 protein was recovered in the IB 
fraction (6.4 mg) compared to the L fraction (1.4 mg) (Figure 3.7B). These 
calculated protein values were used to provide a distribution between the two 
fractions (L/IB = 0.23 for NLRP3). Since the L and IB fractions emanate from the 








Similar elution and distribution profiles were observed for the expression, 
recovery, and affinity purification of ASC (Figure 3.8A) and the caspase-1 p10 
domain (Figure 3.9A). The data presented is for an intracellularly expressed form 
of ASC, in which the gene did not contain an added secretion sequence. The 
L/IB protein ratio for non-secreted ASC was 0.18 (Figure 3.8B). Expression of a 
secreted form of ASC (gene contained secretion sequence) yielded a distribution 
(L/IB = 0.30) similar to the non-secreted form (data not shown). No further 
inflammasome proteins, besides NLRP3 and ASC, were expressed with a 
secretion sequence in the ExpiCHO-S cell system as the leader sequence did 
not dramatically increase the yield of protein. A third protein component of the 
NLRP3 inflammasome complex, the p10 subunit of caspase-1, was expressed, 
Fig 3.7 Affinity purification of His-tagged NLRP3 protein. Panel A. The IB fraction of 
ExpiCHO-S-expressed NLRP3 (day 8 harvest) was isolated and affinity-purified on a 
Ni SepharoseTM 6 Fast Flow column as described in the Methods. The sample was 
loaded on the column and washed in Buffer A (20 mM imidazole) followed by elution 
in Buffer B (500 mM imidazole). Protein concentration was monitored in-line by UV 
absorbance at 280 nm (A280) (solid line) and also determined by BCA assay (circles) 
in the collected 2 mL fractions. Panel B. Integration of the affinity chromatography 
elution peaks of the NLRP3 IB (panel A) and L fractions provided a distribution 
between the two fractions. The integration value was obtained by multiplication of the 
fraction volume and concentration for all of the eluted protein fractions. The L fraction 
was obtained using Protocol #1 as described in the Methods. Fig by Dr. Nichols 
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purified (Figure 3.9A), and also recovered predominantly in the IB fraction with an 







Figure 3.8 Affinity purification of His-tagged ASC protein lysate and IB. Panel A. The 
L fraction of ExpiCHO-S-expressed ASC (day 11 harvest) was isolated and affinity-
purified on a Ni SepharoseTM 6 Fast Flow column as described in the Methods and in 
Figure 3.7 legend. Protein concentration was monitored in-line by A280 (solid line) 
during loading, washing, and elution of the sample and also determined by BCA 
assay (circles) in the collected 2 mL fractions. Panel B. Integration of the affinity 
chromatography elution peaks of the ASC L (Panel A) and IB fractions, as described 











Figure 3.9 Affinity purification of His-tagged caspase-1 p10 subunit. Panel A. The IB 
fraction of ExpiCHO-S-expressed caspase-1 p10 (day 8 harvest) was isolated and 
affinity-purified on a Ni SepharoseTM 6 Fast Flow column as described in the Methods 
and in Figure 3 legend. Protein concentration was monitored in-line by A280 (solid line) 
during loading, washing, and elution of the sample and also determined by BCA 
assay (circles) in the collected 2 mL fractions. Panel B. Integration of the affinity 
chromatography elution peaks of the p10 IB (panel A) and L fractions, as described in 





3.6.2. Fusion proteins enhance solubility of expressed proteins 
In order to shift the distribution of expressed inflammasome proteins to the 
lysate fraction, fusion proteins of ASC were prepared with both small-ubiquitin-
related modifier (SUMO) and maltose-binding protein (MBP). These protein tags 
have been shown to increase expression levels and solubility of difficult proteins 
in mammalian cells [288, 290]. SUMO from Saccharomyces cerevisiae 
containing R64T/R71E mutations was added at the 5’ end of ASC with a tobacco 
etch virus (TEV) protease site engineered between the two proteins. This SUMO 
mutant has been shown to work effectively as a fusion protein in mammalian cell 
expression [288]. A similar construct of ASC was prepared containing a 
mammalianized version of bacterial MBP [290]. A more stringent lysis buffer was 
also employed that contained additional detergent components including 1% 
Triton X-100, 1% deoxycholic acid, and 0.1% SDS. This more stringent lysis 
buffer shifted the L/IB ratio for ExpiCHO-S-expressed ASC to 0.46 (Figure 
3.10A), compared to 0.18 for ASC-expressing ExpiCHO-S cells lysed without 
detergents (Figure 3.8B). Expression of ASC as a fusion protein with SUMO 
further enhanced the solubility with an L/IB ratio of 0.79 (Figure 3.10B). Finally, 
the MBP-ASC demonstrated the best L/IB ratio with a value of 2.85 indicating 
that more of the protein was found in the lysate fraction compared to the 
inclusion body fraction (Figure 3.10C). However, it was noted that even with the 
fusion tags, there was still some degree of protein insolubility. MBP-ASC 
contained the 10 mutated residues (D82A, K83A, E172A, N173A, K239A, 
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A312V, I317V, E359A, K362A, D363A) [290]. Further literature analysis 
confirmed that only 2 mutations (A312V, I317V) were necessary for purification 
and expression. The other mutations facilitate protein crystallization by 
decreasing protein flexibility hence were not vital for our research purposes. 
Follow-up gene constructs for MBP-p20 and MBP-p10 fusion proteins included 






Figure 3.10 Fusion tags enhance the solubility of the ExpiCHO-S-expressed ASC 
protein. L and IB fractions were obtained and affinity-purified from ExpiCHO-S cells 
expressing either ASC (Panel A), SUMO-ASC (Panel B), or MBP-ASC (Panel C). 
Lysates were obtained using Protocol #2 as described in the Methods. Integration of 
the L and IB affinity chromatography elution peaks, as described in the Figure 3.5 
legend, for the L and IB fractions provided a distribution between the two fractions. 










































In conclusion, recombinant expression of the NLRP3 inflammasome 
proteins in an ExpiCHO-S mammalian system was successful. The original gene 
design featured a secretion sequence to allow for easy harvesting of the proteins 
from the expression medium. However, this tag was not included in the later 
constructs because it did not offer any advantage. The ExpiCHO-S cells 
maintained good viability during the expression period (optimized expression 
time from 2-13 days). Dot blot experiments proved that maximum expression was 
reached as early as day 4 therefore expression times were amended to a 
maximum of 4 days. I was able to isolate proteins from both the lysates and 
inclusion bodies. Addition of detergents, reducing agents, and denaturants and 
implementing solubility fusion tags in the gene constructs greatly shifted the 
amount of proteins obtained in the lysate fraction compared to the inclusion 
bodies. High overall yields were obtained for all expressed proteins with slight 
variations based on the type of the plasmids used as revealed by the affinity 
purification curves. Thus, ExpiCHO-S cells presented a great expression system 








CHAPTER 4: OLIGOMERIZATION STATE DETERMINATION OF 
EXPICHO-EXPRESSED INFLAMMASOME PROTEINS 
Although quite a few structural studies have been conducted with 
recombinant NLRP3 inflammasome proteins (as reviewed in Chapter 1), studies 
are yet to be done to determine the actual stoichiometry of each individual 
protein and the NLRP3 inflammasome complex. Knowing the stable forms of 
each protein and the actual components of the inflammasome as a whole can be 
useful in determining which mechanisms are involved in these processes thereby 
pinpointing the exact targets during drug discovery. Biochemical and biophysical 
assays were employed to verify successful expression of proteins and to also 
characterize the recombinant proteins. 
Immunoblotting methods with specific antibodies can verify the presence 
of the proteins of interest. Size-exclusion chromatography separates species 
based on their molecular weights and also gives information on whether soluble 
aggregates are present in the protein sample. Light scattering techniques are 
used to determine relative sizes and structures of proteins while circular 
dichroism studies reveal how the proteins are folded. Additional structural 
information can be obtained by microscopy techniques. In these studies, both 
denaturing and non-denaturing solution conditions were used in the 
characterization studies to obtain information on the oligomerization states of the 
recombinant proteins. Since NLRP3 inflammasome proteins have an inherent 
propensity to aggregate coupled with the unwanted aggregation brought about by 
overexpression, various stringent protocols were used to break the preformed 
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aggregates in order to obtain more soluble, small molecular weight oligomeric 
proteins for analysis. To clarify on the terminology used in this text, 
oligomerization refers to the formation of small molecular weight species, 
eventually leading to aggregation (formation of high molecular weight species). 
 
4.1. Analysis of the oligomerization state of the recombinant proteins 
under denaturing conditions 
4.1.1. Proteins mainly appeared as monomers under denaturing 
conditions 
Immunoblotting analysis of affinity-purified fractions was employed to 
identify each of the expressed proteins. Proteins were probed with specific 
antibodies and selected examples are shown in Figure 4.1 including NLRP3 (118 
kD), ASC (22 kD), NLRP3 pyrin domain (12 kD), MBP-ASC monomers (61kD), 
and caspase-1 proteins [procaspase-1 (45 kD), CARD-p20 (33 kD), MBP-p10 (50 
kD), p20 (19.8 kD)]. Under SDS denaturing conditions, the primary species 








Figure 4.1. Immunoblot analysis confirms identity of affinity-purified inflammasome 
proteins and most of them appeared as monomers under denaturing conditions. Affinity-
purified inclusion bodies (IB) were used for these experiments except MBP-p10 where 
lysate sample was used. Protein samples (15 μL) from affinity elution fractions were 
separated by gel electrophoresis under denaturing conditions, transferred to PVDF 
membrane, and probed with antibodies specific for each protein. Selected proteins are 
shown in the figure at their expected monomeric Mw and include NLRP3 (118 kD), 
NLRP3 pyrin  domain(12 kD), ASC (22 kD), MBP-ASC (61 kD),  procaspase-1 (45 kD), 
caspase-1 CARDp20 (33 kD), MBP-p10 (50 kD) and caspase-1 p20 (20 kD). Mw values 
were determined by running Mw markers in the first and last lane of every gel. Specific 




4.1.2. Expressed proteins showed some degree of oligomerization 
A common feature and probably the greatest challenge during the 
overexpression of proteins is unwanted oligomerization. In this situation, it is 
most likely that protein concentration and the inherent properties of these 
proteins contributed to the aggregation process. The expressed proteins 
exhibited oligomerization even under denaturing conditions as shown in Fig 4.2. 
Selected immunoblots show the presence of SDS-resistant oligomers in FL 
NLRP3 (Panel A), ASC (Panel B), and NLRP3 pyrin domain (Panel C). It was 
interesting to note that FL caspase-1 oligomers were responsive to SDS 
treatment and appeared as single monomeric bands (Panel D). 
 
A.                                        B. 






4.1.3. Inclusion of the secretion sequence resulted in differences in 
oligomerization profiles upon analyzing medium samples 
Presumably, the absence of a secretion sequence in the gene insert 
would prohibit the release of expressed proteins into the cell culture medium. 
Surprisingly however, some of the non-secretion-designed proteins were 
recovered in affinity-purified medium samples. A significant amount of the 
secreted form of ASC was obtained from the medium after affinity purification 
which was expected. However, the non-secreted form of ASC was also 
recovered and purified from the medium indicating that ASC can be released 
from cells. Despite both secreted and non-secreted forms being present in the 
medium, there were differences in their oligomerization profiles (Figure 4.3). 
SDS-PAGE and western blotting indicated that the secreted form of ASC had a 
substantial portion of monomeric protein under denaturing conditions (Figure 
Fig 4.2. Immunoblots of expressed inflammasome proteins show the presence of 
SDS-resistant oligomers except FL caspase-1. Affinity-purified fractions were 
analyzed by SDS-PAGE under denaturing conditions and immunoblot experiments 
were conducted with antibodies specific for each protein. The peak fractions showed 
higher degree of oligomerization (Panels A-C). The red arrows indicate the monomers 
Panel A FL NLRP3 (118 kD),  Panel B (ASC 22 kD), Panel C NLRP3 Pyrin (12 kD), 
Panel D FL procaspase-1 (45 kD).  
108 
 
4.3A), while the non-secreted form was highly oligomerized and no monomeric 








Fig 4.3 Expressed ASC proteins were present in the ExpiCHO-S medium whether or 
not they contained a secretion sequence. Medium was collected after ExpiCHO-S 
expression of ASC containing an Ig κ-chain secretion sequence (panel A, secreted 
form) or not (panel B, non-secreted form). Immunoblot analysis was affinity-purified 
fractions using anti-ASC B-3 primary antibody. Mw markers from the membrane were 
aligned with the film images and are shown in lane 1 for both panels while HL60 
positive control lysate was used in lane 2.  As for lanes 3-5 respectively Panel A. 
Fractions 10-12 were used Panel B. Fractions 9-11. 




4.1.4. Oligomerization profiles of NLRP3 lysates and inclusion bodies 
are quite distinct 
Another interesting observation was the significant difference in 
oligomerization patterns observed between NLRP3 pyrin lysates and inclusion 
bodies (Fig 4.4). The lysates showed the presence of a single oligomeric species 
(trimers). On the other hand, the inclusion bodies had two distinct species around 
12 kD (monomer) and 70 kD (possible hexamer). These differences reveal that 
the lysate sample contains a stable species whereas the multiple species in the 
inclusion bodies indicate aggregation which may be due to improper folding. 
 
Fig 4.4. Oligomerization patterns of NLRP3 pyrin lysates and inclusion bodies are quite 
distinct. Affinity purified NLRP3 fractions were subjected to SDS-PAGE was followed by 
immunoblotting with anti-His antibody. Mw markers are in Lane 1, Lysates fractions 11 & 




4.2.   Analysis of inflammasome proteins oligomerization state in solution 
Due to the oligomerization propensity of the NLRP3 inflammasome 
proteins, size-exclusion chromatography (SEC) was employed to separate any 
soluble protein from pre-formed aggregates. In order to optimize the best 
conditions to isolate stable monomeric species, various stringent conditions were 
exploited in an effort to break the pre-formed protein aggregates, and keep the 
proteins in stable solution states as shown in (Table 4.1) based on previous 
publications [14, 16, 146, 149, 231, 302, 303]. 
 
 
Table 4.1 Various sample treatment conditions employed in order to obtain stable, 
soluble proteins during purification and storage afterwards. Various SEC buffers and 
buffer additives were explored that included detergents (SDS, NP40, Tween-20), 
reducing agents (2 mM DTT/ TCEP, 5% BME), denaturants (2M GuHCl) and 
stabilizers (glycerol, sucrose). 
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4.2.1.    ASC showed some degree of oligomerization 
Since ASC is extremely prone to aggregation, a Superose 6 column which 
has a high fractionation range (5-5000 kD) was used. The column was pre-
blocked with 0.75 mg/mL BSA then 1.5 mg/mL of affinity-purified ASC medium 
(peak 1 Fig 3.6) was centrifuged, loaded, and eluted in phosphate buffer. BSA 
monomer (66 kD) eluted at ~ 17 mL. Overlaying the BSA and ASC elution traces 
showed that ASC (monomer ~ 22 kD) eluted as various oligomeric species as 
shown in Fig 4.5.  
Because I observed mostly monomeric proteins under denaturing SDS-
PAGE conditions, I predicted that I would possibly see monomers if I performed 
chromatography under similar conditions. In an effort to reverse the aggregation/ 
oligomerization process, the same sample was treated with SDS only or SDS/ 
BME then eluted in Tris/ Glycine buffer (same buffer used when conducting SDS-
PAGE). However, even under these stringent conditions, most of the protein still 
eluted in the oligomerized form indicating that the oligomers and/or aggregates 









Fig 4.5 Recombinant ASC exists as oligomers of various molecular weights. Size 
exclusion column purification of ASC was done using a Superose 6 column 
(fractionation range 5-5000 kD) pre-blocked with BSA. Sample used was 1.5 mg/mL 
ASC (affinity peak #1 Fig 3.6). No denaturing conditions were used in sample 
treatment. 200 ul protein was centrifuged for 10 mins at 17,000g, loaded, running 
buffer PBS pH 7.2. The figure above shows an overlay of BSA and ASC elution 
curves. 
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4.2.2.    NLRP3 pyrin existed as a mixture of small and high molecular 
weight species 
For long term storage of proteins with little to no damage to their structural 
integrity, lyophilization is a commonly used method especially with recombinant 
proteins. Since the recombinant proteins were aggregating in solution, 
lyophilization was employed as an alternative storage strategy in order to 
maintain protein stability. Lyophilized affinity- purified NLRP3 pyrin domain was 
reconstituted, as described in the Methods, in 6 M GuHCl/2 mM DTT, heated, 
centrifuged, and the supernatant eluted on a Superdex 200 column pre-blocked 
with BSA. Multiple peaks were observed in the NLRP3 pyrin domain sample 
including a high Mw peak (8 mL) likely comprised of oligomerized pyrin protein 
(Figure 4.6 Panel A). Based on the elution volume, it was determined that the 
peak at 17-18 mL (asterisk, Panel A) potentially represented monomeric pyrin. 
The collected fractions at the 17-18 mL elution volume were reinjected on SEC 
and eluted a second time. The second elution resulted in one peak at the 
expected elution volume for pyrin with a Mw of 12,483 Da (Panel B). BSA (Mw 
66,500 Da) was routinely eluted on Superdex 200 at an elution volume of ~14 
mL. The separation in elution volumes of pyrin and BSA falls easily into the 
Superdex 200 fractionation range of 10- 600 kD. Although I was able to get 
monomeric NLRP3 pyrin, the amounts were too low to perform functional assays. 
Thus, these findings show that NLRP3 pyrin is unstable and prone to aggregation 







Characterization studies on caspase-1 will be covered in detail in Chapter 5.  
 
Figure 4.6 Two rounds of SEC purification yielded monomeric NLRP3 pyrin domain. 
A lyophilized sample of affinity-purified and dialyzed pyrin protein obtained from the IB 
fraction of an ExpiCHO-S expression was reconstituted in PBS containing 6 M GuHCl 
and 2 mM DTT. Panel A. The reconstituted pyrin was treated and SEC-purified on a 
Superdex 200 column as described in the Methods. Elution in PBS was monitored in-
line by A280 (solid line) and the asterisk corresponds to monomeric pyrin. Panel B. A 1 
mL pool of the two peak fractions (asterisk in panel A) was reinjected on Superdex 
200 column and eluted a second time. The protein eluted at the expected volume for 
pyrin monomer (12.5 kD). For comparison, BSA (66.5 kD) was also purified on 
Superdex 200. Fig by Dr. Nichols. 
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4.2.3.   Optimizing various SEC buffers using bovine serum albumin 
(BSA) 
Multi-angle light scattering (MALS) analysis in line with SEC was used to 
determine the molecular weights of the proteins. Protein aggregates, however, 
tend to scatter a lot of light thus distorting data collection. Various sample 
treatment strategies and buffer conditions listed in Table 4.1 were employed to 
maximize obtaining stable solution proteins that could be detected by MALS. For 
the buffer optimization experiments, BSA was eluted on a Superdex 75 column 
and the elution peaks are showed in Fig 4.7. BSA monomer elution peak was 
similar in PBS buffer +/- 2 mM DTT. However, there was a noticeable shift in the 















BSA, 2.5 mg, PBS/DTT
BSA, 5 mg, PBS
BSA, 5 mg, HEPES 





4.2.4.    A large portion of the ASC fusion proteins appeared in the 
aggregated form 
Since the elution volume of BSA monomer was somehow similar in PBS 
buffers +/- reducing agent (DTT) without a significant shift in the peak, follow-up 
experiments were conducted in PBS/ DTT buffer. Fig 4.8 shows the elution 
profiles of ASC fusion proteins [SUMO-ASC (33 kD), MBP-ASC (61 kD), ASC (22 
kD)].  BSA monomer (66 kD) elutes around 10 mL and anything else bigger than 
66 kD elutes before BSA. Ideally, the elution peaks of the fusion proteins would 
have appeared after the BSA elution peak had these proteins been in their 
monomeric forms. For example, I would have expected monomeric MBP-ASC to 
elute right around 10 mL based on its Mw. Likewise, SUMO-ASC dimer and 
intracellular ASC trimer are expected to elute right around the BSA monomer 
elution volume. 
In this case however, a large portion of the proteins appeared as high 
molecular weights species and eluted in the void volume. The maximum 
separation threshold for a Sup 75 column is 70 kD and anything bigger than that 
Fig 4.7 BSA has different elution profiles in different buffers. BSA (2.5 mg or 5 mg) 
was loaded onto the Sup 75 column and eluted in various buffers in order to optimize 
the best buffer conditions to obtain recombinant proteins in their soluble forms. This 
information is important when predicting the sizes of eluted proteins based on their 
elution volumes in different buffers. It is also important to note that the BSA recoveries 
were not consistent.  
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appears in the void volume as shown by the major elution peaks before 10 mL 
mark. Small molecular weight species were observed but at very low amounts. 
Although the presence of solubility-enhancing fusion tags increased the amounts 
of proteins obtained in the lysate fraction, that did not improve the yields of 























BSA, 2.5 mg, PBS/DTT (primary axis)
ASC intra, 0.35 mg
SUMO-ASC, 0.35 mg
MBP-ASC, 0.08 mg
Fig 4.8 Sup 75 purifications of ASC fusion proteins in PBS/ DTT buffer. All the 
proteins eluted in the void BSA monomer elution peak. Amounts of proteins loaded 
are as follows: BSA (2.5 mg), MBP-ASC (0.08 mg), SUMO-ASC (0.35 mg) SDS/BME 




Further optimization of the best buffer conditions was done with the fusion 
protein, MBP-ASC. Superdex 75 elution profiles of MBP-ASC in various buffers 
are shown in Fig 4.9. Just like the previous findings, the proteins mostly eluted as 
high molecular weight species in the void. Interestingly, all the elution peaks 
(except the one in PBS only buffer) showed the signature double-hump 
suggesting presence of smaller oligomers. Considering the elution in Tris/glycine 
(SDS-PAGE buffer) a small monomer peak was observed although a significant 
amount of the protein was aggregated. Since this finding seemed promising, 
Tris/glycine buffer would be later used in subsequent SEC-MALS experiments. 
These data show that addition of buffer additives somehow assisted in 
solubilizing the aggregates into smaller species to some extent. 
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MBP-ASC, PBS, 0.5 mg
MBP-ASC, HEPES, 0.22 mg
MBP-ASC, PBS/DTT, 0.08 mg
MBP-ASC, Tris/Glycine, 0.25 mg
Fig 4.9 Superdex 75 elutions of 
MBP-ASC fusion proteins in 
various buffers. SDS-BME 
treatment was done for lysate 
(0.5 mg) and medium (0.22 mg) 
samples eluted in PBS and 
HEPES buffers respectively. 
0.08 mg medium sample was 
treated with 6M GuHCl/ 2mM 
DTT prior to loading then eluted 
in PBS/DTT, lysate (0.25 mg) 




4.2.5. SEC-MALS analysis confirmed the existence of protein 
aggregates 
SEC-MALS experiments with the recombinant proteins would later reveal 
that light scattering intensities exceeded the threshold thus further confirming the 
presence of aggregates. Fig 4.10 shows the MALS data obtained with MBP-ASC 
eluted in Tris/ Glycine and PBS/ DTT buffers. One main challenge encountered 
when trying to mimic SDS-PAGE conditions during SEC-MALS experiments is 
that BSA eluted as a dimer in this buffer so that threw off the Mw estimations. 
SDS micelles increase the protein size and that explains BSA peak shift and 
incorrect Mw [304, 305]. Despite our attempts to use different denaturing 
conditions, the proteins remained as huge aggregates thus distinct species could 
not be isolated by SEC which made it difficult to properly analyze them by MALS. 










Fig 4.10 SEC-MALS experiments with recombinant MBP-ASC protein revealed the 
presence of aggregates. Superdex 200 elutions were done in PBS/DTT and Tris/ Glycine 
buffers (same buffer used in SDS-PAGE). BSA  (66 kD) eluted as a monomer with 
PBS/DTT buffers (blue dotted line) and the Mw read off the Y-axis confirms the protein as 
monomeric and homogenous (blue straight line). The red dotted line is the BSA elution 
peak in Tris/Glycine Buffer and it showed a significant shift towards the void (from 14.5 mL 
to 8.3 mL) and the Mw estimation showed the protein as a dimer in SDS-PAGE buffer. The 
cyan curves represent MBP-ASC medium (61 kD) eluted in PBS/DTT buffer while purple 
ones show MBP-ASC lysate sample eluted in Tris/Glycine. Both elution profiles show the 
major peaks in the void volume and the MALS Mw estimations show the presence of 




4.3. Analysis of inflammasome protein oligomer structure and morphology 
To further determine the structures of the recombinant proteins, studies 
were conducted to determine their hydrodynamic radii (dynamic light scattering 
DLS), secondary structure (circular dichroism CD), and morphology 
(transmission electron microscopy TEM). 
 
4.3.1. DLS analysis of caspase-1 proteins revealed the presence of 
monomers and dimers 
DLS studies were conducted with caspase-1 proteins purified on a 
Superdex 200 column under various conditions as described in the Methods 
section. The hydrodynamic radii are shown in Table 4. 2.  
 
Table 4.2 DLS experimental data. The experiments indicated that most of 
the proteins exist as oligomers. SEC-purified caspase-1 proteins were 
analyzed by DLS. In some cases, the DLS-determined sizes did not match 




DLS experiments provided some interesting data. Information on the sizes 
of the proteins was obtained with full-length caspase-1 and the truncated 
domains as well. In comparison to BSA monomer (66 kD) which has a 
hydrodynamic radius (RH) of 3.5 nm, the p20 sample had a radius of 2.5 nm and 
a relative molecular weight of 28 kD. These data indicate that the p20 sample 
was possibly monomeric. Similarly, the RH values obtained with procaspase-1 
(45 kD) and CARDp20 (33 kD) were 5.6 nm and 3.2 nm respectively thus 
suggested that both proteins were dimers.  
However, the data obtained by p10 fractions -26 (predicted to be a dimer) 
and -32 (predicted to be monomeric) did not match the SEC predictions. These 
samples showed extremely high hydrodynamic radii which was unexpected. In 
general, large light scattering intensities are indicative of oligomer formation. DLS 
studies with other proteins did not yield good readings as the data revealed that 
most of the proteins existed as aggregates. When conducting DLS 
measurements, aggregated proteins tend to scatter too much light thus giving 










4.3.2. Recombinant ASC exhibits some degree of helicity that is 
unaffected by changes in pH 
 Protein misfolding has been known to induce aggregation. While 
conducting these studies, one lingering question was whether the proteins were 
folding properly. CD studies were then conducted to analyze the secondary 
structures of the expressed proteins. Previous studies by de Alba and colleagues 
[17] explored the structure of ASC under neutral (pH 7.4) and acidic (pH 3.8) 
conditions. Their Nuclear Magnetic Resonance (NMR) and Atomic Force 
Microscopy (AFM) studies showed that the structure of ASC was not perturbed 
by the acidic conditions. Basing on these previous findings, I tested the effect of 
pH on the structure of recombinant ASC. 
CD studies with recombinant ASC revealed some degree of defined 
structure which was not perturbed by pH changes. CD studies were performed 
with affinity-purified ASC medium samples (purification traces previously shown 
in Fig 3.6). Both samples (peak 1 and peak 2) were analyzed at a final 
concentration of 18.5 µM. Published standard CD spectra shown in Fig 4.11 
Panel A were used as references. Under physiological conditions, peak 1 
showed some degree of alpha helicity while peak 2 appeared more like a β-sheet 
(Panel B). Panel C compares the spectra of peak 1 at both pHs. These data 
indicate that the structure of ASC is unperturbed by changes in pH. These results 
were in agreement with the previous studies by de Alba and colleagues [17]. An 
overlay of peak 1 and standard helix spectra shows that recombinant ASC has 
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some degree of helicity (Panel D). Under normal conditions, no protein exists as 
a perfect helix or β-sheet. Proteins thus exhibit some degree of helicity and β-
sheet structure. It is possible though that improper folding of the proteins during 






A.                                         B. 






4.3.3. ASC ball-like aggregates were observed by TEM 
ASC ball-like aggregates were seen by TEM. To further analyze the 
structure and morphology of ASC, TEM studies were done. The images showed 
what looked like ASC ball-like specks/ oligomers (Fig 4.12) thus confirming 
aggregation. ASC is inherently prone to aggregation at physiological pH as has 
been previously confirmed by previous studies [3, 4, 17, 128, 147]. Therefore, it 
was most likely to form aggregates due to overexpression plus under the 
conditions employed during isolation and purification processes. 
 
 
Fig 4.11 CD studies revealed that recombinant ASC had some structure. Studies were 
done using a Jasco spectrophotometer as explained in Methods. Affinity-purified 
recombinant ASC medium peak fractions (affinity-purification shown in Fig 3.6) were used 
for the measurements. BCA assay concentration determined the concentrations of ASC 
peaks 1 (1.5 mg/ml) and 2 (0.4 mg/ml). Peak 1 was diluted 4-fold in PBS buffer to match 
concentration of peak 2 then the samples were spun for 10mins at 17,000g to get rid of 
any aggregates. Panel A. Standard CD spectra obtained from 
https://ceberndsen.github.io/CEBerndsen.github.io/CD.html   
Panel B. CD spectra of ASC peaks 1 and 2 in PBS buffer pH 7.4. In Panel C, the spectra 
of peak 1 were collected under acidic and neutral pH while Panel D compares the 













A.                                     B. 
Fig 4.12 Electron microscopy images show recombinant ASC as aggregates. TEM 
studies were conducted as explained in Methods. Briefly, affinity-purified recombinant 
ASC medium peak fraction 1 (affinity-purification shown in Fig 3.6) was diluted to 18 
µM in PBS buffer then 10 µl of the sample was placed onto a 200-mesh formvar-
coated copper grid (Ted Pella, Inc.), adsorbed for 10 mins, washed and stained with 
uranyl acetate. After air drying, the grid was imaged. Panel A shows ball-like ASC 
aggregates at 43k magnification and Panel B is at 35k magnification. The scale bars 




In summary, expressed NLRP3 inflammasome proteins are highly prone 
to aggregation. Characterization of these proteins to reveal their oligomerization 
states indicated the presence of HMW aggregates as shown by immunoblotting 
techniques and biophysical studies. Various harsh conditions were explored in 
efforts to reverse the aggregation processes with very little success. Because 
these aggregates were quite resistant to the stringent conditions used, a lot of 
questions arose. Are the proteins misfolding during the expression? Could it be 
that the in vitro conditions are not conducive, and that it may not be feasible to 
obtain stable inflammasome proteins under the conditions employed? What are 
the stoichiometric components of each individual protein under physiological 
conditions, and what mechanisms are involved in keeping the proteins in these 
stable forms? A lot of signaling pathways and a variety of factors are involved in 
stabilizing these proteins in a cellular environment hence taking away those 
components may be the cause of aggregation. These and other factors present a 
very complicated system. Due to their propensity to aggregate, maybe the stable 
forms of these proteins exist in the aggregated form. Regardless, I was able to 









CHAPTER 5: ISOLATION OF THE ELUSIVE CASPASE-1 ENZYME 
Caspase-1 is a cysteine protease that is activated upon assembly of the 
NLRP3 inflammasome through a sequence of events leading to IL-1β maturation 
and subsequently pyroptosis. However, the actual mechanisms surrounding 
caspase-1 activation are still to be determined. Although a lot of studies have 
been done on caspase-1, there are still unanswered questions regarding the 
actual structure of the active enzyme. The general consensus, however, is that 
procaspase-1 possesses little to no activity thus the goal of these studies is to 
determine the actual form of the enzyme that is active. Some of the outstanding 
questions regarding the actual conditions required for enzyme activity include: is 
the FL procaspase-1 active by itself? If so, do all three proteins need to be 
present to render the enzyme active? What domains make up the active 
conformer of caspase-1? To answer these questions, recombinant FL, mutant, 
and truncated versions of caspase-1 were assessed for enzymatic activity in 
these studies. 
 
5.1. What is the actual structure of active caspase-1? 
Cell-stimulation assays with inflammasome activators revealed the 
presence of the processed p20 and p10 subunits in the cell-free supernatants 
and lysates [3, 39, 153, 161, 162, 166, 170, 171, 245, 293, 306]. Processed 
caspase-1 fragments indicate caspase-1 activation and maturation. Biotin pull-
down probes such as biotin valyl-alaninyl-aspartyl chloro/fluoromethylketone (b-
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VAD-cmk/-fmk) [15, 21, 245] and fluorochrome labeled inhibitors of caspases 
(FLICA) have been used to trap caspase-1 in the active form [21, 293, 307-310]. 





Fig 5.1 Schematic showing possible active confomers of active caspase-1. Designs 
based on the published literature findings. Panel A shows the full-length, unprocessed 
proenzyme which is presumed to have little or no activity. Panels B-D show the 
various forms of active caspase-1 discussed in the literature. Panel B shows the 
p33p10 processed form with an intact CARD domain for anchoring to the 
inflammasome. Panel C is the p20p10 heterodimeric form of active caspase-1 while 





Early studies reported the active enzyme to be p20p10 heterodimer [6] 
and these findings were confirmed by other groups [9, 15, 16]. In contrast, some 
groups proposed the active enzyme to be a heterotetramer (p20p10)2 [7, 8, 13]. 
Two groups reported the existence of an equilibrium between the heterodimer 
and heterotetramer species [10, 277]. Interestingly, both species were found to 
be catalytically active. High substrate concentrations and presence of inhibitors 
promoted heterotetramer assembly [10].  
Recent studies by the Schroder group completely dispute previous reports 
[21]. Using a bVAD-fmk probe that labels and pulls-down active caspases from 
stimulated macrophages, they identified the full-length proenzyme p46 and the 
transient p33p10 heterodimer as the dominant active species. They proposed 
that the CARD domain anchors the active form of caspase-1 onto the activating 
inflammasome thus removal of the CARD-domain linker (CDL) releases the 
enzyme from the inflammasome platform ultimately rendering it inactive. This 
generates “unstable” p20p10 species [21]. Currently, there are two distinct 
models for caspase-1 activation as shown in Fig 5.2. Scenario 1 represents the 
widely-accepted model while Scenario 2 is the most recent model as proposed 
by Schroder and colleagues [21]. Due to the complexity of the caspase-1 
activation process, it is possible that other mechanisms could be involved in 
these processes. Nonetheless, there are still lingering questions regarding the 
actual composition and stability of active caspase-1 as discussed in our recent 






Fig 5.2 Possible scenarios to explain caspase-1 activation mechanisms. The 
inflammasome facilitates caspase-1 activation via induced proximity mediated 
autoproteolysis. Scenario 1 proposes that CDL processing is a prerequisite for 
obtaining an active enzyme. The liberated p20 and p10 subunits recombine to form 
either the heterodimer or heterotetramer (both which have been found to have 
enzymatic activity) [6-16]. Presumably, removal of the CDL causes release of the 
active enzyme from the inflammasome complex to catalyze its substrate elsewhere. 
Scenario 2, however, suggests the inflammasome as the site for IL-1β cleavage. The 
CARD domain anchors the active caspase onto the inflammasome hence CDL 
processing to remove the CARD inactivates the enzyme resulting in it dissociating 
from the activating complex [21]. 
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5.2. Recombinant caspase-1 p20p10 reconstitution experiments 
5.2.1. Caspase-1 p20p10 reconstitution studies from the literature 
Apart from cell-stimulation assays, many groups have utilized recombinant 
systems to express full-length procaspase-1 and/or the individual domains for 
functional assays as summarized in Table 5.1. Detailed reports described the 
various methods of expression, purification, and functionalization of caspases 
under different conditions [285, 286].  
Table 5.1 Recombinant expression of inflammasome proteins from the literature. *In some 




5.2.2. Caspase-1 stability 
Caspase-1 exists as a monomer under normal conditions. Substrates and 
inhibitors, however, promote dimerization of the enzyme thus stabilizing it and 
keeping it in its active form [7, 8, 11, 12, 311]. For example, addition of aldehyde-
based caspase-1 inhibitor (Ac-YVAD-CHO) or concentrations of malonate 
exceeding 100 mM prevented autoproteolytic cleavage of the purified refolded 
enzyme [12]. The main challenge faced by researchers during recombinant 
expression, purification, and refolding of caspase-1 is to maintain an active 
enzyme. Various factors to take into consideration include enzyme 
concentrations, optimum temperatures and pH, ionic strength, inhibitors, half-life, 
buffer components/ various stabilizing additives (denaturants, detergents, 
reducing agents) as well as storage conditions [7-9, 11-13, 15, 277, 311]. 
Despite many reports supporting the fact that inhibitors stabilize caspase-
1 [7, 8, 11, 12, 15], surprising findings revealed that cowpox serpin crmA, a 
caspase-1 inhibitor, caused dissociation of the active heterotetramer resulting in 
the loss of the p10 subunit [13]. One group discovered that refolding the enzyme 
under non-reducing conditions prevents autoproteolysis [9]. In addition, too dilute 
enzyme solutions below 30 nM result in subunit dissociation while enzyme 
concentrations exceeding 2 µM promote autoproteolysis [10, 312]. Using cross-
linked recombinant caspase-1, Martin and colleagues also reported dissociation 
of caspase-1 at concentrations below 10 nM and that the enzyme exhibited a 
very short active life of just 9 mins at 37 oC [15]. Taking all these factors into 
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consideration, finding the right conditions to maintain an active enzyme can be 
quite a daunting task. 
 
5.2.3. Caspase-1 p20p10 reconstitution assays +/- inhibitors were 
unsuccessful 
Considering that other groups were able to successfully reconstitute an 
active enzyme from p20 and p10 fragments, I performed caspase-1 
reconstitution experiments with recombinant p20 and p10 fragments. Equimolar 
amounts of the subunits were solubilized separately, combined then refolded. 
Initial caspase-1 reconstitution assays with SEC-purified caspase-1 p10 and p20 
fragments were unsuccessful. In follow-up studies, affinity-purified p10 and p20 
lysates were solubilized overnight (separately) in 6 M GuHCl/ 20 mM DTT to 
break any pre-formed aggregates. To test the effect of inhibitors, equimolar 
amounts of solubilized p10 and p20 were refolded +/- inhibitors (1 µM Ac-YVAD-
CHO, 100 mM malonate). Fig 5.3 shows the SEC traces of the refolded proteins 
purified on Superdex 75 column. The purification traces show two peaks (with an 
anomaly peak ~ 5 mL) in the absence of inhibitor while addition of inhibitors 
yielded a single species that eluted in one peak ~ 8 mL. A possible explanation 
for the differences in these elution profiles is that presence of inhibitors results in 
a stable, single species. Since the 8 mL peak slightly overlays with BSA 
monomer (66 kD), it is most likely a 60 kD species. There were many possibilities 









A.                                        B. 
Figure 5.3 Analysis of refolded caspase-1 p20p10 +/- inhibitors. Panel A. p20 
Equimolar amounts of solubilized p20 & p10 IB samples were combined to a total of 1 
mL and added dropwise to 49ml refolding buffer in the presence/ absence of an 
inhibitor, refolded overnight and affinity purified. 1 mL of affinity peak fraction was 
centrifuged at 17,000g for 10 mins then loaded onto a Superdex 75 column pre-
blocked with BSA.  Refolded p20p10 samples were eluted in (10mM Phosphate, 150 
mM NaCl, 2mM DTT, 5% glycerol, 0.05% Tween-20) buffer. Panel B. Immunoblots of 
SEC-purified refolded p20 and p10 fragments +/- inhibitors. After overnight refolding, 
proteins were purified by affinity and SEC. Sup 75 peak fraction (13) was used for 
SDS-PAGE analysis. Immunoblotting was done with anti-His antibody. Lanes 1 has 
the MWM, Lane 2 blank, Lane 3 p20p10 (13) no INH, Lane 4 p20p10 (13) Ac-YVAD 
CHO, Lane 5 p20p10 (13) malonate. 
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The peak fractions were analyzed by SDS-PAGE followed by 
immunoblotting with anti-His antibody. Table 5.2 shows the estimated UV250 nm 
protein concentrations and the amounts of proteins loaded. The immunoblot 
snippets in Fig 5.3B show similar band patterns with all samples regardless of 
the presence/ absence of inhibitor which was quite unexpected. The dominant 
species detected were ~ 20 kD. A minor species (~40 kD) was also detected. 
Stripping and re-probing the membrane with an antibody targeting the p20 
domain (anti-p20 Ab, Boster Biological, Cat# PA1440) was unsuccessful. 
Another problem with the p20 antibody is that it could not distinguish between the 
p20 and p10 species. Furthermore, crosslinking experiments with a water-
insoluble maleimide crosslinker targeting sulfhydryl groups (BMH) did not provide 
usable data. Therefore, I could not determine whether the bands were entirely 
p20 or p10 fragments or a combination of the two.   
 
 
Table 5.2 UV280nm determined concentrations of the refolded caspase-1 p20p10 peak 
fractions that were used for the immunoblot assay. Mw used for the calculations is for 




5.3. Caspase-1 activity assays 
5.3.1. The enzymatic assay was optimized using commercial active 
caspase-1 and inhibitors 
Some groups previously reported observing enzyme activity with refolded 
p20p10 fragments (reviewed above). On the contrary, no single publication as of 
now has shown activity studies with recombinant pro-caspase-1 since it is 
assumed to be in an inactive state. To determine which particular domain(s) of 
the proenzyme are required for activity, caspase-1 activity assays were 
conducted with recombinant proteins.  
To begin, I had to optimize the assay using a purchased human active 
enzyme and two commercially available coumarin-based caspase-1 tetrapeptide 
synthetic substrates, Ac-YVAD-AMC and Ac-WEHD-AMC. The 4-residue 
cleavage site of pro-IL-1β (YVHD116) is quite similar to that of the synthetic 
tetrapeptide substrates. As Fig 1.8 Panel B shows, amino acid substitutions in 
the P2 position are tolerable and have no effect on enzyme activity. The 
fluorescence-based assay showed Ac-WEHD-AMC as a more potent substrate 
compared to the YVAD version as shown in Fig 5.4 Panel A. Subsequent activity 
assays were thereby conducted with Ac-WEHD-AMC. To further optimize the 
assay, caspase-1 inhibitors were introduced. As Panel B shows, enzyme activity 
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A.                                 
Fig 5.4 Optimizing the caspase-1 activity assays with commercial fluorogenic 
tetrapeptide substrates and inhibitors. Panel A. Ac-WEHD-AMC proved to be the 
more potent synthetic substrate. Panel B. Both the reversible (cho) and irreversible 
(fmk) caspase-1 inhibitors erased enzymatic activity. Figs by Dr. Nichols. 




5.3.2. Recombinant full-length (FL) procaspase-1 exhibited transient 
enzyme activity 
To verify whether the caspase-1 p20p10 reconstitution experiments 
(shown in Fig 5.3) were successful, activity studies were conducted with the 
synthetic substrate. As Fig 5.5 shows, no activity was observed with the refolded 
proteins regardless of the conditions in which the refolding occurred i.e presence 
or absence of inhibitors.  
 
Time (min)



















Refolded p20p10 + 100 mM malonate
Refolded p20p10 + 1uM Ac-YVAD-CHO
Refolded p20p10 no inhibitor
Refolded CARDp20 no inhibitor
Fig 5.5: Caspase activity assays of refolded p20p10. Refolded p20p10 (+/- inhibitors) 
and CARDp20 have no enzymatic activity. Sup 75 elutions for refolded p20p10 are 
shown in Fig 5.3. CARDp20 was purified on a different day but under the same 
conditions described in Fig 5.3 legend except that the SEC elution buffer did not 
contain glycerol. Peak fractions 13 were assayed for activity. 
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These findings were in contrast to previous published findings that stated 
that refolded p20p10 possesses enzymatic activity (see Table 5.1). A variety of 
factors may be responsible for these discrepancies with the main one being the 
expression system used (previous studies use E. coli). In addition, the 
experimental conditions employed greatly affect the type of stable species 
formed and subsequent enzymatic activity. It was not clear if our refolding 
experiments were successful to begin with. Attempts to obtain activity with the 
CARDp20 fragment and refolded CARDp20/p10 (data not shown) proved 
fruitless too. 
After unsuccessful attempts to obtain caspase activity with both the 
CARDp20 and the refolded p20p10 fragments, I decided to test enzymatic 
activity of procaspase-1. To conduct these studies, lysates and refolded inclusion 
bodies of procaspase-1 were purified by SEC. The Superdex 75 elution profiles 
in Fig 5.6 Panel A show that all the protein eluted in the void. Surprisingly, FL 
caspase-1 obtained from both the lysates and inclusion bodies exhibited 
enzymatic activity when tested with the fluorescence assay. This was the first 
time any enzymatic activity had been observed with the unprocessed proenzyme. 
Panel B shows the activity assay data for the lysate sample. However, there was 
a drastic loss of activity overnight and over the course of the next few days, 
activity decreased to none. Addition of a commercial protein stabilizer helped 
retain some of the activity after 6 days (Panel C). Interestingly though, the active 
enzyme was a high molecular weight species which eluted in the void whose 
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exact conformation is unknown. These observations were intriguing and only add 





















































































5.4. Various conditions were optimized in order to retain a stable, active 
enzyme 
In an attempt to find out what caused the loss of activity over time, I 
explored various storage conditions such as concentration, storage temps, 
buffers, stabilizers, and storing the enzyme in the affinity-purified vs SEC form. 
Enzyme concentration plays an important factor when conducting caspase-1 
activity studies. Based on my findings, a minimum amount of recombinant 
enzyme was required to obtain activity (7 µM stock solution amounting to 700 nM 
final enzyme concentration in the reaction cuvette) and below that threshold, 
Figure 5.6 FL procaspase-1 possesses activity as shown by the fluorogenic peptide 
assay.  Panel A. Recombinant expressed FL procaspase-1 lysates and inclusion bodies 
peak fractions were affinity-purified, centrifuged at 17,000g for 10mins, loaded onto a 
Superdex 75 column pre-blocked with BSA. The proteins were eluted in (10 mM 
Phosphate, 150 mM NaCl, 2 mM DTT, 5% glycerol, 0.05% Tween-20) buffer and the 
collected fractions were assayed for caspase-1 activity. Panel B. SEC purified full-length 
procaspase-1 (700 nM) was incubated with 30 μM Ac-WEHD-AMC in caspase-1 buffer at 
25 oC and time-dependent caspase activity was monitored. Both lysate and inclusion 
bodies samples exhibited activity. Panel C. Protein stabilizer cocktail helps retain 
caspase-1 activity. Another ExpiCHO-S expression and purification of FL procaspase-1 
was conducted. A slightly modified version of SEC buffer was used (10mM Phosphate 
buffer, 150 mM NaCl, 2mM DTT, 0.05% CHAPS). Panels B, C Figs by Dr. Nichols. 
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there was no observed activity. That could also explain why the refolded p20p10 
and CARDp20 domains did not exhibit any activity as their stock concentrations 
were 4 µM and 2.8 µM respectively. Higher concentrations of the enzyme may 
also promote aggregation or auto-degradation so obtaining the right 
concentrations that yield an active enzyme can be challenging. 
 
To test whether SEC is a requirement to obtain activity, side-by-side 
activity assays were done with affinity- and -SEC-purified procaspase-1. Affinity-
purified samples were found to have no activity but only gained activity after SEC 
purification. That raised another question whether buffer exchange assisted in 
yielding an active enzyme. If a simple buffer-exchange process is required, then 
dialyzed protein (to get rid of the high imidazole in affinity-purified samples) 
should have activity. Affinity purified FL caspase-1 lysate sample was dialyzed 
overnight in SEC buffer (10mM Phosphate buffer, 150 mM NaCl, 2mM DTT, 
0.05% CHAPS) then assayed for activity for 2 consecutive days. The activity of 
the dialyzed sample was considerably low by many orders of magnitude 
compared to the SEC-purified sample (data not shown). Although initial activity of 
the dialyzed enzyme was low, there was noticeable loss of activity overnight 
similar to previous observations with SEC-purified enzyme. 
Since the enzyme showed significant reduction in activity when stored in 
SEC buffers (10 mM Phosphate, 150 mM NaCl, 2mM DTT, 5% glycerol, 0.05% 
Tween-20), I decided to test whether storing it in the affinity-purified form had any 
significance. Two weeks after the initial activity studies, I purified the remaining 
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affinity sample by SEC and tested its activity. The enzyme still retained some 
activity although the initial activity was not as high as the previously obtained 
activity in Fig 5.6 Panel B. These findings were quite useful as they indicated that 
storing the proteins in the affinity-purified form helped in slightly retaining enzyme 
activity over time compared to storing them as SEC-purified samples.  
Another possible explanation for the loss of activity could be aggregation. 
To circumvent this, the enzyme was stored in the affinity-purified form at -80 oC 
(previously stored at 4 oC) then subjected to SEC after some time. That also 
proved to be unsuccessful as those samples had no activity. Since aggregation 
during transfection was another issue, expression times were optimized ranging 
from 2-13 days. However, there was no difference in total protein yields, and 
neither was there any improvement in enzymatic activity and/ or stability.  
 
5.5. Recombinant procaspase-1 was unable to cleave the pro form of 
interleukin 1-beta (IL-1β) 
After observing enzymatic activity with the recombinant procaspase-1 via 
fluorescence methods, I sought to further test the potency of the enzyme using 
pro-interleukin-1-beta (pro-IL-1β), well-known caspase-1 substrate. To optimize 
the cleavage assay, commercial active human recombinant caspase was used. 
Time-dependent cleavage of pro-IL-1β was observed as indicated by the 
disappearance of the 35 kD band (pro-IL-1β) and appearance of a 17 kD band 









Fig 5.7 Optimizing IL-1β cleavage assay with active commercial caspase-1. To 
conduct the assay, 1.8 μg caspase-1 enzyme was mixed with 500 ng/mL IL-1β protein 
in caspase-assay buffer cocktail (25 mM HEPES, 1 mM EDTA, 25 mM KCl, 10% 
Sucrose, 1 mM DTT, pH 7.4) to make a total volume of 100 µL. The reaction was 
conducted for 4 hours at 25 oC. Aliquots were collected at different time points and the 
reaction was quenched by adding SDS/BME. Samples were analyzed by SDS-PAGE 
and immunoblotting (as mentioned in Methods section) then probed with human IL-
1β/ IL-1F2 polyclonal goat antibody. Pro-IL-1β is 35 kD while the cleaved, mature 
form ~17 kD. Immunoblot done by Shikha Grover. 
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The next goal was to perform the pro-IL-1β cleavage assays using the 
recombinant procaspase-1. These experiments were performed on the same day 
as the fluorescence assay. However, no cleavage occurred after a 4hr incubation 
at room temp (data not shown). Further optimization was done by incubating the 
reaction vessel overnight to maximize the cleavage reaction. Again, the assay 
did not give positive results. Although recombinant procaspase-1 showed 
enzymatic activity with the synthetic substrate in the fluorescence assay, it did 
not exhibit any activity with the biological substrate. The synthetic substrate has 
been widely used in caspase-1 activity assays and is considered a good model 
[the recognition site in the synthetic fluorogenic substrate (WEHD) and the pro-
IL-1β cleavage site (YVHD)]. Hence, it is still to be determined why the 
recombinant procaspase-1 did not cleave pro-IL-1β. 
 
5.6. Tobacco etch virus (TEV) protease cleavage reactions to remove 
fusion tags  
5.6.1. The cleavage experiments showed half maximal cleavage 
efficiency 
TEV protease cleavage experiments were conducted to remove the MBP 
and SUMO fusion tags from our proteins of interest. Considering the size of the 
MBP protein, its removal would prevent interference with other subsequent 
assays. For these experiments, affinity-purified MBP-p10 was used. Initial 
cleavage reactions were conducted with 20 µg of protein and 10 U of enzyme but 
there was barely any cleavage as revealed by western blotting analysis. Upon 
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realizing that the high amounts of imidazole in the affinity-purified samples (500 
mM) were probably inhibiting the enzyme, subsequent cleavage assays were 
conducted with samples dialyzed overnight in 50 mM Tris-HCl buffer. In addition, 
amounts of MBP-p10 and enzyme were scaled up 10 times (200 µg and 100 U 
respectively) to maximize the cleavage reaction.  
Under these new conditions, there was time-dependent cleavage of MBP-
P10. Immunoblotting with an antibody recognizing the p10 fragment revealed the 
appearance of bands ~10 kD (Fig 5.8 Panel A). The cleaved protein appeared as 
early as 30 minutes into the reaction and maximum cleavage had occurred after 
4 hours. Re-probing the same membrane with anti-His antibody showed the time-
dependent decrease of His-tagged MBP-p10 (50 kD) coupled with the increase 
of His-MBP ~40 kD (Panel B). In addition, TEV protease is also His-tagged at the 












Although there was obvious cleavage, there were still significant amounts 
of uncleaved protein. Adding the enzyme to the reaction vessel at various time 
points (instead of adding all the enzyme at once) did not improve the cleavage 
efficiency either (data not shown). A possible explanation is that due to 






Fig 5.8 TEV cleavage reactions with MBP-p10 showed time-dependence cleavage 
although there were significant amounts of uncleaved protein. Cleavage experiments 
were conducted inorder to remove the fusion tags for downstream assays as outlined 
in Methods. Briefly, affinity-purified MBP-p10 caspase lysate fraction that was stored 
at -80 oC was dialyzed overnight in 50 mM Tris-HCl buffer. 200 ug protein sample 
was treated with 100 units TEV (10 µL) protease (1 mL volume total). 15 µL aliquots 
were taken at various time points and quenched with 15 µL Laemmli sample buffer 
with BME, 95 oC heating for 5 mins then analyzed by SDS-PAGE. Panel A. 
Immunoblotting was done with anti-p10 primary and anti-rabbit secondary antibodies. 
Cleaved p10 was observed ~10 kD while uncleaved mbp-p10 was detected at ~50 
kD. Panel B. Membrane was stripped and re-probed with anti-His and anti-mouse 
primary and secondary antibodies respectively. The TEV protease also contains a His 
tag and appears ~ 25 kD. 
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5.6.2. Analysis of cleaved MBP-p10  
After the cleavage reactions, affinity chromatography was used to 
separate the cleaved and uncleaved proteins. Fig 5.9 Panel A shows the affinity-
purification curves. Peaks 1 and 2 represent the flow through. Cleaved p10 is 
expected to be in the flow through. On the other hand, the TEV protease, His-
MBP, and uncleaved His-MBP-p10 were expected to appear in the elution peak 
3. The peak fractions were collected for dot blot analysis. Due to very low protein 
amounts, the samples were concentrated first. Dot blotting with both anti-p10 and 
anti-His antibodies was used to distinguish the fractions in the flow through 
(fractions 6, 17, 20) and the elution fraction 62. The caspase-1 p10 antibody 
detected both the cleaved p10 (fraction 6) and uncleaved His-MBP-p10 with 
similar intensities as shown in Fig 5.9 Panel B. This could mean that somehow 
equal amounts of cleaved vs uncleaved protein. Probing with an anti-His 
antibody showed the presence of the His tag in the eluted fraction 62 as 
expected (due to residual His-MBP-p10 and the TEV protease). However, the 
fact that His-tagged was detected in the flow through was quite puzzling 














A.                                         B. 
Fig. 5.9 Analysis of cleaved MBP-p10 by affinity purification and immunoblotting. 
Panel A. Affinity-purified mbp-p10 caspase lysate peak fractions were dialyzed in 
Tris/HCl overnight then concentrated. About 1.26 mg protein was treated with 100 U 
(10 µL) TEV protease for 6 hr at 30 oC. The sample was centrifuged at a speed of 
17,000g for 10 mins to remove debris then 1 mL supernatant was loaded on affinity 
column. Collected fractions 5,7 (peak 1), 17-21 (peak 2), and 58-65 (peak 3) for 
further analysis. Panel B. Dot blot analysis using affinity-purified cleaved mbp-p10 
fractions. The dot blot protocol was done as outlined in Methods followed by 
immunoblotting with anti-p10 antibody. **Assumption is that the flow through fractions 
(6, 17, 20) contain cleaved p10 protein and the imidazole-eluted fraction 62 contains 




These studies revealed, for the first time, enzymatic activity of 
recombinant procaspase-1. However, the activity was transient, and the enzyme 
was unstable under the conditions employed for purification and storage. Since 
the active enzyme eluted in the void volume using a Sup 75 column, this means 
that the active species had a Mw > 70 kD. These findings suggest the possibility 
of another active conformation of active caspase-1 apart from the known active 
forms shown in Fig 5.1. Despite exhibiting enzymatic activity with the 
fluorescence assay, the recombinant enzyme was unable to cleave pro-IL-β, a 
well-known caspase-1 substrate. Due to the similarity in the recognition 
sequences of the synthetic and biological substrates, caspase-1 is expected to 
cleave both substrates, but this was not the case with our recombinant 
procaspase-1. Future studies may involve using various caspase-1 substrates to 
test the potency of our recombinant enzyme. Contrary to previous studies, 
caspase-1 reconstitution experiments with refolded caspase-1 p20 and p10 
fragments were not successful due to variability in experimental conditions. 
Subsequent TEV cleavage reactions with caspase-1 domain fusion protein, 
MBP-p10, indicated about 50% cleavage efficiency. It is possible that protein 
aggregation may have concealed the TEV cleavage site thus making it 
inaccessible to the protease.  Nevertheless, caspase-1 studies yielded some 
useful and interesting results that will help in understanding this enzyme better 





CHAPTER 6: INTERACTION OF INFLAMMASOME PROTEINS WITH 
THE ALZHEIMER’S DISEASE AMYLOID-β PROTEIN 
As described in Chapter 1, Aβ is known to activate the NLRP3 
inflammasome [19, 23, 37, 53, 56, 100, 115] resulting in caspase-1 activation 
and IL-1β secretion. Exactly how Aβ stimulates the inflammasome is still unclear 
and not many studies have been conducted in this area. Either there are direct 
interactions between Aβ and the inflammasome proteins or there could be 
indirect interactions involving an alternative pathway. Heneka and colleagues 
have reported interactions between Aβ and ASC specks [2, 116]. Another group 
performed cell-free assays to show direct interactions between Aβ and NLRP3 
[281]. Since NLRP3 is the sensor protein, it is more likely to interact with Aβ. 
Therefore, we decided to investigate these interactions using a two-way 
approach; in vitro interaction assays with recombinant inflammasome proteins 
and immune cell stimulation assays to isolate the endogenous inflammasome 
complex by immunoprecipitation methods. 
 
6.1. There is a direct interaction between Aβ PF and NLRP3 protein 
Previous studies from our lab identified Aβ-42 protofibrils (PF) as robust 
activators of microglia [19]. Additional studies revealed that primary microglia 
cells preferentially take up Aβ PF compared to monomers [22] hence cell 
stimulation experiments were conducted with PF. Aβ-42 PF purification was 




The purification curves in Fig 6.1 show distinct PF and monomer peaks. 
The PF peak was selected for the binding assays. Our studies are quite distinct 
due to the fact that we use SEC to isolate pure PFs compared to other studies 

























Fig. 6.1 Superdex 75 purification of Aβ-42. The column was pre-blocked with 2.5 mg/ 
mL BSA. The elution trace shows the presence of both protofibrils  PF (1st peak) and 
monomers (2nd peak). Briefly, 0.9 mg HFIP-treated, lyophilized Aβ1-42 (ERI) was 
reconstituted in 0.1 mL 50 mM NaOH/0.9 mL aCSF. The sample was incubated for 30 
mins at room temp, centrifuged at 17000g for 10 min, 1 mL supernatant was loaded 





6.1.1. In vitro interaction assays 
To conduct in vitro interaction assays, Aβ and recombinant proteins (FL 
NLRP3 or pyrin domain only, ASC, caspase-1) were combined in an eppendorf 
tube as shown in Table 6.1. The final concentration of each protein in the 
reaction vessel was 2 µM. The experiment proceeded for 2-4 hours at 4 oC 
(control tube left at room temperature) followed by co-immunoprecipitation with 1-
2 µg anti-ASC and anti-NLRP3 antibodies. SDS-PAGE and immunoblotting 
experiments with antibodies targeting Aβ and the inflammasome proteins.  
 
Table 6.1 In vitro inflammasome reconstitution assays were conducted to study 
interactions between Aβ binding and the inflammasome. Inflammasome proteins were 
purified on a Superdex 200 column in PBS-only buffer. Void peak fractions were used 
for in vitro binding assays. All proteins were combined as shown in the table. The final 
concentration of each protein in the reaction tube was 2 µM. Samples were incubated 
for 2-4 hours or overnight to allow binding (if any) between the proteins, then 
proceeded to Immunoprecipitation step using anti-ASC and /or anti-NLRP3 antibodies 




However, the experiments were not successful as no protein was detected 
by immunoblotting (data not shown). Increasing the incubation time or quantity of 
antibodies for co-IP did not help either. This suggested that the protein amounts 
were below detection limits. Attempts to increase the amounts were quite 
challenging because that varied with the Aβ isolation preps and yields were not 
always consistent. Scaling up the protein expression amounts using bigger flasks 
did not improve the overall recovery. Due to these challenges, I shifted my focus 
to cell stimulation assays. 
 
6.1.2. Cell stimulation assays 
Primary murine microglia, BV-2 microglia, and differentiated THP-1 
macrophages were used to conduct the cell stimulation assays as outlined in 
detail in the Methods. Cells were stimulated with 5-10 µM Aβ PF for 6 hours 
followed by cell lysate extraction, co-IP assay with anti-NLRP3 antibody, gel 
electrophoresis under denaturing conditions, and immunoblotting with a 
conformational-specific antibody generated in the Nichols lab that targets the PF 
(AbSL). According to Fig 6.2, the input lanes show that the cell took up the PF 
and nothing was detected in the control lane. The huge smears indicate high Aβ 
concentrations, and also the presence of various Aβ (oligomeric) species. The 
output (IP lanes) revealed a high molecular weight Aβ species that was bound to 
NLRP3. These findings thus indicate a direct interaction between the two 
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proteins. Further attempts to detect the inflammasome proteins (ASC, NLRP3, 





Fig 6.2 Co-immunoprecipitation assays show direct interactions between Aβ PF and 
NLRP3. Cell stimulation assays were conducted with murine primary microglia. 300 
μL cells (1x106 cells/ mL) were plated into 24-well plates then allowed to adhere 
overnight. After rinsing the cells with sterile PBS, cells were treated with 5 µM-10 µM 
Aβ PF (triplicates) and the control wells had assay medium. Cells were incubated for 
6 hrs at 37 oC followed by lysate extraction with RIPA buffer. Immunoprecipitation was 
done with anti-NLRP3 antibody (2 µg). After running an SDS-PAGE and transfer, PF-
specific apAbSL was used for immunoblotting. Lanes 2-4 represent the input while 




The fact that I was not able to detect the proteins in both the crude lysates 
and immunoprecipitated samples pointed to the possibilities that either the 




Table 6.2 Inflammasome proteins were not detected in both the crude and 
immunoprecipitated cell lysates. To verify the amounts of total protein present, BCA 
assays were conducted. ELISA assays for secreted cytokines verified successful cell 
stimulation. Cell stimulation assays were conducted with PMA-differentiated THP-1 
monocytes. Cells were plated overnight (500 ul of 1x106 cells/mL) in 24-well plates 
then treated with 5 uM and/or 10 uM Aβ PF and control wells had CSF only in assay 
medium (triplicates). Cells were incubated for 6 hrs at 37 oC as outlined in Methods. 
Immunoprecipitation was done with 2 ug NLRP3 antibody. SDS-PAGE, transfer, and 
immunoblotting were performed. Panel A. human TNFα ELISA assay showing 
concentration- dependent TNFα release. Panel B. BCA concentration assay Panel C. 
To scale up the experiments, 3 mL of 1x106 cells/mL were plated into 6-well plates 
overnight then underwent similar treatment as before. BCA assay was conducted with 
cell lysates.  
A.                       B.                   C.        
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ELISA assays revealed that the stimulation experiments worked as the 
untreated wells showed extremely low amounts of secreted TNFα (Table 6.2A). 
Various factors affect protein recovery during Co-IP including protein-antibody 
binding efficiency. In addition, immunoprecipitation does not always provide 
efficient sample recovery hence large amounts of total proteins must be present 
in the lysates to rule out any losses during the experimental procedures. In our 
case, bicinchoninic acid (BCA) protein concentration assays showed that the 
lysates had low protein amounts to begin with (Table 6.2B). Scaling up the 
experiments (from 24-well plates to 6-well plates) did not increase the amount 
total protein present in the lysates (Table 6.2 C).  
To conduct further studies of the endogenous inflammasome, another 
strategy was to stimulate cells with LPS/nigericin. Nigericin is a well-known 
inflammasome activator. As explained in Methods, five conditions were tested 
during the cell stimulation assays. As Table 6.3A shows, initial BCA assay 
revealed low protein amounts in the lysates. Interestingly, total protein amounts 
in the lysates from stimulated vs unstimulated cells were quite similar except for 
the noticeably low amounts in the lysates of the wells subjected to 10 µM 
nigericin treatment. Toxicity assays confirmed that at concentrations of 10 µM, 
nigericin was toxic to the cells (data not shown). 
Trichloroacetic acid (TCA)/ acetone precipitation was explored as an 
alternative method to improve the amounts of total protein extracted from the 
lysate samples. As described in the Methods section, samples were mixed in a 
1:1 ratio with 20% TCA, incubated on ice for an hour, centrifuged at 4 oC for 10 
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min then went through successive acetone washes and centrifugation 3 more 
times. Protein pellets were left to air dry, resuspended in SDS buffer and 
assayed for total protein. Table 6.3B shows significant increase in total protein 
after TCA precipitation and those samples were used for Co-IP assays.  
 
 
Despite the improvement in total protein amounts after TCA precipitation, 
detecting the inflammasome proteins in the crude lysates and the Co-IP output 
proved to be difficult. Nonetheless, I was able to demonstrate direct interactions 
between Aβ and NLRP3 protein. 
 
Table 6.3 PMA-differentiated THP-1 monocytes were plated overnight (2 mL of 1x106 
cells/mL) in 6-well plates then treated with 100 ng/mL LPS for 6 hours followed by 5-
10 uM Nigericin for 0.5 hrs as outlined in Methods. Serum-free medium was used in 
this assay. To maximize amount of lysate extracted, both chemical and mechanical 
(cell scrapping) methods were used. Total protein in lysates was verified by BCA 
assay. TCA precipitation was conducted, as described in Methods, to increase 
amount of protein extracted. Protein amounts of crude lysates (Panel A) and TCA 
precipitated protein (Panel B) are shown.  




6.2. Glutathione-S- transferase (GST) fusion tag improves protein 
solubility 
Protein aggregation is the main challenge we have encountered when 
performing recombinant expression. Addition of MBP- and -SUMO fusion tags 
slightly improved protein solubility although most of the proteins were still in 
aggregated form. Due to previous aggregation problems with our recombinant 
proteins, we introduced a glutathione-s-transferase (GST) solubility tag into our 
new gene constructs. In addition, two linkers were incorporated in order to further 
improve protein flexibility and solubility; a GST linker SDGSSMGSS (Temple & 
Dong PDB 6N8U) and a His-tag C-terminal linker GSGSLE [4]. Fig 6.3 shows the 
GST-ASC constructs: GST-ASC PYD, GST-ASC PYD K21A (mutation prevents 
oligomerization), and GST-CARD [2-5, 136, 283]. Full-length ASC as well as the 
individual PYD and CARD domains are known to self-associate forming 
oligomers and specks [3-5, 17, 135, 136, 142, 283]. To improve ASC solubility, 
some groups suggested the use of buffers containing 150 mM of potassium 
[147], low pH [17], purification at 4 °C and including 2 mM DTT in all buffers [4], 
0.9 M NaCl [283] or numerous dialysis steps against H2O at pH 4.0 [135].  
GST-ASC proteins were expressed in mammalian ExpiCHO-S cells as 
explained in the Methods. The proteins were purified by affinity purification on a 
Ni2+ column. The overall yields and quantities were quite similar to those seen in 
previous expressions. Affinity-purified proteins were further subjected to SEC 
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purification in order to isolate soluble monomeric (stable) forms of the proteins. 
Both Sup 75 and 200 columns (with different fractionation ranges) were used. 
 
 
6.2.1. Optimizing protein purification conditions using GST-ASC PYD 
K21A 
Various protein solubilization methods were employed to reverse the 
aggregation process in a bid to obtain soluble, stable proteins. The GST-ASC 
PYD K21A mutant exhibited improved protein solubility and significant changes 
in elution profiles under various conditions are shown in Fig 6.4.  
Fig 6.3 Glutathione s-transferase (GST) fusion tags enhance solubility of ASC 
proteins. Apart from introducing the GST tag, the new genes contain a C-terminal His 
tag and two linker regions [SDGSSMGSS, GSGSLE ] to improve protein flexibility and 
solubility. Three GST-ASC constructs were designed: GST-ASC PYD, GST-ASC PYD 
K21A  mut (prevents aggregation), and GST-ASC CARD [2-5]. GST-ASC protein 
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GST-ASC K21A, 230 ug
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       E.                                      F.    





Initially, there was no sample treatment prior to SEC purification resulting 
in most of the protein eluting in the void volume after purification with Sup 200 
(Panel A) and Sup 75 (Panel B) columns. To shift the elution profile, the next 
strategy involved using a combination of a denaturants and reducing agents (6 M 
urea/ 6 M GuHCl and 2 mM DTT) followed by overnight incubation at room temp 
(Panels C, D) but there was no noticeable improvement. Ionic interactions play a 
big part in ASC self-assembly and these can be easily disrupted by high amounts 
of salt. Since previous studies [147] revealed that ASC was soluble at high 
concentrations of K+ (150 mM), the GST-ASC recombinant proteins were 
subjected to 150 mM KCl treatment then incubated overnight, 2-or 4-days at 4 oC 
(Panel E). Just like the prior sample treatments, there was not a significant shift. 
Ultimately, overnight dialysis at 4 oC in 20 mM HEPES buffer containing 2 mM 
DTT & 150 mM KCl, pH 8.0 yielded the best results. As seen in Panel F, there 
was a huge shift towards the included volume.  
Fig 6.4. Optimizing sample treatment and purification conditions using affinity-purified 
GST-ASC PYD K21A mut. All purifications were done in PBS buffer. Panel A. Sup 
200, no prior sample treatment. Panel B. Sup 75, no prior sample treatment Panel C. 
Sup 75, 6 M GuHCl 2 mM DTT treatment Panel D. Sup 200, 6 M GuHCl 2 mM DTT 
Panel E. Sup 200, 150 mM KCl treatment at 4 oC for 2 days Panel F. Sup 200, 
overnight dialysis at 4 oC in 20 mM HEPES, 150 mM KCl, 2 mM DTT.  
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Although the solubilization methods yielded stable protein with the PYD 
mutant, there was not much improvement with GST-ASC PYD and GST-ASC 
CARD domains as most of the protein still eluted in the void volume thus 
indicating high degrees of aggregation. 
 
6.2.2. The fusion proteins exhibited concentration-dependent 
aggregation 
Protein concentration is another important factor when looking at protein 
aggregation. SEC traces of affinity-purified peak fractions vs side fractions 
showed concentration-dependent aggregation (Fig 6.5). Considering GST-ASC 
PYD, the elution profiles for the peak and side fractions look very similar (Panel 
A). The WT protein showed high levels of aggregation even at low 
concentrations. On the other hand, there are distinct differences between the 
peak and side fractions of the K21A MUT (Panel B). The peak fraction showed 
significant amounts of aggregated protein (void) while most of the protein in the 
less-concentrated side fraction eluted in the included volume. The included peak 
was proposed to be a dimer. As expected, the K21A mutation in the pyrin domain 







6.2.3. The soluble and insoluble fractions of GST-ASC CARD showed 
distinct elution profiles 
Additional interesting observations were made with GST-ASC CARD. 
Overnight dialysis of the affinity-purified peak fractions in HEPES buffer resulted 
in some of the protein precipitating out of solution. Centrifugation for 10 mins at 
17,000g yielded a significant pellet which was solubilized in 6 M GuHCl. Both the 
supernatant and solubilized pellet were eluted in PBS and the elution traces are 
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GST-ASC PYD K21A, 480 ug
GST-ASC PYD K21A, 210 ug
A.                                      B.                    
Fig 6.5 Superdex 200 elutions of GST-ASC proteins show concentration-dependent 
aggregation. Briefly, proteins were harvested 2 days post-transfection. Lysates were 
affinity-purified the same day. Peak fractions were immediately pooled then dialyzed 
overnight at 4 oC in 20 mM HEPES buffer containing 2 mM DTT & 150 mM KCl, 




shown in Fig 6.6. The pellet represents the insoluble fraction of the protein as 
evidenced by most of the sample eluting in the void. In contrast, a larger 





























GST-ASC CARD pellet, 105 ug
GST-ASC CARD sup, 105 ug
Fig 6.6 Elution profiles of GST-ASC CARD pellet and supernatant samples are 
distinct. Dialysis was done right after affinity purification in 20 mM HEPES buffer 
containing 2 mM DTT & 150 mM KCl. The sample precipitated out of the solution 
during dialysis. After 17,000g centrifugation for 10 mins, a pellet was observed and 
was later solubilized in 6 M GuHCl. Both solubilized pellet and supernatant were 




6.2.4. SEC-purified GST-ASC proteins were fairly stable over time 
Since full-length ASC and/or domains are prone to aggregation over time, 
stability studies were conducted after 1 month of storing the proteins at 4 oC. For 
these studies, I compared the stabilities of affinity-purified samples (dialyzed 
overnight in HEPES KCl buffer) and the included fractions after Sup 200-
purification. As Fig 6.7 Panel A shows, dialyzed, affinity-purified GST-ASC PYD 
K21A  was unstable over time as evidenced by the drastic decrease in the dimer 
peak  when compared with the original sample. On the other hand, the re-purified 
SEC fraction 25 was quite stable during the same period of time. Its elution 
profile matched that of the original sample although the yields were quite low. 
This was also confirmed by DLS experiments as shown in Table 6.4. These 
findings highlight the importance of SEC to remove pre-formed aggregates that 
may promote seeding and subsequent oligomerization leading to aggregate 
formation. 
 In comparison, dialyzed GST-ASC CARD (Panel B) was stable over time. 
The elution traces of the dialyzed sample after a month were quite similar to that 
of the original dialyzed sample. Re-purification of the included fraction 25 dimer 
resulted in extremely low yields. Interestingly, data obtained from DLS 
experiments revealed that the GST-ASC CARD was not stable over time as 
evidenced by the increase in the hydrodynamic radius (Table 6.4). These 
findings, however, were in disagreement with the  SEC data. The DLS data also 
indicated that the WT PYD is highly aggregated compared to the K21A MUT thus 
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confirming the importance of the single mutation in preventing self-association of 
the domain.  
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GST-ASC CARD sup, 105 ug
GST-ASC CARD sup, 105 ug, 1 month
Sup frac 25, 1 month later
Fig 6.7 Stability of GST-ASC fusion proteins. To check protein stability over a 1-month 
period, both dialyzed affinity-purified and Sup 200 included fraction 25 samples were 
assessed. BSA was used as a control protein (blue trace). Panel A. Sup 200 elution 
traces for GST-ASC K21A MUT; dialyzed sample on day 1 (dark green trace), dialyzed 
sample after 1 month (light purple trace), re-purification of SEC-purified fraction 25 after 
1 month (red trace).  Panel B. Sup 200 elution traces for GST-ASC CARD; original 
dialyzed sample ( grey trace) and 1-month later (light purple trace), re-purification of frac 
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6.2.5. The oligomerization state of SEC-purified GST-ASC  fusion 
proteins affects detection by immunoblotting methods 
SEC-purified GST-ASC fusion proteins were also assessed by western 
blotting as shown in Fig 6.8. For these studies, void and included peak fractions 
were analyzed. The void and included peak fractions of GST-ASC PYD K21A 
were detected as monomers using the anti-His antibody. However, the same 
antibody did not recognize any of the GST-ASC PYD WT samples. While the 
included sample of the CARD domain was detected, the void sample was not 
recognized by the antibody just like the PYD WT samples. These findings show 
Table 6.4 DLS data of GST-ASC fusion proteins. DLS experiments 
were conducted with Sup 200-purified proteins to test the changes in 
the sizes of the proteins over a 1-month period. Included (GST-ASC 
CARD & PYD K21A MUT) or void fractions ( GST-ASC PYD) were 




that the antibody only recognizes certain oligomeric forms of the proteins and 
that the binding epitope may be inaccessible in some conformations.  The WT 
PYD and the CARD domains are more prone to aggregation compared to the 
PYD K21A MUT thus these findings make sense. Similar trends were observed 
using anti-GST antibody hence these findings confirm the importance of the 
oligomerization state of the proteins when it comes to detection by 





Fig 6.8 Western blot of SEC-purified GST-ASC fusion proteins. Sup 200-purified void 
and included peak fractions were analyzed by SDS-PAGE followed by immunoblotting 
with anti-His primary antibody and anti-mouse secondary antibody. Loaded amounts 






A lot of valuable information was obtained from the GST-ASC fusion 
domains. After testing a variety of buffers and sample treatment conditions, 
overnight dialysis of affinity-purified proteins in HEPES KCl buffer prior to SEC 
purification emerged as the best strategy for obtaining stable, soluble proteins. 
Inclusion of the K21A mutation immensely helped with the solubility of the PYD 
as shown by the SEC, DLS, and immunoblotting experiments. The WT PYD, 
however, was highly aggregated and resistant to all the solubilizing methods that 
were employed.  Interesting findings were also obtained from the CARD domain 
sample which precipitated during dialysis. The soluble form of the protein proved 
to be very stable while the insoluble fraction (in the pellet) was highly aggregated. 
From these findings, the aggregation trend of these GST-ASC fusion proteins is 
as follows: PYD> CARD> PYD K21A MUT. This means that the PYD of ASC is 
mainly responsible for its aggregation. 
 Besides aggregation, another huge challenge with the GST-ASC proteins 
were the extremely low percent recoveries < 40% during SEC indicating that 
most of the protein was lost during the purification process. Since this trend was 
not observed in the previous preps with other constructs, it is possible that the 
GST tag was interfering with the SEC purifications. Nonetheless, including the 
GST solubility tags proved to be extremely helpful as that shifted the elution 
profiles from the void towards the included volume when compared to other 
fusion tags (MBP, SUMO). Of course, it is quite evident that overnight dialysis in 
HEPES KCl buffers also played a major part in solubilizing the aggregates. Due 
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to the promising data with the ASC domains, follow-up studies will involve 
incorporating the GST solubility tag and dialysis strategies in future expressions 
of full-length ASC, NLRP3, and procaspase-1. 
 
6.3. Aβ-ASC aggregation assays 
A complex relationship exists between the NLRP3 inflammasome 
(proteins) and Aβ. Studies have revealed that ASC cross-seeding promotes 
deposition of Aβ fibrils. Co-immunoprecipitation experiments showed that ASC 
specks co-sedimented with Aβ forming plaques [2, 35, 56, 116, 158]. Hence, I 
studied the effect of the GST-ASC domains on Aβ monomer aggregation. 
Aggregation assays were conducted as outlined in detail in the Methods section 
and the increase in thioflavin T (ThT) fluorescence was measured over time. 
 
6.3.1. GST-ASC domains did not promote aggregation of Aβ 
monomer 
GST-ASC proteins were purified by SEC and eluted in PBS. The void and 
included peak fractions were used for the aggregation assays. Preliminary 
studies show that the ASC domains have no effect on Aβ aggregation (Fig 6.9). 
Aggregation studies were conducted with Sup 75 oligomer (Panel A) and void 
peak fractions (Panel B). Studies in Panel C were conducted with ASC fusion 
proteins from a different purification, and Sup 200 void peak fractions were 
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selected for both GST-ASC PYD and GST-CARD domains. The included peak 



















Although these preliminary studies have shown that the GST-ASC fusion 
proteins have no effect on Aβ monomer aggregation, we are yet to determine 
whether the GST tag interferes with these assays. Important data can be 
obtained from the aggregation studies with ASC domains i.e the contribution of 
each domain in promoting aggregation of Aβ or vice versa. However, 
experiments with the individual ASC domains  do not model the actual 
physiological processes. Follow up studies will need to be conducted with both 
soluble and insoluble fractions of full-length ASC to get a better understanding of 
the interplay between Aβ aggregation and ASC speck formation. 
Fig 6.9 ASC domains had no effect on Aβ aggregation. GST-ASC proteins were 
purified by SEC under various conditions and eluted in PBS Panel A. Oligomer peak 
fractions (16) from sup 75 purifications (no prior sample treatment) were used. 
Aggregation assays were conducted at 37 oC as described in Methods. In this assay, 
the ratio of Aβ:ASC in the reaction vessel was 100:1. Panel B. Void peak fractions 
(13) from the same SEC purification as Panel A were used and assays conducted in a 
similar manner. Panel C. Another purification was done using Sup 200 column. Prior 
GST-ASC sample treatment was done in 6 M GuHCl/ 2 mM DTT and elutions were 
done in PBS. Void peak fractions (12 or 13) were selected for PYD and CARD 
domains. Included fraction 23 was used for PYD K21A mut. In these assays, the ratio 
of Aβ:ASC in the reaction vessel was 100:1 for the PYD WT and MUT domains. 
Aβ:ASC ratio of 10:1 was used for the CARD domain. Aggregation assays were 




CHAPTER 7: OVERALL DISCUSSIONS, CONCLUSIONS, & FUTURE 
DIRECTIONS 
The NLRP3 inflammasome still remains a mystery in terms of its actual 
structure and the exact processes leading to its activation. So far, no group has 
done comprehensive structural studies of the NLRP3 inflammasome as a whole 
to determine its actual stoichiometry. In addition, the exact mechanisms 
employed by NLRP3 activators are still not clear. Understanding the mechanistic 
pathways leading to the activation of the NLRP3 inflammasome and procaspase-
1 is crucial in establishing targets for therapeutic intervention in an effort to treat 
inflammatory disorders. To study the NLRP3 inflammasome in detail, this project 
involved overexpressing the three inflammasome proteins in a mammalian cell 
system, conducting structural studies to study the stoichiometry of the 




Recombinant expression of NLRP3 inflammasome proteins is quite a 
challenging process due to their inherent propensity to aggregate. Some studies 
have shown attempts to reconstitute the inflammasome in vitro by co-expressing 
the proteins with pro-IL-1β and monitoring cleavage of caspase-1 and IL-1β as a 
measure of inflammasome activity. However, no group so far has attempted to 
reconstitute the inflammasome using the individual recombinant proteins. 
176 
 
Conducting these studies in vitro is quite a challenging task considering the fact 
that a variety of cell signaling pathways and regulatory proteins normally found in 
vivo are not available under laboratory settings.  
Endogenous inflammasome protein amounts in immune cells are very low 
and not enough for large scale functional studies thus we resorted to 
recombinant overexpression of the proteins. We specifically selected the 
ExpiCHO-S mammalian cell system for our studies because the cell line has 
been successfully used to express secreted antibodies. Because the cells grow 
in suspension and survive at high cellular densities, this allows for more efficient 
overexpression of proteins without drastic changes in cell viability. Hence, I was 
able to successfully express full-length, truncated, and mutant versions of the 
inflammasome proteins. Proteins isolated from both the lysates and inclusion 
bodies were selectively purified by affinity chromatography on a Ni2+ column. I 
obtained relatively large yields of all the proteins and most of them were found in 
the lysates. 
Subsequent analysis of the purified samples by SDS-PAGE and 
immunoblotting revealed the presence of monomeric proteins and SDS-resistant 
aggregates. I was able to obtain some structural information on some of the 
proteins pertaining to their sizes and conformations using biophysical techniques 
(SEC, MALS, DLS, CD, TEM). The main challenge, however, was obtaining 
stable, solution proteins for subsequent functional assays since majority of the 
proteins existed as aggregates in solution. Efforts to break these aggregates 
using stringent conditions and inclusion of solubility tags were successful to a 
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certain extend as small amounts of the proteins were obtained in monomeric 
form. 
Expressing the proteins for various periods of times did not produce any 
differences in the amounts expressed or degree of aggregation. Thus, protein 
aggregation most likely occurred during expression. Inherent properties of the 
inflammasome proteins tend to promote aggregation under physiological 
conditions. In addition, various groups that have recombinantly expressed the 
inflammasome proteins also reported aggregation. Therefore, in vitro studies with 
inflammasome proteins can be quite challenging. Our attempts to reconstitute the 
NLRP3 inflammasome in vitro were not successful. This also brings about the 
question whether this is actually feasible, and also if the ExpiCHO-S cells present 
a good expression system for these proteins. 
In other studies, caspase-1 activity assays produced some interesting 
findings. For the first time ever, I observed enzyme activity with the recombinant 
procaspase-1 using a fluorescence assay. This was quite unexpected and raised 
more questions regarding the actual form of the active caspase and what 
domains are required for activity. Whether procaspase-1 activity is relevant under 
physiological conditions is yet to be determined. Since recent literature findings 
contradicted the precious findings on the exact form of active caspase-1, this 
raises the possibility that there could be many forms of the active enzyme, some 
of which may not have been identified yet. In that case, this makes caspase-1 a 
difficult target for therapeutic intervention when treating inflammatory disorders. 
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Another important aspect of my studies was to study the interactions 
between Aβ and the inflammasome proteins. What makes this study distinct from 
others is the fact that I used SEC-purified Aβ-42 protofibrils which have been 
previously identified as the most robust form of Aβ. Other studies, however, used 
a mixture of different Aβ species in their experiments. I was able to show direct 
interactions between Aβ protofibrils and NLRP3. These interactions are relevant 
in the immune response pathway and blocking these interactions seems a 
plausible approach towards preventing AD-related neuroinflammation.  
Although direct interactions between Aβ and NLRP3 have been studied, 
more studies are leaning towards Aβ-ASC interactions. ASC studies are 
important since formation of ASC specks is a crucial step in the assembly of the 
NLRP3 inflammasome. For these studies, I used ASC domains tagged with a 
GST tag for added solubility. Compared with the previous expressions, the yields 
obtained with the GST-tagged proteins were comparatively low. The PYD K21A 
MUT (does not oligomerize) and CARD domains showed enhanced solubility and 
appeared as dimers in solution. In addition, the soluble forms of these domains 
were quite stable when stored at 4 oC. Meanwhile, the PYD WT was highly 
aggregated even in the presence of the GST fusion tag. Although the single 
mutation in the PYD binding surfaces prevents self-oligomerization and may not 
represent actual physiological states, I was able to obtain important structural 
information using the PYD K21A mutant with enhanced solubility. With regards to 
the GST-ASC domains, the overall propensity for oligomer formations is as 
follows: PYD> CARD> PYD K21A MUT. These data also reveal that PYD of ASC 
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has the greatest contribution to the overall aggregation of full-length ASC 
compared to the CARD domain. 
Preliminary studies showed that the ASC domains had no effect on Aβ 
monomer aggregation contrary to previous published studies. However, it is yet 
to be established whether the GST tag may be interfering with the assays hence 
future aggregation experiments will be conducted after removal of the fusion tag. 
It will be interesting to explore the stability of these domains in solution over time 
and how they affect Aβ aggregation. Since the current studies have utilized ASC 
domains, follow-up aggregation studies with the full-length GST-ASC will be 
conducted to get a better model system for the actual physiological events. In 
sum, the studies presented above revealed some crucial findings pertaining to 
the interplay between Aβ and the NLRP3 inflammasome. In addition, they also 
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